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Abstract 
This work outlines two different projects. The first project was the study of a 
stereodivergent oxy-Michael cyclisation and its application towards the synthesis of 
natural products, diospongin A, diospongin B and psymberin/ircinistatin A.  
 
The α,β-unsaturated thioesters under TBAF-mediated conditions gave the 
2,6-trans-tetrahydropyran; under acid-mediated conditions gave the 
2,6-cis-tetrahydropyran. The 4-hydroxyl group is crucial for the stereodivergence; 
when the hydroxyl group was removed or protected the stereodivergence vanished. 
 
The second project was the study of (L)-proline benzyl ester-catalysed asymmetric 
aldol reactions in water. The reaction was carried out in a pH 7 buffered aqueous 
solution of cyclohexanone and a series of aryl aldehydes to provide anti aldol 
products in 7-89% ee. 
 
The aldol reaction between various ketone donors with 4-nitrobenzaldehyde under 
the same conditions were also developed to provide products in 13-61% ee.  
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1. Studies Towards the Total Synthesis of (±)-Diospongin A and B via a 
Stereodivergent Oxy-Michael Cyclisation 
1.1. Introduction 
1.1.1. General approaches towards the synthesis of tetrahydropyrans 
Tetrahydropyrans are important structural motifs that are found in many natural 
products, including diospongin A 1 and B 2, psymberin/ircinistatin A 3, phorboxazole 
A 4 and phorboxazole B 5 (Figure 1). 
 
 
Figure 1 Tetrahydropyran-containing natural products. 
 
In recent years, interest in the development of robust strategies for synthesising 
tetrahydropyrans has significantly increased due to the intriguing biological 
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properties that many tetrahydropyran-containing natural products possess.1, 2 
Phorboxazoles A 4 and B 5 have been reported to have anticancer properties,1, 3 
whereas diospongin B 2 has been reported to have anti-osteoporotic activities.2 
 
For the synthesis of tetrahydropyran derivatives, several approaches have been 
established, including Prins cyclisation,4 oxy-Michael reactions,5 transition metal 
catalysed cyclisations,6 nucleophilic addition to cyclic oxocarbenium ions7 and 
hetero-Diels–Alder cycloadditions.8 In a recent study, the Clarke group developed a 
novel and efficient synthetic route to construct tetrahydropyrans via a 
stereodivergent oxy-Michael cyclisation, which was then applied to synthesise the 
C-20–C-32 core of phorboxazole B 7 (Scheme 1).9 
 
 
Scheme 1 Synthesis of C-20–C-32 core of phorboxazole B 7.9 
 
1.1.2. Isolation and structure elucidation of diospongin A and B 
In 2003, diospongin A 1 along with its diastereomer diospongin B 2 were initially 
isolated from the rhizomes of Dioscorea spongiosa via bioassay-guided fractionation 
by Kadota and co-workers.2 As shown in Figure 2, both diospongin A 1 and B 2 have a 
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six-membered tetrahydropyran core with two aromatic side chains, and only differ in 
their 3,7 stereochemical configuration.  
 
 
Figure 2 Structure of diospongin A 1 and B 2. 
 
In diospongin A 1 C-3 has an R configuration whereas in diospongin B 2 it has an S 
configuration. Kadota and co-workers were the first to elucidate the absolute 
configuration of diospongin A 1 and B 2.2 
 
As shown in Figure 3, diospongin A 1 is presented as 
(3R*,5S*,7S*)-1,7-diphenyl-3,7-epoxy-5-hydroxy-1-heptanone and diospongin B 2 is 
presented as (3S*,5S*,7S*)-1,7-diphenyl-3,7-epoxy-5-hydroxy-1-heptanone. 
 
 
Figure 3 3-D structure of diospongin A 1 and B 2. 
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Despite the structural similarities between diospongin A 1 and B 2, their biological 
activities are remarkably different. Diospongin B 2 has anti-osteoporotic activity 
whereas diospongin A 1 does not.2  
 
Osteoporosis is a skeletal disease which is often called a silent disease. This is due to 
the challenges of diagnosing bone loss in the early stages. Diospongin B 2 has shown 
to have effective inhibitory activities of 45Ca release at 200 μM (30.5%) and 20 μM 
(18.2%).2 Due to their promising activities in the treatment of osteoporosis, the 
diospongins have proven to be popular synthetic targets and have therefore been 
widely reported. 
 
1.1.3. Previous synthesis of diospongin A and B 
Various approaches to synthesise diospongin A 1 and B 2 have been published. To 
date, the total synthesis of diospongin A 1 has been reported by 21 groups,10-30 
whereas diospongin B 2 synthesis has been reported by 12 groups.12, 16-19, 22, 28, 30-34 
The most important step in the synthesis of diospongin A 1 and B 2 is the 
construction of the tetrahydropyran core. The strategies used include intramolecular 
oxy-Michael reaction,10, 11, 13, 26 Prins cyclisation,14, 15 intramolecular Pd(II)-catalysed 
cyclisations,16 hetero-Diels–Alder (HDA) reactions,19, 21, 22 nucleophilic addition to a 
cyclic oxocarbenium ion12 and palladium(II)-catalysed hydroxycarbonylation of 
hexenols.23 
 
In 2006, the first synthesis of diospongin A 1 was reported by Chandrasekhar and 
co-workers. The tetrahydropyran formation step, which is key in this process, is 
shown in Scheme 2.10 
24 
 
 
Scheme 2 Synthesis of diospongin A 1 as reported by Chandrasekhar and 
co-workers.10 
 
Diospongin A 1 was obtained by hydrolysis of the benzylidene acetal group and 
subsequent intramolecular oxy-Michael addition of 9 in the presence of TFA in a 
one-pot process. 
 
Surprisingly, Chandrasekhar claimed that the compound that was generated was 
diospongin B. However, the NMR spectroscopic data of their diospongin “B” did not 
correspond to the findings reported by Kadota (Table 1).2 In a subsequent study, 
Jennings and co-workers, confirmed that this compound was in fact diospongin A 1.12 
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Table 1 Comparison of 1H NMR spectroscopic data of diospongin A 1 and B 2 as 
reported by the Kadota and Chandrasekhar groups.2, 10 
Diospongin A 
(Kadota)2 
Dioaspongin B 
(Kadota)2 
Chandrasekhar10 
δH (CDCl3) δH (CDCl3) δH (CDCl3) 
3.41 dd (16.0, 6.0 Hz) 
3.07 dd (16.0, 6.8 Hz) 
4.65 dddd (11.2, 6.8, 6.0, 
1.7 Hz) 
1.97 ddd (14.0, 3.0, 1.7 Hz) 
1.67 ddd (14.0, 11.2, 3.0 
Hz) 
4.35 quint (3.0 Hz) 
 
1.94 ddd (14.0, 3.0, 1.7 Hz) 
1.75 ddd (14.0, 12.0, 3.0 
Hz) 
4.95 dd (12.0, 1.7 Hz) 
7.97 dd (7.8, 1.0 Hz) 
7.44 t (7.8 Hz) 
7.55 t (7.8 Hz) 
7.30 m 
7.30 m 
7.28 m 
3.45 dd (15.8, 6.8 Hz) 
3.17 dd (15.8, 6.8 Hz) 
4.23 dddd (9.5, 6.8, 5.8, 
3.0 Hz) 
2.05 ddd (12.4, 5.2, 3.0 Hz) 
1.50 dt (12.4, 9.5 Hz) 
4.02 dddd (9.8, 9.5, 5.2, 
3.9 Hz) 
2.51 ddd (13.3, 4.1, 3.9 Hz) 
1.92 ddd (13.3, 9.8, 4.1 Hz) 
5.19 t (4.1 Hz) 
7.98 dd (7.8, 1.0 Hz) 
7.47 t (7.8 Hz) 
7.57 t (7.8 Hz) 
7.35 m 
7.32 m 
7.23 t (6.8 Hz) 
3.38 dd (16.2, 6.03 Hz) 
3.38 dd (16.2, 6.4 Hz) 
4.50 dddd (11.8, 6.4, 6.0, 2.8 
Hz) 
2.12 ddd (14.5, 2.8, 1.8 Hz) 
1.74 ddd (14.5, 11.8, 1.0 Hz) 
4.75 ddd (11.7, 2.5, 1.0 Hz) 
 
2.08 ddd (14.5, 2.8, 2.5 Hz) 
1.84 ddd (14.5, 11.8, 2.8 Hz) 
5.46 t (2.8 Hz) 
7.90 m 
7.40 m 
7.47 m 
7.24 m 
7.22 m 
7.20 m 
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Later in 2006, an alternative synthetic approach towards diospongin A 1 and B 2 was 
presented by Jennings and coworkers (Scheme 3 and Scheme 4).12 The key reaction 
involved nucleophilic addition to a cyclic oxocarbenium ion.  
 
 
Scheme 3 Synthesis of diospongin B 2 as reported by the Jennings group.12 
 
Addition of boron trifluoride diethyl etherate to lactol 10 allowed for the formation 
of oxocarbenium cation 11. Synthesis was completed via nucleophilic attack of the 
trimethylsilyl enol ether, which was followed by deprotection. In the favoured 
conformer of 11, the phenyl ring was placed in an equatorial position and the 
triethylsiloxy enol ether attacked from a pseudo-axial trajectory to generate 
diospongin B 2 (Scheme 3).12  
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Scheme 4 Synthesis of diospongin A 1 as reported by the Jennings group.12 
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The synthesis of diospongin A 1 is presented in Scheme 4. The dehydration of 12 
using TFA provided the key oxocarbenium cation intermediate 13 which was 
subsequently reduced with triethylsilane. In a similar fashion to the synthesis of 
diospongin B 2, the phenyl ring was in the pseudo-equatorial position whereas the 
silyl ether group was in the axial position 14. This chair-like transition state allowed 
for the stereoselective axial nucleophilic attack by hydride to generate 15 with 
2,6-cis stereochemistry in the tetrahydropyran ring. Synthesis was completed after 
ozonolysis, Grignard addition, oxidation and deprotection.  
 
Jennings and co-workers presented the synthesis of both diospongins A 1 and B 2 
and verified the structures involved,12 which were in agreement with the 
configuration as proposed by Kadota.2 
 
1.1.3.1. Synthesis of tetrahydropyrans via the intramolecular oxy-Michael 
reaction 
In 2006, Cossy and co-workers demonstrated the synthesis of diospongin A 1 via 
deprotection and an intramolecular oxy-Michael reaction of 1,7-diarylheptanoid 18 
in a one-pot process to generate diospongin A 1 in a yield of 60% (Scheme 5).11 
 
Moreover, Bates and co-workers also reported the synthesis of diospongin A 1 with a 
similar strategy, however resin was used to generate diospongin A 1 in a yield of 
83%.13  
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Scheme 5 Synthesis of diospongin A 1 as reported by the Cossy group11 and the 
Bates group.13 
 
In 2011, Meshram proposed the stereoselective synthesis of diospongin A 1 via 
intramolecular oxy-Michael addition (Scheme 6).26  
 
 
Scheme 6 Synthesis of diospongin A 1 as reported by Meshram and co-workers.26 
 
Deprotection and cyclisation of 19 was successfully achieved by using a one-pot 
process by adding of CSA (5 mol%) in methanol to give the target molecule, 
diospongin A 1 in high yield (94%).26 
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1.1.3.2. Synthesis of tetrahydropyrans via the Prins reaction 
Tetrahydropyran rings can also be formed by the Prins reaction as reported in a study 
by the Yadav14 (Scheme 7) and Piva15, 24 groups (Scheme 9). 
 
 
Scheme 7 Synthesis of diospongin A 1 via the Prins reaction as reported by Yadav 
and co-workers.14 
 
The synthesis of diospongin A 1 as reported by Yadav and co-workers began with a 
Prins cyclisation reaction, which provided 22 from cinnamaldehyde 21 and 
1-phenylbut-3-en-1-ol 20 in 78% yield as a single diastereomer. The mechanism 
involved is shown in Scheme 8. 
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Scheme 8 Mechanism of the Prins reaction as reported by the Yadav group.14 
 
In Piva’s synthesis, the key step in the formation of the tetrahydropyran ring also 
involved a Prins reaction.15 The homoallylic alcohol 20 with benzaldehyde 23 gave 24 
in 83% yield. Inversion of the hydroxyl group at the C-4 position was carried out via 
the Mitsunobu reaction to generate diospongin A 1 (Scheme 9). 
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Scheme 9 Synthesis of diospongin A 1 via a Prins reaction as reported by the Piva 
group.15, 24 
 
1.1.3.3. Synthesis of tetrahydropyrans via Pd(II)-catalysed cyclisation 
In a previous study, Uenishi and co-workers demonstrated a novel synthetic 
approach towards the synthesis diospongin A 1 and B 2 by using a Pd(II) catalyst to 
promote cyclisation, followed by a Wacker oxidation reaction (Scheme 10).16, 35-38 
 
When triol 25 was treated with bis(acetonitrile)dichloropalladium(II), the desired 
cis-tetrahydropyran 26 was obtained in 92% yield, along with trans-tetrahydropyran 
28 in 6% yield. This was followed by Wacker oxidation to generate diospongin A 1 in 
56% yield. The triol 27, under the same reaction conditions, formed 
trans-tetrahydropyran 28 in 86% yield, along with cis-tetrahydropyran 26 in 5% yield. 
Compound 28 was then protected with MOMCl, followed by Wacker oxidation and 
deprotection to give diospongin B 2 in 91% yield. 
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Scheme 10 Synthesis of diospongin A 1 and B 2 as reported by Uenishi and 
co-workers.16  
 
Gracza and co-workers have developed a diastereoselective synthesis of 
2,6-cis-tetrahydropyranyl carboxylic acids based on intramolecular 
hydroxycarbonylation by using palladium(II) as a catalyst (Scheme 11).23 
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Scheme 11 Synthesis of diospongin A 1 as reported by Gracza and co-workers.23 
 
The synthesis of 2,6-cis-diastereomer 30 was achieved by the treatment of protected 
diol 29 under hydroxycarbonylation with carbon monoxide in acetic acid in the 
presence of palladium(II) chloride. Next, the 2,6-cis-tetrahydropyranyl carboxylic acid 
30 was converted to 31 in 2 steps. The reaction started with treatment of 30 with 
oxalyl chloride to give acid chloride, followed by Stille coupling39 with 
tributylphenyltin and bis(dibenzylideneacetone)palladium(0) to generate 31 in 88% 
yield over two steps. Finally, after deprotection gave the target molecule 1 in 83% 
yield. 
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1.1.3.4. Synthesis of tetrahydropyrans via dihydropyranone 
In 2016, the Clarke group also reported the synthesis of diospongin B 2.32 The 
trans-tetrahydropyran core was obtained via conjugate addition of Gilman cuprates 
to dihydropyran-4-one 32. Decarboxylation of 33 and followed by reduction to give 
34 in 66% yield. Protection of 34 with MOMCl, followed by a Wacker oxidation gave 
35. Finally, deprotection of 35 using hydrochloric acid in THF to complete the 
synthesis of diospongin B 2 (Scheme 12). 
 
 
Scheme 12 Synthesis of diospongin B 2 as reported by the Clarke group.32 
 
1.1.3.5. Synthesis of tetrahydropyrans via the Diels–Alder reaction 
In addition to other reactions, the hetero-Diels–Alder reaction has also been used to 
form the tetrahydropyran core. In 2010, groups led by More21 and Hashimoto22 
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accomplished the synthesis of diospongin A 1 and B 2 by using a hetero-Diels–Alder 
reaction (Scheme 13). 
 
 
Scheme 13 Synthesis of compound 42 as reported by Hashimoto and co-workers.22 
 
The synthesis of diospongin A 1 and B 2 reported by Hashimoto and co-workers was 
shown in Scheme 13. The synthesis began with an enantioselective 
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hetero-Diels–Alder reaction between Danishefsky-type diene 36 and benzaldehyde 
23 using 1 mol% Rh2(S-BPTPI)4 37 as a catalyst to give 38. Then, 10 mol% of TMSOTf 
was used to give dihydropyranone 39, after which the Mukaiyama–Michael addition 
was immediately performed with silyl enol ether 40 to give 41. Addition of TFA 
resulted 42 in 85% yield with >99% ee. Diospongin B 2 was obtained as a single 
diastereomer in 86% from 42 via a chemo and stereoselective reduction with 
K-selectride®. Diospongin A 1 was synthesised from diospongin B 2 using 30% 
hydrochloric acid in THF (Scheme 14). 
 
 
Scheme 14 Synthesis of diospongin A 1 and B 2 as reported by Hashimoto and 
co-workers.22 
 
1.1.4. Stereodivergent oxy-Michael reaction 
In 2011, Fuwa and co-workers reported an oxy-Michael cyclisation of 
α,β-unsaturated thioesters to form tetrahydropyrans.40 Treatment of 
α,β-unsaturated thioesters 43 with a Brønsted acid catalyst, leads to high 
diastereoselectivity for the 2,6-cis-tetrahydropyran product 44; under basic 
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conditions using potassium tert-butoxide the cyclisation favoured the formation of 
2,6-trans product 45 (Scheme 15).  
 
 
Scheme 15 Synthesis of cis- and trans-tetrahydropyran ring through an oxy-Michael 
reaction as reported by Fuwa and co-workers.40 
 
The transition state model proposed by Fuwa and co-workers showed that the 2,6-cis 
product possibly went through the chair-like transition state 46a via an allylic 
carbocation mechanism (Scheme 16). The cis-product 44 was formed because this 
conformation showed the minimum steric interactions between its substituents.  
 
 
Scheme 16 Mechanistic studies of the cis-tetrahydropyran as proposed by Fuwa.40 
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The preferential formation of the 2,6-trans tetrahydropyran ring under potassium 
tert-butoxide-catalysed reaction condition could be explained by the 
chelation-controlled model (Scheme 17). 
 
 
Scheme 17 Mechanistic studies of the trans-tetrahydropyran as proposed by Fuwa 
and co-workers.40 
 
The potassium ion was coordinated with the thioester oxygen atom and hydroxyl 
group to form the transition state 47a and 47b. However, for the 47b transition state, 
the thioester oxygen atom would be more difficult to chelate with the potassium ion 
as it would be too far away. Therefore, under potassium tert-butoxide condition, 
trans-tetrahydropyran was preferentially formed. 
 
The Clarke group discovered a similar reaction as the sterodivergent reaction 
described above; the α,β-unsaturated thioesters 6 under acetic acid-buffered TBAF 
conditions produced 2,6-trans-tetrahydropyran rings 8 in 35% yield and in >20:1 
diastereoselectivity, however, under TFA conditions the formed tetrahydropyran had 
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a 2,6-cis configuration 7 in 71% yield and in >13:1 diastereoselectivity (Scheme 18).9 
In order to explain this diastereoselectivity, computational studies were carried 
out.41, 42  
 
 
Scheme 18 Stereodivergent oxy-Michael reaction.9 
 
The computational studies showed that under acidic conditions the TFA plays a dual 
role to protonate the thioester and to deprotonate the alcohol (transition state 49). 
With this coordination, the electrophilicity and nucleophilicity of the thioester and 
alcohol were increased, respectively and only two possible (E)-thioenols 50 and 51 
were formed (Scheme 19).
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Scheme 19 Mechanistic studies of TFA-mediated cyclisation.41 
 
Several transition states may lead to the formation of two possible(E)-thioenols 50 
and 51. Using DFT calculations (B3LYP/6-31G*), four lowest energy transition states 
with both chair (50a and 51a) and boat (50b and 51b) conformations were shown in 
Figure 4. 
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Figure 4 Transition states for the TFA-mediated cyclisation. Activation enthalpies 
calculated in dichloromethane implicit solvent model and were relative to the 
ground state conformation of diol 53 complex with TFA. Tolyl and i-Pr groups were 
omitted for clarity.41 
 
The transition state leading to the cis-product with chair configuration 50a was 
calculated to have the lowest activation enthalpies and was 2.4 kcal/mol lower in 
energy when compared to the trans-chair-like transition state 51a. Compared to the 
trans-configuration, fewer steric interactions were found between the 6-proton and 
the 2-thioester substituent in cis-configuration, therefore the formation of the 
cis-product was favoured, supporting the results seen in our synthetic studies.  
50a  50b 
51a 51b 
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Figure 5 Energy diagram for the TFA-mediated lowest energy pathways for the 
2,6-cis 52 (red) and 2,6-trans 53 (blue). Enthalpies calculated in dichloromethane 
implicit solvent model and were relative to the ground state conformation of 53 
complex with TFA.41 
 
Moreover, these calculations also confirmed that the reaction was kinetically 
controlled, because the activation energy of the reverse reaction was higher 
compared to the forward reaction (Figure 5). In contrast, the 2,6-trans-configuration 
was obtained under buffered TBAF conditions.  
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Figure 6 Mechanistic considerations of TBAF-mediated cyclisation. 
 
It was assumed that the alkoxide attacked the conjugate double bond to form the 4 
possible thioenolates : both (E) and (Z)-thioenolate of the trans-tetrahydropyran 55 
and both (E) and (Z)-thioenolate of the cis-tetrahydropyran 56 (Figure 6). Several 
transition states may lead to the formation of four possible thioenolates (E)-55, 
(Z)-55, (E)-56 and (Z)-56. As shown in Figure 7, 6 possible transition states are 
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presented with lowest in energy to form the (E) and (Z)-thioenolates.  
It was found that the (E)-55a had the lowest energy and with a boat-like 
conformation. The unusual boat-like transition state might be due to a strong 
hydrogen-bonding interaction between the 4-hydroxyl and the alkoxide to stabilise 
the conformation.43, 44 In contrast with the TFA case, the 4-hydroxyl group was 
directly involved in stabilization of the transition state, which might be involved in 
the stereodivergence. 
 
 
 
 
Figure 7 Transition states for the TBAF-mediated cyclisation.41 Activation enthalpies 
calculated in the THF implicit solvent model and were relative to the ground state 
conformation of alkoxide 54. Tolyl and i-Pr groups were omitted for clarity. 
 
As demonstrated in energy diagram (Figure 8), the energy barrier of 
trans-tetrahydropyran (E)-55a was 9.1 kcal/mol and that of cis-tetrahydropyran 
(E)-56a was 10.4 kcal/mol. These two energy barriers were small, which may account 
for the rapid product formation (usually fewer than 10 minutes at room 
temperature). (E)-55a was 1.3 kcal/mol lower in energy compared to (E)-56a, which 
were consistent with the diastereoselectivity results obtained in our synthetic 
studies. 
(E)-55a   (Z)-55a   (Z)-55b         (E)-56a   (Z)-56a   (Z)-56b 
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Figure 8 Energy diagram for theTBAF-mediated lowest energy pathways to the 
2,6-trans 53 (blue) and 2,6-cis 52 (red). Enthalpies calculated in THF implicit solvent 
model and were relative to the ground state conformation of alkoxide 54. 
 
The reaction is likely under kinetic control if the energy barrier in the forward 
direction is much smaller than in the reverse reaction. The total energy barrier of the 
cis-tetrahydropyran in the reverse direction was 14.4 kcal/mol (Figure 8), which 
supported the hypothesis that the reaction under TBAF conditions was kinetically 
controlled. 
 
1.1.5. Synthetic investigation of the role of the 4-OH group in the 
stereodivergent oxy-Michael cyclisation 
Based on the computational studies described in chapter 1.1.4, it was deduced that 
the 4-hydroxl group was an important functional group that was essential for 
stereodivergence. To confirm this, synthetic studies were performed by using 
compounds 57, 58, 59 and 60 as the substrates. Compounds 57, 58 and 59 which did 
not have the hydroxyl group at the C-4 position, and the 4-hydroxl group in 
compound 60 was protected as a methyl ether (Figure 9). 
f 
47 
 
 
Figure 9 Structure of compounds 57, 58, 59 and 60. 
 
The general synthetic routes to synthesis 57, 58 and 59 are depicted in Scheme 20. 
  
 
Scheme 20 Overview of the synthesis of compounds 57, 58 and 59. 
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The synthesis started with Grignard addition to aldehydes 23, 61 and 62 to provide 
corresponding products 63 (68%), 64 (54%) and 65 (62%). Next, the alcohols 63, 64 
and 65 underwent the cross-metathesis reaction with S-p-tolyl prop-2-enethioate 66 
in the presence of 10 mol% of 2nd generation of Hoveyda-Grubbs catalyst and 10 
mol% of copper(I) iodide to generate the thioesters 57 (58%), 58 (30%) and 59 (49%). 
 
After successful synthesis of the cyclisation precursors 57, 58 and 59, evaluation of 
the stereodivergent oxy-Michael cyclisation was performed. 
 
Table 2 The evaluation of stereodivergent oxy-Michael cyclisation to 57, 58 and 59 
substrates. 
 
 
Entry 
Ratio 
cis:trans 
TFA 
Yield/% 
R 
TBAF 
Yield/% 
Ratio 
cis:trans1 
1 8:1 56 67 Ph  57 53 67 >20:1 
2 4:1 27 68 i-Pr  58  27 68 >20:1 
3 5:1 36 69 C7H15 59 25 69 >20:1 
1. 1Determined by 1H NMR. 
 
When thioesters 57, 58 and 59 were submitted to the acid cyclisation conditions, the 
cyclisation smoothly proceeded to form the cis-products 67 (56%), 68 (27%) and 69 
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(36%) with 8:1, 4:1 and 5:1 of diastereoselectivities for 67, 68 and 69, respectively. 
Treatment of thioesters 57, 58 and 59 under buffered TBAF conditions also lead to 
the formation of cis-products 67 (53%), 68 (27%) and 69 (25%) with more than 20:1 
diastereoselectivity (Table 2). 
 
 
Scheme 21 Synthesis of thioester 60. 
 
The synthesis of cyclisation precursor 60, which had the 4-hydroxyl group protected 
as a methyl ether, began with an aldol reaction. Aldehyde 70 could be synthesised in 
two steps from a tin metal mediated45 Barbier-type reaction46 and subsequent 
cleavage of diol. Aldehyde 70 was then treated with silyl enol ether 71 to give 72 in 
91% yield. This was methylated to give 73 in 64% yield. Compound 73 was then 
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converted into 74 via reduction with sodium borohydride to give both syn- and 
anti-products. Without the separation of these two diastereoisomers, 
cross-metathesis was carried out to give product 60 in 30% yield after purification 
(Scheme 21).  
 
Next, the protected thioester 60 was also submitted to both the acid and the 
buffered TBAF reaction conditions (Scheme 22). 
 
 
Scheme 22 Investigating of stereodivergent oxy-Michael cyclisation to substrates 60. 
 
Treating 60 under TFA conditions gave the cis-product in 48% yield. Under buffered 
TBAF conditions a hydrolysis product was the major product, detected the 
cis-cyclised product peak was identified in the crude reaction mixture (Scheme 22). 
 
The above results indicated that the formation of the trans-tetrahydropyrans under 
buffered TBAF condition was dependent on the presence of the 4-hydroxyl group.  
This was consistent with the computational studies, which was showed that the 
4-hydroxyl group was a hydrogen-bond donor in the stereodivergent oxy-Michael 
cyclisation. 
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Interconversion experiments were performed, to prove that the formation of both 
cis- and trans-products were under kinetic control. The cis-product 76 was treated 
with buffered TBAF conditions, while the trans-product 77 was submitted to acidic 
cyclisation conditions (Scheme 23). 
 
 
Scheme 23 Interconversion studies for the cis-product 76 and trans-product 77. 
 
The reaction was monitoring by TLC and by analysis of the 1H NMR spectrum. 
Interestingly, no interconversion was observed. Therefore it was deduced that the 
formation of the cis and trans cyclisation products 76 and 77 were under kinetic 
control, as indicated by the computational studies. 
 
The stereoselective oxy-Michael addition was successfully applied to form the 
tetrahydropyran ring of phorboxazole B 7. The aim was to apply this remarkable 
reaction towards the synthesis of both (±)-diospongin A 1 and B 2 from a single 
acyclic precursor. 
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1.2. Results and discussion 
1.2.1. Background and previous results 
Previous work by the Clarke group showed that the C-20–C-32 penta-substituted 
tetrahydropyran core of phorboxazole B 7 could be accessed by the use of thioesters 
as electophiles in the stereodivergent oxy-Michael reaction (Scheme 24).9 The 
deprotection of TBS-ether 6 under acetic acid-buffered TBAF conditions, resulted in 
formation of the 2,6-trans-tetrahydropyran ring 8 in which no traces of the 
2,6-cis-tetrahydropyran ring 7 were detected. However, under TFA conditions, the 
tetrahydropyran formed had the 2,6-cis configuration 7. Because of this unique 
stereodivergence, it was envisaged that the oxy-Michael reaction could be applied 
for the synthesis of diospongin A 1 and B 2. 
 
 
Scheme 24 Synthesis of C-20–C-32 fragment of the phorboxazole B 7 via 
stereodivergent oxy-Michael reaction.9 
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1.2.2. Retrosynthetic approaches  
The retrosynthetic analysis of diospongin A 1 and B 2 is illustrated in Scheme 25.  
 
 
Scheme 25 Retrosynthetic analysis of diospongin A 1 and B 2. 
 
We envisioned that the synthesis of diospongin A 1 and B 2 could be achieved in one 
step from the thioesters 76 and 77 by a Liebeskind–Srogl type coupling reaction.47 
The key tetrahydropyran forming step to generate both diastereomeric, 
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cis-tetrahydropyran 76 and trans-tetrahydropyran 77 was proposed via a 
stereoselective oxy-Michael addition onto an α,β-unsaturated thioester 78. 
Additional disconnection at the C-6 and C-7 bond of α,β-unsaturated thioester 78 
resulted in diol 79 and S-p-tolyl prop-2-enethioate 66. Diol 79 was accessible through 
diastereoselective reduction of the Mukaiyama aldol product 80. The aldol product 
80 could be obtained by coupling the silyl enol ether 81 and 3-butenal 70. 
 
1.2.3. Total synthesis of (±)-diospongin A and B  
Preparation of the key cyclisation precursor 78 for the synthesis of diospongin A 1 
and B 2 is presented in Scheme 26. 
 
 
Scheme 26 Synthesis of α,β-unsaturated thioesters 78. 
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It was anticipated that the C-4 hydroxyl group could be installed via a Mukaiyama 
aldol reaction. Therefore, the proposed synthetic route to diospongin A 1 and B 2 
began with the coupling reaction between freshly-made of 3-butenal 70 and 
trimethyl((1-phenylvinyl)oxy) silane 81 to form the β-hydroxy ketone 80. 
 
The preparation of 3-butenal 70 originated from a tin metal-mediated45 Barbier-type 
reaction46 between commercially available glyoxal 82 and allyl bromide 83 to form 
1,7-octadiene-3,4-diol 84 in 72% yield.48 Subsequent cleavage of the diol 84 with 
sodium (meta)periodate in a biphasic dichloromethane-water system generated 
3-butenal 70 (Scheme 27).49  
 
 
Scheme 27 Synthesis of 3-butenal 70. 
 
Treatment of commercially available acetophenone 312 with trimethylchlorosilane in 
the presence of triethylamine and sodium iodide in acetonitrile resulted in the 
formation of trimethyl ((1-phenylvinyl)oxy) silane 81 in high yield (97%) (Scheme 
28).50-52 
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Scheme 28 Synthesis of trimethyl ((1-phenylvinyl)oxy) silane 81. 
 
After having successfully synthesised of both aldehyde 70 and silyl enol ether 81, the 
Mukaiyama aldol reaction was carried out. The reaction was completed using a 
standard procedure,53 in which the aldehyde 70 was coupled with the silyl enol ether 
81 in the presence of titanium tetrachloride at −78 °C in dichloromethane. The 
desired aldol product, β-hydroxy ketone 80 was obtained in a moderate yield (51%) 
(Scheme 26). 
 
The next step in the synthetic sequence involved the diastereoselectivity reduction 
of β-hydroxy ketone 80 to syn-diol 79.  
 
 
Scheme 29 Diastereoselective reduction to reduce β-hydroxy ketone 80. 
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According to the literature,54-58 under different reaction conditions, both syn- and 
anti-1,3-diols can easily be synthesised from the same β-hydroxy ketone. The 
formation of syn-diols was favoured under Narasaka–Prasad conditions,57, 58 whereas 
when using Evans–Saksena conditions,54-56 the formation of anti-1,3-diols was 
favoured (Scheme 29). 
 
In the Evans–Saksena reduction, tetramethylammonium triacetoxyborohydride 
reducing agent was used in a 1:1 acetic acid and acetonitrile solvent system, and 
resulted in the formation of anti-1,3-diols. This reaction proceeded through an 
intramolecular hydride delivery to ketone with the hydroxyl directing the reduction 
in the transition state. Two possible competing chair-like transition states 86 and 87 
were proposed to account for the diastereoselectivity (Scheme 30). 
 
 
Scheme 30 Transition state of the Evans–Saksena reduction.54-56 
58 
 
Given the 1,3-diaxial interactions presented in the transition states 87, the transition 
state 86 is more favourable. Therefore, under Evans–Saksena reduction, anti-diol 
was preferentially formed.  
 
In contrast, to gain access to the syn-diol 79 the approach as reported by Narasaka58 
and Prasad57 was used. In brief, β-hydroxy ketone 80 was treated with sodium 
borohydride and triethyl borane in a solvent mixture of THF and methanol at −78 °C 
to generate the desired syn-diol 79 in a high yield (94%) (Scheme 26). Triethylborane 
may acts as a chelating agent that coordinated with β-hydroxy ketone 80 to form 
diethylborinic ester through a chelated 6-membered transition state in a 
half-chair-like conformation 88a and 88b (Scheme 31).  
 
 
Scheme 31 Transition state of the Narasakand–Prasad reduction.57, 58 
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The approach of a reducing agent is through an external hydride delivery. Addition of 
hydride from the bottom face 88b, leading to an initial conformation and formation 
of a twist-boat intermediate. On the other hand, hydride addition from the top face 
(pseudo-axial attack) 88a, resulting in an initial conformation of a product being in 
the chair conformation. 
 
The chair conformation would be lower in energy compared to that of the twist-boat, 
therefore the addition of hydride reagents showed a preference in attacking from 
the top face (pseudo-axial attack) 88a to form syn-diol as the major product. 
 
Following the successful synthesis of syn-diol 79, the next step involved synthesis of 
the cyclisation precursor 78 via olefin cross-metathesis.  
 
 
 
Scheme 32 Synthesis of S-(4-methylphenyl) 2-propenthioate 66. 
 
The S-(4-methylphenyl) 2-propenthioate 66 was prepared by following the 
procedure described by Fuwa (Scheme 32).40 Treatment of 4-methylbenzenethiol 90 
with sodium borohydride resulted in sodium thiolate formation. Subsequently, 
acryloyl chloride 89 was added in the presence of BHT and the desired 
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S-(4-methylphenyl) 2-propenthioate 66 was obtained in 51% yield. The sodium 
thiolate was a harder nucleophile and prone to react with the acid chloride. In this 
reaction, sodium borohydride will also reduce disulfide 91 back to thiol (Figure 10). 
 
 
Figure 10 Structure of disulfides 91. 
 
To prevent polymerization of both acrolyl chloride 89 and S-(4-methylphenyl) 
2-propenthioate 66, BHT was added into the reaction. 
 
The metathesis reaction that was used to form the α,β-unsaturated thioester 78 was 
a variation of the conditions reported by Lipshutz.59 Treatment of syn-diol 79 with 
excess S-(4-methylphenyl) 2-propenthioate 66, used 10 mol% of 2nd generation of 
Hoveyda-Grubbs catalyst and copper(I) iodide as a co-catalyst allowed for the 
formation of α,β-unsaturated thioester 78 in a high yield (93%) (Scheme 26). In the 
absence of copper(I) iodide co-catalyst, lower yields were obtained.42 After 
completion of the synthesis of α,β-unsaturated thioester 78, the oxy-Michael 
reaction was performed (Scheme 33). 
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Scheme 33 Stereoselective oxy-Michael addition to form di-substituted 
tetrahydropyran rings 76 and 77. 
 
Treatment of α,β-unsaturated thioester 78 with CSA formed the corresponding 
cis-tetrahydropyran product 76 in 90% yield. While, cyclisation of thioester 78 under 
buffered fluoride conditions resulted in trans-tetrahydropyran product 77 in 84% 
yield (Scheme 33). The products were confirmed by both 1-D, 2-D NMR spectroscopy 
and mass spectrometry and the data were consistent with previous findings of 
stereodivergent reactions reported by our group. Under TBAF-mediated conditions 
gave the 2,6-trans-tetrahydropyran, however under acid-mediated conditions 
2,6-cis-tetrahydropyran was obtained. Giving access to both cis- and 
trans-tetrahydropyran rings from the same starting material.41  
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Figure 11 1H and 1H-1H COSY NMR spectra of the cis-tetrahydropyran product 76.  
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The 1H NMR spectrum peaks at 7.37-7.17 ppm, which were assigned as the aromatic 
protons. A double-doublet peak at 4.89 ppm was assigned as H-9. Correlation of H-9 
in the COSY spectrum was shown with peaks at 1.95-1.90 ppm and 1.72 ppm, which 
were assigned as H-10a and H-10b with the coupling constants of 2.2 Hz and 11.8 Hz, 
respectively. Both H-10a and H-10b correlated with the peak at 4.31 ppm, which was 
assigned as H-11 with a coupling constant of 2.8 Hz. Correlation of H-11 in the COSY 
spectrum was shown with peaks at 1.83-1.79 ppm and 1.65 ppm and were assigned 
as H-12a and H-12b with a coupling constant of 2.8 Hz. Correlation of H-12a and 
H-12b in the COSY spectrum was shown with peaks at 4.49 ppm, which were 
assigned as H-13 with the coupling constants of 2.1 and 11.7 Hz. H-13 correlated 
with H-14a and H-14b at 2.98 and 2.77 ppm with the coupling constants of 6.9 and 
6.0 Hz (Figure 11 and Figure 12). 
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Figure 12 Coupling constants of the cis-tetrahydropyran product 76. 
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The structure of trans-tetrahydropyran product 77 was also elucidated by the same 
method (Figure 13 andFigure 14).
 
Figure 13 1H and 1H-1H COSY NMR spectra of the trans-tetrahydropyran product 77. 
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Figure 14 Coupling constants of the trans-tetrahydropyran product 77. 
 
The 1H NMR spectrum exhibited peaks at 7.33-7.11 ppm range which referred to the 
aromatic protons. A double-doublet peak at 4.89 ppm was assigned as H-9. 
Correlation of H-9 in the COSY spectrum was shown with peaks at 2.23-2.21 ppm and 
1.84 ppm, and were assigned as H-10a and H-10b with a coupling constant of 7.0 Hz 
for both. Both H-10a and H-10b correlated with the peak at 4.15-4.08 ppm, which 
was assigned as H-11. H-10b and H-11 had a coupling constant of 4.5 Hz. In the COSY 
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spectrum, H-11 correlated with peaks at 2.23-2.21 ppm and 1.56 ppm, which were 
assigned as H-12a and H-12b, respectively. H-11 and H-12b had a coupling constant 
of 11.7 Hz. Correlation of H-12a and H-12b was shown with peaks at 3.29-3.19 ppm 
and were assigned as H-13. H-12b and H-13 had a coupling constant of 11.7 Hz. H-13 
correlated with H-14a and H-14b at 2.80 ppm and 2.36 ppm, respectively. H-14b and 
H-13 had a coupling constant of 10.9 Hz. Because the peaks of H-11, H-13, H-10a and 
H-12a in NMR spectrum were multiplets, corresponding coupling constants could not 
be obtained. 
 
The stereochemistry of both the cis-tetrahydropyran product 76 and 
trans-tetrahydropyran product 77 were confirmed by NOE correlation. It was 
presumed that the H-9 should have the NOE correlation to H-13 in the 
cis-tetrahydropyran 76 product. 
 
 
Figure 15 NOE correlation of the cis-tetrahydropyran 76. 
 
As expected, irradiation of H-9 was found to have large correlation (4%) with H-13 92. 
These two protons were oriented from the same side in spce. The H-9 also correlated 
with H-11 (0.3%) and H-10 (2%), which confirmed the stereochemistry of compound 
68 
 
76 as cis-tetrahydropyran (Figure 15). 
 
It was assumed that the H-9 in the trans-tetrahydropyran product 77 would not 
correlate with H-13, instead a correlation was expected between H-11 and H-13 in 
the trans-tetrahydropyran product 77, which was not present in the 
cis-tetrahydropyran 76 product. 
 
 
Figure 16 NOE correlation of the trans-tetrahydropyran product 93. 
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Irradiation of H-9 of the trans-tetrahydropyran product 77, no NOE correlation was 
observed between H-9 and H-13 (93), H-9 only correlated with H-11 (1%) and H-10 
(2%). The trans configuration was further confirmed by irradiation of H-13 (94). H-13 
correlated with H-12a (2%), H-12b (1%) and H-11 (3%) which supported the findings 
that H-13 and H-11 were on the same side. Irradiation of H-11 (95), showed a 
correlation with H-13 (3%), H-12a (2%), H-12b (1%), H-10a (1%) and H-10b (2%) 
confirming that the compound had the trans- stereochemistry (Figure 16). 
 
In 2000, Liebeskind and Srogl presented a new reaction for the synthesis of 
ketones.47, 60 The palladium-catalysed cross-coupling reaction between a thioesters 
96 and a boronic acids 97 proceeded in the presence of a copper co-catalysts to 
generate the corresponding ketones 98 (Scheme 34).  
 
 
Scheme 34 Ketones synthesis by the Liebeskind–Srogl reaction.47, 60 
 
Although the mechanism remains unclear, the ternary complex 100 as the reactive 
key intermediate was proposed by Liebeskind in 2004 (Figure 17).47 The soft copper 
(I) 99 reagent was shown to have an important role in the reaction process. This was 
based on the fact that soft copper (I) 99 favoured to coordinate with sulfur 96. As a 
thiophilic agent, CuTC 99 was assumed to help Pd–S bond polarised. The carboxylate 
group on CuTC 99 was also coordinated to boron 97, which may help to activate the 
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boron compound (Figure 17). 
 
Figure 17 Proposed mechanism for the Liebeskind–Srogl reaction.47, 60 
 
The synthesis of diospongin A 1 was carried out via a Liebeskind–Srogl reaction47, 60 
by following the procedure reported by Fuwa and co-workers to convert the 
thioester to the aryl ketone.40, 61  
 
 
Scheme 35 Synthesis of diospongin A 1 via Liebeskind–Srogl reaction. 
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Treatment of cis-tetrahydropyran 76 with phenylboronic acid in the presence of 
commercially available CuTC, triethyl phosphite ligand and 
tris(dibenzylideneacetone)dipalladium(0) as a catalyst resulted in the desired 
diospongin A 1 at an excellent yield (97%) (Scheme 35).  
 
The NMR data was consistent with those published in the isolation paper and the 
recent publication by Hashimoto and coworkers22 and are presented in Table 3. 
 
Table 3 Comparison of NMR data of diospongin A 1 between experimental and 
published data.22 
Experimental data (500 MHz, CDCl3) Literature
22 (500 MHz, CDCl3) 
7.98 (2H, dd, J = 5.2, 3.3 Hz, H-Ar) 7.99 (2H, dd, J = 7.4, 1.1 Hz)  
7.56 (1H, t, J = 7.4 Hz, H-Ar) 7.56 (1H, t, J = 7.4 Hz) 
7.46 (2H, t, J = 7.6 Hz, H-Ar) 7.45(2H, t, J = 7.4 Hz) 
7.31-7.21 (5H, m, H-Ar) 7.32-7.21 (5H, m) 
4.93 (1H, dd, J = 11.8, 2.0 Hz, H-6) 4.93 (1H, dd, J = 11.5, 1.7 Hz) 
4.68-4.62 (1H, m, H-2) 4.65 (1H, dddd, J = 11.5, 6.9, 5.7, 1.7 Hz) 
4.38 (1H, p, J = 2.8 Hz, H-4) 4.37 (1H, quint, J = 2.9 Hz) 
3.42 (1H, dd, J = 16.0, 5.8 Hz, H-1a) 3.42 (1H, dd, J = 16.0, 5.7 Hz) 
3.07 (1H, dd, J = 16.0, 6.8 Hz, H-1b) 3.07(1H, dd, J = 16.0, 6.9 Hz) 
1.99-1.93 (2H, m, H-3a, H-5a) 1.98-1.94 (2H, m) 
1.76 (1H, ddd, J = 14.4, 11.8, 2.8 Hz, H-5b) 1.76 (1H, ddd, J = 14.3, 12.0, 2.9 Hz) 
1.69 (1H, ddd, J = 14.2, 11.4, 2.8 Hz, H-3b) 1.68 (1H, ddd, J = 13.8, 11.5, 2.3 Hz) 
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Figure 18 1H-1H coupling constants of diospongin A 1. 
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Figure 19 1H and 1H-1H COSY NMR spectra of diospongin A 1. 
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The 1H NMR spectrum exhibited peaks at 8.00-7.21 ppm which were assigned as 
aromatic protons. A double-doublet peak at 4.93 ppm was assigned as H-6. 
Correlation of H-6 was shown with peaks at 1.99-1.96 ppm and 1.76 ppm, and were 
assigned as H-5a and H-5b with the coupling constants of 2.0 Hz and 11.8 Hz, 
respectively. Both H-5a and H-5b correlated with the peak at 4.38 ppm, which was 
assigned as H-4 with a coupling constant of 2.8 Hz. Correlation of H-4 in the COSY 
spectrum was shown with peaks at 1.95-1.93 ppm and 1.69 ppm, and were assigned 
as H-3a and H-3b with a coupling constant of 2.8 Hz. Correlation of H-3 in the COSY 
spectrum was shown with peaks at 4.68-4.62 and was assigned as H-2 with a 
coupling constant of 11.4 Hz. H-2 showed correlation with H-1 at 3.42 ppm and 3.07 
ppm with the coupling constants of 6.8 Hz and 5.8 Hz (Figure 19). 
 
Attempts to prepare diospongin B 2 using the same coupling conditions were 
unsuccessful. Disappointingly, the reaction did not proceed and only starting 
material was recovered, even when catalyst loadings (Table 4, Entries 1 and 2), 
temperature (Table 4, Entries 2 and 5) and reaction times (Table 4, Entries 1 and 3) 
were increased. 
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Table 4 Conditions applied to the synthesis of diospongin B 2. 
 
 
 
Entry 
Pd2(dba)3 
/mol% 
PhB(OH)2 
/eq. 
CuTC 
/eq. 
(EtO)3P 
/eq. 
Time 
/h 
Temperature Result 
1 5 1.5 1.5 4 24 rt 
starting 
material1 
2 10 1.5 1.5 8 24 rt 
starting 
material1 
3 5 1.5 1.5 4 48 rt 
starting 
material1 
4 10 3.0 3.0 8 24 rt 
starting 
material1 
5 10 1.5 1.5 8 24 reflux 
starting 
material1 
1. 1Fully recovered and characterised 
 
Changing the ligand from triethyl phosphite to Xphos or tri(o-tolyl) phosphine also 
did not result in a discernible formation of product and only starting material was 
recovered. 
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Given that the attempt to use the reaction conditions published by Liebeskind and 
Srogl.60 The reaction was instead treated with TFP as a ligand. However, this reaction 
also failed to generate the desired product 2.  
 
Next, the conversion of the thioester 77 to the desired phenyl ketone 2 was 
attempted by using Fukuyama coupling (Scheme 36).62 
 
 
Scheme 36 Attempted synthesis of diospongin B 2 via Fukuyama coupling. 
 
Initially, the thioester 77 was coupled with phenylzinc chloride in the presence of 
bis(triphenylphosphine)palladium(II) dichloride in toluene. The phenylzinc chloride 
was synthesised by treating zinc chloride with phenyllithium solution. The coupling 
reaction was monitored by TLC, and after 48 hours the starting material was fully 
consumed and several products were formed at room temperature. Comparing the 
crude 1H NMR data to published data,33 indicated that no diospongin B 2 had been 
formed. The purification process was challenging; therefore, no identifiable products 
were isolated. The Fukuyama coupling reaction was also attempted by treating 
thioester 77 with commercially available 5 M phenylzinc iodide solution. However, 
the reaction also did not result in any products of interest. 
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Alternative routes for the synthesis of diospongin B 2 were carried out according to 
another procedure reported by Liebeskind and Srogl.63 Cross-coupling the thioesters 
102 with organostannanes 103 with CuDPP 109, 
tris(dibenzylideneacetone)dipalladium(0) and TFP may provide the corresponding 
ketones 104 (Scheme 37). 
 
 
  
Scheme 37 Ketones synthesis by coupling of thioesters and organostannanes. 
 
A model study was conducted before applying the Liebeskind organostannane 
conditions to our system. The dodecanethioic acid S-p-tolyl ester 107 was chosen as 
the starting material for the model study because this starting was easy to synthesis 
and was one of examples shown in Liebeskind’s paper.63 The synthesis started with 
lauric acid 105 and thionyl chloride to generate acid chloride 106, which was then 
treated with 4-methylbenzenethiol 90 to provide dodecanethioic acid S-p-tolyl ester 
107 in a two-step sequence in 64% yield (Scheme 38). 
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Scheme 38 Synthesis of dodecanethioic acid S-p-tolyl ester 123. 
 
The CuDPP 109 catalyst was synthesised by refluxing diphenylphosphinic acid 108 
and copper(I) oxide in toluene according to a previously published procedure 
(Scheme 39).63  
 
 
Scheme 39 Synthesis of Cu(I) diphenylphosphinate 109. 
 
After successful completion of the synthesis of CuDPP 109 and dodecanethioic acid 
S-p-tolyl ester 107, the coupling reaction of dodecanethioic acid S-p-tolyl ester 107 
with 2-(tri-n-butylstannyl)furan, which was reported by Liebeskind and Srogl, was 
attempted (Scheme 40).63 
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Scheme 40 Synthesis of ketone 110 for the model study. 
 
The results show 1-furan-2-yl-dodecan-1-one 110 was successfully obtained and the 
1H NMR data corresponded to the paper.63 Given that the model study was 
successful, the same batch of CuDPP 109 was directly used for the reaction system 
(Scheme 41).  
 
 
Scheme 41 Attempted synthesis of diospongin B 2 by using organostannane coupling 
with thioester 77 as reported by Liebeskind and Srogl.63 
 
Using the same approach to the reaction with thioester 77 and tributylphenyltin, no 
observable reaction occurred, only the starting material was recovered. Moreover, 
the use of commercial sources of Cu(I) (CuTC), did not result in conversion to product 
(Scheme 41). Given the difficulty to direct conversion of 77 into diospongin B 2, an 
alternative multi-step approach was adopted (Scheme 42). 
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Scheme 42 Alternative routes to the synthesis of diospongin B 2. 
 
The revised synthesis of diospongin B 2 was proposed with the aim to form the 
Weinreb amide 112 from the protected thioester 113, followed by addition of single 
equivalent of phenyl lithium and deprotection with TBAF to generate diospongin B 2 
(Scheme 42).  
 
Initially, TIPS protection of the free hydroxyl on 77 was investigated. Unfortunately, 
no reaction was observed even when using excess TIPSCl, imidazole (Table 5, Entries 
1-3) and extended reaction times (Table 5, Entries 2 and 3).  
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Table 5 Conditions applied to the synthesis of 113. 
 
 
 
Entry Im/eq. TIPSCl/eq. Times/h Result 
1 1.2 1.1 24  Starting material 
2 3.6 3.0 24  Starting material 
3 3.6 3.0 48 Starting material 
4 10.8 9.0 72 2.3% yield 
 
Only a trace amount (2.3%) of product detected when using 10.8 equivalents of 
imidazole and 9.0 equivalents of TIPSCl (Table 5, Entry 4). TLC analysis indicated that 
the reaction was not complete after being stirred for 3 days.  
 
Attempts to protect the hydroxyl with TBSCl were also unsuccessful, the reaction 
was very slow and after 4 days, product 114 was only obtained in 15% yield (Scheme 
43). 
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Scheme 43 Synthesis of TBS-protected thioester 114. 
 
Further studies investigated the use of TIPSOTf with pyridine in an attempt to 
protect the free hydroxyl group on 77 (Scheme 44). Subsequently, it was found that 
if the reaction was carried out with 2 equivalents of TIPSOTf in pyridine and that the 
desired product 113 was formed in 57% yield after a reaction time of 24 hours, 
however trace amounts of starting material were still observed. Attempts to push 
the reaction to completion with 4 equivalents of TIPSOTf after 24 hours, complete 
consumption of the starting material was observed, resulting in product 113 in 69% 
yield.  
 
 
Scheme 44 Synthesis of TIPS-protected thioester 113. 
 
Weinreb amide 112 formation was attempted by adding N,O-dimethylhydroxyamide 
to 113 in THF (Scheme 42). The reaction mixture was monitored by TLC, and after 24 
hours, TLC analysis of the reaction mixture indicated the presence of several 
different products. Analysis of the crude reaction mixture by 1H NMR spectroscopy 
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resulted in a complex spectrum with no evidence for the formation of 112.  
 
 
Scheme 45 Attempted synthesis of aldehyde 116 via Fukuyama reduction. 
 
Next, the procedure reported by Fuwa was followed and we envisaged that 
reduction of the thioester 77 to aldehyde 116 may occurred via Fukuyama reduction 
by utilising palladium on carbon and triethylsilane.40 Disappointingly, after 2 days, no 
reduction of the thioester was observed (Scheme 45). Only the TES-protected 
thioester was obtained 115. Due to the failed reduction, alternative routes were 
sought to reduce the thioester 77 to aldehyde 116 by using DIBAL-H (Scheme 46). 
 
 
Scheme 46 Attempted synthesis of aldehyde 116. 
 
Difficulties were also encountered when DIBAL-H was used as the reductant. The 
reaction resulted in complex mixtures and with no aldehyde peak was observed in 
the 1H NMR spectrum. 
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Due to the failed efforts to convert the thioester 77 to aldehyde 116 by using 
Fukuyama procedure and DIBAL-H reduction, attention was turned to reduction of 
the thioester 77 to alcohol 118, followed by a literature procedure reported by 
Xian18 to give access to generate diospongin B 2 (Scheme 47). 
 
 
Scheme 47 Synthetic approach towards diospongin B 2 as proposed by Xian and 
co-workers.18 
 
The Xian group proposed that synthesis of diospongin B 2 began with selective 
oxidation of the primary alcohol 118 by using TEMPO and sodium hypochlorite 
generated aldehyde 116. Subsequently, 116 was transferred to 117 under the 
Grignard reaction. Finally, Dess–Martin oxidation was applied to complete the 
synthesis of diospongin B 2.18 
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Scheme 48 Attempted synthesis of alcohol 119. 
 
Initial attempts to prepare alcohol 119 by treating protected thioester 113 with 
lithium aluminium hydride gave thioether 120 (Scheme 48). The structure of 120 was 
elucidated by using 1D, 2D NMR techniques and 1H-1H COSY spectroscopy (Figure 20). 
The 1H NMR spectrum exhibited peaks in the 7-8 ppm which were assigned as 
aromatic protons. A triplet peak at 5.06 ppm which was assigned as H-9. Correlation 
of H-9 in the COSY spectrum was shown with peaks at 2.11-2.03 ppm and 1.78-1.54 
ppm, which were assigned as H-10a and H-10b with a coupling constant of 6.8 Hz. 
Both H-10a and H-10b correlated with the peak at 4.16-4.11 ppm, which was 
assigned as H-11. H-11 in the COSY spectrum correlated with peaks at 1.78-1.54 ppm 
for one proton, which was assigned as H-12.The peak at 2.11-2.03 ppm was assigned 
to another proton of H-12. H-12 in the COSY spectrum correlated with peaks at 
3.66-3.60, which was assigned as H-13. H-13 correlated with H-14 at 1.78-1.54 ppm. 
H-14 correlated with peaks at 3.58-3.51 ppm, and was assigned as H-15. 
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Figure 20 1H-1H COSY spectrum of compound 120. 
 
Alternative methods for reducing thioester 113 with L-selectride® and sodium 
borohydride were considered. Surprisingly, with the use of different reducing 
reagents also resulted in the formation of thioether 120 (Scheme 49). 
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Scheme 49 Reduction of thioester 113. 
 
An alternative approach to synthesise diospongin B 2 was also attempted. The 
synthetic approach started with transesterification of the thioester 113 to ether 121, 
followed by reduction, Grignard addition, benzylic oxidation with manganese dioxide 
and finally deprotection to form diospongin B 2 (Scheme 50). 
 
 
Scheme 50 Alternative approach to the synthesis of diospongin B 2 starting from 
transesterification of the thioester 113. 
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The transesterification was attempted using a procedure reported by Hanessian.64 
The reaction was carried out by treatment of the thioester 113 with silver(I) 
trifluoromethanesulfonate in a 1:1 dichloromethane and methanol solvent system in 
the presence of triethylamine. Unfortunately, the reaction failed to provide the 
desired product 121. Analysis of the crude reaction mixture by 1H NMR spectrum 
resulted in a complex mixture, which made it challenging to isolate all the individual 
products (Scheme 50). 
 
Table 6 Conditions applied to the synthesis of 111. 
 
 
 
Entry PhLi/eq. Solvent Additive Result 
1 1.1 THF - Complex mixture 
2 1.5 THF - Complex mixture 
3 2.0 THF - Complex mixture 
4 1.1 THF TMEDA Complex mixture 
5 1.1 Et2O - Complex mixture 
6 1.1 Et2O TMEDA Complex mixture 
 
It was assumed that the diospongin B 2 would be synthesised by phenyllithium 
addition. Several approaches to synthesise 111 via phenyllithium to 113 were 
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attempted. Surprisingly, different amounts of PhLi resulted in a complex mixtures, 
which was difficult to purify (Table 6, Entries 1-3). Using TMEDA as an additive (Table 
6, Entries 4 and 6) as well as using different solvents (Table 6, Entries 5 and 6) were 
also attempted. However, these conditions resulted in the formation of many 
unknown products but were unsuccessful at generating the desired product 111. 
 
Finally, the synthesis of diospongin B 2 was completed by treating thioester 77 with 
phenyllithium (2.2 eq.) at −78 °C, which was warmed up to room temperature 
overnight to form diospongin B 2 in 55% yield (Scheme 51). 
 
 
Scheme 51 Synthesis of diospongin B 2 with phenyllithium. 
 
The NMR spectroscopic data of diospongin B 2 was consistent with those presented 
in the paper published by Tong and co-workers, as shown in Table 7.33  
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Table 7 Comparison of NMR data of diospongin B 1. 
Experimental data (500 MHz, CDCl3) Literature
33 (500 MHz, CDCl3) 
8.00-7.98 (2H, m, H-Ar) 8.01-7.94 (2H, m) 
7.60-7.53 (1H, m, H-Ar) 7.62-7.55 (1H, m) 
7.49-7.46 (2H, m, H-Ar) 7.51-7.44 (2H, m) 
7.37-7.22 (4H, m, H-Ar) 7.37-7.31 (4H, m) 
7.24-7.22 (1H, m, H-Ar) 7.25-7.19 (1H, m) 
5.20 (1H, t, J = 4.3 Hz, H-6) 5.19 (1H, t, J = 4.3 Hz) 
4.24 (1H, dddd, J = 9.5, 6.6, 7.0, 3.0 Hz, 
H-2)  
4.23 (1H, ddt, J = 9.2, 6.6, 3.4 Hz) 
4.06-4.00 (1H, m, H-4) 4.02 (1H, tt, J = 9.2, 4.2 Hz) 
3.46 (1H, dd, J = 15.8, 7.0 Hz, H-1a) 3.45 (1H, dd, J = 15.7, 7.2 Hz) 
3.18 (1H, dd, J = 15.8, 6.6 Hz, H-1b) 3.17 (1H, dd, J = 15.8, 6.0 Hz) 
2.53 (1H, ddt, J = 13.8, 4.3, 1.7 Hz, H-5a)  2.52 (1H, dtd, J = 13.4, 3.8, 1.7 Hz) 
2.09-2.04 (1H, m, H-3a)  2.11-2.01 (1H, m) 
1.92 (1H, ddd, J = 13.8, 9.9, 4.3 Hz, H-5b) 1.92 (1H, ddd, J = 13.4, 9.8, 5.2 Hz) 
- 1.73 (1H, br) 
1.51 (1H, dt, J = 12.5, 9.5 Hz, H-3b) 1.51 (1H, dt, J = 12.6, 9.5 Hz) 
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Figure 21 1H and 1H-1H COSY NMR spectra of diospongin B 2. 
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Figure 22 Coupling constants of diospongin B 2. 
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The structure of diospongin B 2 was elucidated by 1-D and 2-D NMR techniques with 
1H-1H COSY spectroscopy (Figure 22). The 1H NMR spectrum exhibited peaks at 
8.00-7.22 ppm which were assigned as aromatic protons. A triplet peak at 5.20 ppm 
was assigned as H-6. Correlation of H-6 in the COSY spectrum were shown with 
peaks at 2.53 ppm and 1.92 ppm and were assigned as H-5a and H-5b, respectively, 
with a coupling constant of 4.3 Hz. Both H-5a and H-5b correlated with the peak at 
4.06-4.00 ppm, which was assigned as H-4. Correlation of H-4 in the COSY spectrum 
was shown with peaks at 2.09-2.04 ppm and 1.51 ppm, and were assigned as H-3a 
and H-3b. H-3b and H-4 had a coupling constant of 9.5 Hz. Correlation of H-3a and 
H-3b in the COSY spectrum was shown with peaks at 4.24 ppm, whihc was assigned 
as H-2. H-3a and H-2 had a coupling constant of 3.0 Hz. H-3b and H-2 had a coupling 
constant of 9.5 Hz. H-2 correlated with H-1 at 3.46 ppm and 3.18 ppm with the 
coupling a constant of 7.0 Hz with H-1a, and a coupling constant of 6.6 Hz with H-1b 
(Figure 22).  
 
1.2.4. Invesitigating the stereodivergent oxy-Michael cyclisation to 
α,β-unsaturated ketones 
Thioesters are shown to be more enone-like compared to oxoesters because the 
oxygen lone pair of oxoesters has a better orbital overlap with C=O π*.65 We decided 
to investigate the possibility of distereo divergence on an enone system. To test this 
hypothesis, ketones 122 and 123 were used as cyclisation precursors, which 
underwent both acid and buffered TBAF oxy-Michael cyclisation conditions (Scheme 
52). 
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Scheme 52 Invesitigating the stereodivergent oxy-Michael cyclisation to ketones 122 
and 123. 
 
Synthesis of ketones 122 and 123 is presented in (Scheme 53 and Scheme 56). 
 
 
Scheme 53 Synthesis of ketone 122. 
 
Treatment of syn-diol 79 with excess 3-buten-2-one 124 using 10 mol% of 2nd 
generation of Grubbs catalyst in refluxing diethyl ether gave ketone 122 in a good 
isolated yield (71%), however the spontaneously cyclised product 125 was also 
formed in 4% yield. This may be due to the greater reactivity (lower LUMO) of the 
α,β-unsaturated ketone compared to the thioester. 
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The cross-metathesis substrate 128 was synthesised from acrolein 126 by the 
Grignard addition to form product 127 in a yields of 42%. Subsequently, 
manganese(IV) oxide oxidation provided 128 enone with a low yield of 10% (Scheme 
54).  
 
 
Scheme 54 Synthesis of 1-phenylprop-2-en-1-one 128. 
 
In order to improve the yield, an alternative reaction as proposed by Iwasa,66 was 
considered (Scheme 55). 
 
 
Scheme 55 Synthesis of 1-phenylprop-2-en-1-one 128 by following the procedure as 
reported by Iwasa and co-workers.66 
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Synthesis of 128 was instead carried out by treating 3-chloropropiophenone 129 
with triethylamine in chloroform for 18 hours at room temperature. To our delight, 
128 was successfully obtained in a high yield (98%). 
 
Ketone 123 was obtained in a good isolated yield (65%) by treatment of syn-diol 79, 
with excess of 1-phenylprop-2-en-1-one 128, in the presence of 10 mol% of 2nd 
generation of Hoveyda-Grubbs catalyst in refluxing diethyl ether for 5 hours. The 
spontaneously cyclised product was also obtained in 30% yield. The phenyl enone 
was even more reactive (had a lower LUMO) compared to methyl enone, which was 
presumably due to conjugation. 
 
 
Scheme 56 Synthesis of ketone 123. 
 
With the cyclisation precursor 122 and 123 being synthesised, investigating the 
stereodivergent oxy-Michael reaction to ketones were performed under both TFA 
and buffered TBAF conditions (Scheme 57 and Scheme 58).  
 
97 
 
 
Scheme 57 Invesitigating the stereodivergent oxy-Michael cyclisation to ketone 122 
under buffered TBAF and TFA conditions. 
 
Treating ketone 122 with both TFA-mediated and buffered TBAF conditions only 
generated the cis-tetrahydropyran product 125, where the stereodivergence 
phenomenon had disappeared.  
 
 
Scheme 58 Invesitiging the stereodivergent oxy-Michael cyclisation to ketone 123 
under buffered TBAF and TFA conditions. 
 
By using ketone 123 as a cyclisation precursor, under TFA condition, was provided the 
expected cis-tetrahydropyran in 30% yield. Under TBAF condition the 
cis-tetrahydropyran was also obtained in 65%. Taken together, it can be concluded 
that by using ketones as cyclisation precursors no stereodivergent formation of 
cis-tetrahydropyran and trans-tetrahydropyran could be realised.   
98 
 
1.3. Conclusions and Future work 
The stereodivergent oxy-Michael reaction was successfully applied for the synthesis 
of the natural products, diospongin A 1 and B 2. The method provides a new 
synthetic route to produce both diospongin A 1 and B 2 in 6 steps with an overall 
yield of 24% and 13%, respectively. 
 
The α,β-unsaturated thioesters were found to be good cyclisation precursors for the 
stereodivergence to form both cis- and trans-tetrahydropyrans. The α,β-unsaturated 
thioesters under TBAF-mediated conditions gave the 2,6-trans-tetrahydropyran, 
however under acid-mediated conditions 2,6-cis-tetrahydropyran was obtained. In 
contrast, by using ketones as cyclisation precursor no stereodivergence was 
observed.  
 
Previous computational studies have shown that the 4-hydroxyl group was crucial for 
the stereodivergence to form both cis- and trans-tetrahydropyrans.41 When 
cyclisation was attempted with the 4-hydroxyl group removed or protected, it was 
found that the stereodivergence vanished. These findings are in agreement with the 
data presented in the previous computational studies. 
 
The α,β-unsaturated thioesters were found to be good cyclisation precursors, 
however converting the thioesters to other substrates was not always easy.  
It was found that by reducing the α,β-unsaturated thioesters with NaBH4 or LiAlH4 or 
L-selectride® led to thioether formation. For these interesting results, future work 
will need to be performed to investigate the thioester reduction by exploring other 
thioester substrates to verify this type of reaction.  
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trans-tetrahydropyran  N-acyl aminal 
2. Studies Towards the Synthesis of Tetrahydropyran Core of 
(±)-Psymberin/Ircinistatin A 
2.1. Introduction 
Psymberin and ircinistatin A 3 were isolated from different sponges and were proven 
to have an identical structure. Psymberin/ircinistatin A 3 is one of the 36 natural 
products that is contained in the pederin family; several of these natural products 
are presented in Figure 23.67 The skeleton of the pederin group generally possesses 
an N,O-aminal moiety and a 2,6-trans-tetrahydropyran core.  
 
 
  
Figure 23 Natural products in the pederin family. 
 
 
 
 dihydroisocoumarin 
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In addition to their structural similarity, many of natural products in the pederin 
family were found to possess significant antitumor activity.68, 69 However, in contrast 
with other natural products in the pederin class, psymberin/ircinistatin A 3 was 
discovered to have remarkably different biological acitivity when compared to other 
family members against a wide range of cancer cell lines.67, 70 It was suggested that 
the unique structural feature, the dihydroisocoumarin unit resulted in a distinct 
cytotoxicity in comparison to other members of the pederin family.71 
 
2.1.1. Isolation and structure elucidation of Psymberin/Ircinistatin A 
In 2004, psymberin and ircinistatin A were discovered by two different research 
groups, Pettit70 and Crews.67 Ircinistatin A was initially isolated by the Pettit group 
from the Indo-Pacific marine sponge, Ircinia ramose, which had been collected in 
1991. Later, the Crews group also extracted the natural product psymberin, which 
was proven to possesse an identical structure to ircinistatin A from a Psammocinia sp. 
The name “psymberin” was derived from Psammocinia symbiont pederin.67 
 
In 2004, the configuration of ircinistatin A was first elucidated by the Pettit group.70 
The relative stereochemistry of the tetrahydropyran core in ircinistatin A was 
assigned as 8R*, 9S*, 11R*, 13R* by analysis of NOE data (Figure 24), however, only 
4 chiral centres had been assigned. 
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Figure 24 NOE contacts for C-5–C-12 Ircinistatin A. 
 
Interestingly, attempts to interpret the stereochemistry of psymberin by the Crews 
group has assigned all the configurations except for the C-4 position to give 5S*, 8S*, 
9S*, 11R*, 13R*, 15S*, 16R*, 17R*  based on NOE data and comparison to the 
related structure of the natural product, pederin 130.67 The results were compared 
with findings presented by the Pettit group, however at that time, ircinistatin A and 
psymberin were believed to be diastereomers with different stereochemistry at the 
C-8 position. Because of the unsuccessful efforts to fully assign the stereochemistry 
for these two natural products by NMR spectroscopic data, the synthesis of its 
analogues was used. 
 
In 2005, the Williams group initially confirmed the ambiguous configuration at C-4 
position via synthesis of model compounds of both anti (4S*,5S*) 134 and syn 
(4R*,5S*) amide side chain 133 as shown in Figure 25.72  
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Figure 25 Synthesis of amide side chain 133 and 134 as reported by the Williams 
group.72 
 
The structure of model compounds 133 and 134 were also confirmed by X-ray 
crystallographic analysis and concluded that the C-4 and C-5 stereocentres have an 
anti relationship. In the same year, the first total synthesis and completed 
stereochemical assignment of psymberin/irciniastatin A 3 was presented by De 
Brabander group, in which was confirmed that psymberin/irciniastatin A 3 had 9 
chiral centres with 4S*, 5S*, 8S*, 9S*, 11R*, 13R*, 15S*, 16R*, 17R* stereochemistry, 
and also clearly revealed that psymberin and irciniastatin A were identical.73 
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Table 8 Stereochemistry elucidated of psymberin/irciniastatin A 3 carried out by 
different groups. 
 
 C-4 C-5 C-8 C-9 C-11 C-13 C-15 C-16 C-17 
2004 
Pettit group70 
(Ircinistatin A) 
N/A N/A R S R R N/A N/A N/A 
Only elucidated 4 chiral centres 
2004 
Crews group67 
(Psymberin) 
N/A S S S R R S R R 
1. Elucidated all chiral centres except C-4 position 
2. C-8 position is opposite to Ircinistatin A 
2005 Williams 
group72 
S S N/A N/A N/A N/A N/A N/A N/A 
The first one to confirm the C-4 position 
2005 De 
Brabandergroup73 
S S S S R R S R R 
1. The first total synthesis to confirm all stereochemistry 
2. Ircinistatin A and psymberin are identical 
 
2.1.2. Biological activity 
Natural products derived from marine organisms have attracted considerable 
interest in the search for therapeutic efficacy in the treatment of cancer.74 
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Psymberin/ircinistatin A 3, natural products extracted from marine sponges, have 
shown to be potential anticancer drug candidates, because of their extremely potent 
cytotoxicity, and highly selectivity against numerous cancer cell lines.67, 70 
 
Psymberin/ircinistatin A 3 was first isolated by using bioassay-guided techniques, in 
which it displayed strong growth inhibition (GI50, 50% growth inhibition) at 
concentrations ranging from 4.1 to 2.4 nM to against the P388 leukemia and six 
other human cancer cell lines, including BXPC-3, MCF-7, SF268, NCI-H460, KM20L2 
and DU-145.70 In addition, psymberin/ircinistatin A 3 has also displayed antivascular 
activity and inhibited human umbilical vein endothelial cells (HUVEC) at GI50 <0.0005 
μmg/mL, as shown in Table 9. 
 
Table 9 Inhibition of cancer cell line growth (GI50, μg/mL) by psymberin/ircinistatin A 
3.70 
 Human cancer cell line Psymberin/Ircinistatin A 
pancreas BXPC-3 0.0038 
breast MCF-7 0.0032 
CNS SF268 0.0034 
lung NCI-H460 <0.0001 
colon KM20L2 0.0027 
prostate DU-145 0.0024 
leukemiaa P388 0.00413 
normal endothelial HUVECb <0.0005 
a Murine. b BD-Biosciences Clontech. 
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Psymberin/ircinistatin A 3, was further investigated by the national cancer institute 
(NCI), Developmental therapeutics program against 60 human cancer cell lines, as 
shown in Table 10.67  
 
Table 10 Differential sensitivities (LC50) of various cell lines to psymberin/ircinistatin 
A 3 as identified by the national cancer institute developmental therapeutics in vitro 
screening program.67 
Cell line LC50 (M) Cell line LC50 (M) 
leukemia  melanoma  
CCRF-CEM >2.5 x 10-5 LOX IMVI >2.5 x 10-5 
HL-60(TB) >2.5 x 10-5 MALME-3M <2.5 x 10-9 
K-562 >2.5 x 10-5 SK-MEL-2 >2.5 x 10-5 
MOLT-4 >2.5 x 10-5 SK-MEL-5 <2.5 x 10-9 
RPMI-8226 >2.5 x 10-5 SK-MEL-28 1.41 x 10-5 
SR >2.5 x 10-5 UACC-257 >2.5 x 10-5 
  UACC-62 <2.5 x 10-9 
breast cancer  colon cancer  
MCF7 >2.5 x 10-5 HCC-2998 3.76 x 10-7 
HS 578T >2.5 x 10-5 HCT-116 <2.5 x 10-9 
MDA-MB-435 <2.5 x 10-9 HT29 >2.5 x 10-5 
NCI/ADR-RES 1.9 x 10-5 SW-620 >2.5 x 10-5 
T-47D 1.36 x 10-5   
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Psymberin/ircinistatin A 3 displayed excellent antitumor activity at the nanomolar 
level concentration with a LC50 value <2.5 x 10
-9 M against colon cancer cell lines 
(HCT-116), melanoma cancer lines (MALME-3M, SK-MEL-5 and UACCC-62) and a 
breast cancer cell line (MDA-MB-435). Based on the results, psymberin/ircinistatin A 
3 was found to have a high level of selectivity towards melanoma cancer cell lines, 
with 104-fold potency differences in cytotoxicity among some closely related cell 
lines. 
 
2.1.3. Previous synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin 
A 
Reviewing the literature, synthetic approaches to the total synthesis of 
psymberin/ircinistatin A 3 have been reported by 9 different research groups.73, 75-82 
Strategies to construct the tetrahydropyran core include oxidative cyclisation,73, 83, 84 
PhI(OAc)2-mediated cyclisation,
76 oxidative cyclisation of allenic alcohols, 
intromolecular cyclisation of epoxy alcohols,77, 80, 85, 86 lactone intermediate,78, 79 and 
oxy-Michael addition.81, 82, 87 
 
2.1.3.1. Synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin A via 
oxidative cyclisation 
In 2005, the first total synthesis of psymberin/ircinistatin A 3 was carried out by De 
Brabande and co-workers (Scheme 59).73 Retrosynthetically, psymberin/ircinistatin A 
3 was disconnected to three main fragments, including psymberic acid 135, aromatic 
aldehyde 136 and tetrahydropyran core 137.  
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The key tetrahydropyran formation step was accessed by ozonolysis of 138 to 
provide lactol, which was then trapped as acetate and generated 139 in 81% yield, 
over two steps. 
 
 
Scheme 59 Synthesis of the tetrahydropyran core of psymberin/ircinistatin A 
139 as reported by De Brabander and co-workers.73 
 
In the same year, Floreancig and co-workers presented partial synthesis of the N-7– 
C-25 fragment of psymberin/ircinistatin A 140.83 The key tetrahydropyran formation 
step used the same strategy as described by De Brabander group.73 
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Scheme 60 Retrosynthetic analysis of N-7 to C-25 fragment of psymberin/ircinistatin 
A 140 as reported by Floreancig and co-workers.83 
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As presented in Scheme 60, the cyclisation precursor 143 was obtained via a 
Mukaiyama aldol reaction, which coupled the fragments 144 and 145. Followed by 
the reduction of 143 to give 142. Next, the key tetrahydropyran core 141 was 
synthesised by applying the ozonolysis and an acetylation reaction. 
 
In 2013, Pietruszka and co-workers reported the synthesis of 
8-desmethoxypsymberin 146.84 The retrosynthetic plan was to disconnect the 
8-desmethoxypsymberin 146 into three fragments 147, 150 and 151, which were in a 
similar manner to the retrosynthetic plan proposed by De Brabander’s group.73 
Ozonolysis, acetylation and allylation of diol 152 in the presence of 
allyltrimethylsilane and boron trifluoride diethyl etherate provided the 
tetrahydropyran core 153 in 60% yield (Scheme 61). 
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Scheme 61 Retrosynthetic analysis of desmethoxypsymberin 146 as reported by 
Pietruszka and co-workers.84 
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2.1.3.2. Synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin A via 
PhI(OAc)2-mediated cyclisation 
In 2007, the Huang group reported a new method for the synthesis of 
2-(N-acylaminal)-substituted tetrahydropyrans 157 by the use of iodobenzene 
diacetate as an oxidant.76 
 
Coupling the fragments 162 and 163 by a Mukaiyama aldol reaction provided 161. 
The aldol product 161 was then carried through a multi-step sequence to prepare 
enamide 160. The reactions included reduction of ketone to form diol, deprotection 
of the benzyl protecting group, and were followed by Dess–Martin oxidation and 
Takai vinyl iodide formation giving 160. Next, the vinyl iodide 160 was coupled with 
amide 159, which resulted in the cyclisation precursor 158. The synthesis of 
2-(N-acylaminal)-substituted tetrahydropyrans 157 was completed via a 
iodobenzene diacetate oxidative cyclisation (Scheme 62).  
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Scheme 62 Retrosynthetic analysis of psymberin/ircinistatin A 3 as reported by the 
Huang group.76 
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2.1.3.3. Synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin A via 
intromolecular cyclisation of epoxy alcohols 
In 2008, Smith III and coworkers reported the total synthesis of 
psymberin/ircinistatin A 3 in a 21-step linear sequence.85 The intermolecular 
cyclisation of 168 via a 6-exo-tet pathway was performed by using 20 mol% CSA and 
resulted in the desired trans-tetrahydropyran 167 in 74% yield (Scheme 63). 
 
The other possible 7-endo-tet cyclised product was not observed by NMR. It was 
assumed that the cationic character in α-position was destablilised by the methyl 
ester electron-withdrawing group, thus the reaction favoured to occur in the 
β-position via a 6-exo-tet pathway. 
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Scheme 63 Synthesis of the tetrahydropyran core 167 of psymberin/ircinistatin A as 
reported by Smith III and co-workers.77, 85 
 
The same cyclisation method was also presented by Iwabuchi and co-workers.80, 86 
Treating 169 with catalytic amount of CSA led to the formation of the 
tetrahydropyran ring in 83% yield (Scheme 64). 
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Scheme 64 Synthesis of the tetrahydropyran core of psymberin/ircinistatin A as 
reported by Iwabuchi and co-workers.80, 86 
 
2.1.3.4. Synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin A via 
lactone intermediate 
 
In 2000, Konopelski and co-workers demonstrated the total synthesis of 
psymberin/ircinistatin A 3. Synthesis of the tetrahydropyran ring was achieved via 
the lactone intermediate 174 (Scheme 65).78 
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Scheme 65 Synthesis of the tetrahydropyran core of psymberin/ircinistatin A 177 as 
reported by Konopelski and co-workers.78 
 
The reaction to form lactone involved acetylation of 172 followed by Dieckmann 
condensation to generate β-keto lactone 174. The resulting intermediate 174 was 
then processed through the following 3-step sequence: methyl enol ether formation, 
DIBAL-H reduction and conjugate addition of vinylmagnesium bromide to the 
dihydropyranone 176, which resulted in β-vinyl ketone 177. 
 
In the same year, Crimmins and co-workers reported the total synthesis of 
psymberin/ircinistatin A 3 in 19 steps with an overall yield of 6% (Scheme 66 and 
Scheme 67).79 
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Scheme 66 Retrosynthetic analysis of psymberin/ircinistatin A 3 as reported by 
Crimmins and co-workers.79 
 
The retrosynthetic disconnections for the psymberin/ircinistatin A 3 relied on the 
coupling of acid chloride 178 with hemiaminal 179. The tetrahydropyran ring 180 
was derived from the addition of enolsilane 182 to acetate 181. 
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Scheme 67 Synthesis of tetrahydropyran core of psymberin/ircinistatin A 
 181 as reported by Crimmins and co-workers.79 
 
Synthesis of the tetrahydropyran ring 181 began with p-methoxybenzylidine acetal 
183, which was obtained in 2 steps from 2-deoxy-D-ribose. The key lactone 
intermediate 189 was prepared in a multi-step sequence, including methylation of 
183, followed by dihydroxylation-oxidative cleavage, aldol reaction, TBS-protection 
and deprotection to yield the cyclisation precursor 188. The cyclisation precursor 
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188 was then subjected to acid-catalysed cyclisation to provide lactone 189. 
Subsequently, lactone 189 was protected as benzyl ether and then processed 
through reductive acetylation to generate acetate 181.88 Acetate 181 was obtained 
from 2-deoxy-D-ribose in 9 steps with an overall yield of 34% (Scheme 67). 
 
2.1.3.5. Synthesis of the tetrahydropyran core of (±)-psymberin/ircinistatin A via 
oxy-Michael addition 
In 2011, Hong and co-workers synthesised the psymberin/ircinistatin A 3 with 24 
steps as the longest sequence.81 The key tetrahydropyran was formed via 
organocatalytic oxa-conjugate addition of 191 in the presence of 
9-anthracenecarboxylic acid, which catalysed the reaction to form the cyclised 
product 192 in 92% yield with a diastereomeric ratio of 10:1 (trans:cis) (Scheme 68). 
 
 
Scheme 68 Synthesis of the tetrahydropyran core of psymberin/ircinistatin A 
192 as reported by Hong and co-workers.81 
 
Both the Harrowven82 and Pietruszka87 groups also used the oxy-Michael addition to 
form the tetrahydropyran (Scheme 69). 
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Scheme 69 Synthesis of the tetrahydropyran core of psymberin/ircinistatin A as 
reported by the Harrowven82 and Pietruszka groups.87  
 
The cyclisation precursor 193 was prepared from lactone 198 in the presence of 
liquid ammonia in THF. Both Harrowven82 and Pietruszka87 used the same lactone 
198 to prepare the cyclisation precursor 193. The synthesis of lactone 198 was 
shown in Scheme 70. 
 
 
Scheme 70 Synthesis of lactone 198 as reported by the Pietruszka group.87 
 
The synthesis began with aldol reaction between 156 and 195 to generate 196 in 
high yield (83%), followed by the reduction and acid-catalysed cyclisation to form 
121 
 
lactone 198 in 75% yield. 
 
2.1.4. Structure–activity relationship (SAR) 
Structure–activity relationships (SAR) provide a way to probe the relationship 
between chemical structures and their biological activities. Moreover, they help to 
determine the biological effects of certain structural features. Understanding the 
relationship between the structure of a drug and its biological activity enables the 
preparation of more effective drugs.89, 90  
 
Many SAR studies of psymberin/ircinistatin A 3 have been reported.71, 75, 80, 86, 91-96 In 
2006, the first SAR study was carried out by De Brabander group, in which two 
psymberin/ircinistatin A analogues were synthesised: C-8 and C-4-epimers 199 and 
200 (Figure 26).71  
 
 
Figure 26 Structure of 199 and 200.71 
 
It was hypothesised that the dihydroisocoumarin fragment may be an important 
subunit, which showed distinct cytotoxicity in psymberin/ircinistatin A 3 among 
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other members of the pederin family. Based on this hypothesis, psympederin 201 
and its epimer 202 were synthesised. The psymberin-pederin hybrid 201 and 202 
were modified to contain a pederin-like side chain with a dimethoxy unit rather than 
containing the dihydroisocoumarin moiety present in the originally structure of 
psymberin/ircinistatin A 3 (Figure 27).71 
 
 
 
Figure 27 Structure of psympederin and its C-8 epimer 201 and 202.71 
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The cytotoxicities of the four analogues (199, 200, 201 and 202) were tested for 
human cell lines, including colon tumour (KM12), prostate tumour (PC3), melanoma 
(SK-MEL-5) and glioblastoma (T98G), the results are summarised in Table 11. 
 
Table 11 Cytotoxicities of psymberin/ircinistatin A 3 and its analogues 199, 200, 201 
and 202 against various human tumour cell lines.a71 
 
  
            IC50 [nM] 
Entry Compound 
Colon 
tumour 
(KM12) 
Prostate 
tumour 
(PC3) 
 
Melanoma 
(SK-MEL-5) 
Glioblastoma 
(T98G) 
1 3 0.45 ± 0.01 0.98 ± 0.12 2.29 ± 0.13 1.37 ± 0.06 
2 199 37.1 ± 5.5 200.2 ± 27.6 352.0 ± 12.1 85.8 ± 48.4 
3 200 
126.08 ± 
8.6 
346.5 ± 
102.8 
762.8 ± 70.0 186.7 ± 51.3 
4 201 
710.9 ± 
35.8 
821.8 ± 89.1 >1000 >1000 
5 202 >1000 255.5 ± 11.4 >1000 >1000 
1. a The Promega Cell Titer Glo assay was utilised to measure cell viability after 
cells were exposed to compounds for 48 hours. 
2. IC50 values represent the mean of triplicate experiments ± standard error of the 
mean. 
124 
 
As shown in Table 11, psymberin/ircinistatin analogues, C-8 epimer 199 and C-4 
epimer 200 have displayed cytotoxicity activity against cancer lines (Table 11, Entries 
1-3). However, analogues 199 and 200 were about 100-fold less active compared to 
psymberin/ircinistatin A 3. Therefore, it was suggested that it is important to 
maintain the original stereochemistry of psymberin/ircinistatin A 3 at the C-4 and C-8 
position. On the other hand, without the dihydroisocoumarin unit in 
psymberin-pederin hybrid 201 and its C-8 epimer 202, a significant reduction in 
cytotoxicity was observed compared to psymberin/ircinistatin A 3 (Table 11, Entries 
4 and 5). The dihydroisocoumarin moiety has been described as a significant 
fragment in psymberin/ircinistatin A 3.  
 
In 2008, psymberin/ircinistatin A 3 was synthesised via oxidised of 
seco-psymberin/ircinistatin A 203 by the Huang group (Scheme 71).91 
 
 
Scheme 71 Psymberin/ircinistatin A 3 was synthesised via an oxidisation of 
seco-psymberin/seco-ircinistatin A 203.91 
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The antiproliferation activity of seco-psymberin/seco-ircinistatin 203 was evaluated 
in a human lung cancer cell line (HOP62). Interestingly, without the tetrahydropyran 
ring in the molecule, the antitumor activity of seco-psymberin/seco-ircinistatin A 203 
was significantly reduced, with a IC50 value >1 x 10
4 nM. Convincingly, the 
2-(N-acylaminal) substituted tetrahydropyran component in psymberin/ircinistatin A 
3 was an essential structure for its potent cytotoxic activity. 
 
In the same year, the Huang group published other SAR studies. The C-8 and C-9 
epimer of psymberin/ircinistatin A 204 was initially chosen as an analogue for the 
treatment of different human cancer cell lines.92, 93 The results are presented in 
Table 12. 
 
 
Figure 28 Structure of 8,9-epi-psymberin/8,9-epi-ircinistatin A 204.92, 93 
 
There is no doubt that psymberin/ircinistatin A 3 showed excellent cytotoxicity to all 
the cell lines investigated. However, the cytotoxic activity of the 
8,9-epi-psymberin/8,9-epi-ircinistatin A 204 was markedly reduced. Therefore, it was 
determined that the stereochemistry at the C-8 and C-9 position affected 
psymberin/ircinistatin A 3 cytotoxicity. 
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Table 12 Cytotoxicities of psymberin/ircinistatin A 3 and 
8,9-epi-psymberin/8,9-epi-ircinistatin A 204 against various human tumour cell 
lines.92, 93 
 
Psymberin/ 
Ircinistatin A  
3 
(IC50 nM) 
8,9-epi-psymberin/ 
8,9-epi-ircinistatin A  
204 
(IC50 nM) 
Cell line 
Human 
tissue 
type 
0.76 ± 0.07 6800 ± 244 ACHN kidney 
0.30 ± 0.03 3800 ± 301 DU145 prostate 
0.18 ± 0.02 2400 ± 431 H226 lung 
0.81 ± 0.14 4900 ± 187 HCT-116 colon 
0.42 ± 0.02 4600 ± 68 HOP62 lung 
0.27 ± 0.01 4200 ± 174 MB231 breast 
0.28 ± 0.03 3600 ± 155 MB435 melanoma 
0.28 ± 0.02 5200 ± 195 MKN45 gastric 
0.19 ± 0.02 3100 ± 341 PC3 prostate 
0.82 ± 0.04 4800 ± 177 SW620 colon 
0.84 ± 0.08 n.d NHDF normal 
1. a The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Technical bulletin 
288) was employed in this study. 
2. IC50 data are the mean value of six experiments with statistical significance 
calculated. 
3. n.d., not detected 
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In addition to the biological activities of the 8,9-epi-psymberin/8,9-epi-ircinistatin A 
204, modifications were made to the “psymberate” side chain of 205 and 206 and 
were tested against human lung cancer cell line HOP62. The results are displayed in 
Table 13. 
 
 
Figure 29 Structures of 205 and 206.92, 93 
 
When the side chain of psymberin/ircinistatin A 3 was modified to a methyl group 
(Table 13, Entry 2), the cytotoxic activities of both 205a and 206a were greatly 
decreased compared to that of psymberin/ircinistatin A 3. By changing the terminal 
double bond to a hydroxy group in 205b and 206b (Table 13, Entry 3), it was found 
that 205b was roughly 600-fold less effective when compared to 
psymberin/ircinistatin A 3, although it still demonstrated good cytotoxic activity 
against cancer cell lines (HOP62). Therefore, the terminal olefin was assumed to be 
an important group for the biological activity of psymberin/ircinistatin A. By 
replacing the terminal double bond for an aryl group in 205c and 206c (Table 13, 
Entry 4), the cytotoxic activity was highly decreased (>10000 nM). However, 
substitution of the aryl side chain in 205d and 206d resulted in a moderate 
cytotoxicity (Table 13, Entry 5). Based on these studies, C-4 and C-5 substitution 
cannot be removed to maintain a high cytotoxicity. The cytotoxicity was not 
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significantly dependent on modifying the double bond of the psymberate side chain 
to an aryl group. 
 
Table 13 Antitumor activities of “psymberate” side chain modified 
pysmberin/ircinistatin A 3 analogues against human lung cancer cell line (HOP62).a 92, 
93 
Entry R Compound IC50 (nM) Compound IC50 (nM) 
1 Psymberate 3 
0.42 ± 
0.02 
3 
4600 ± 
68 
2  205a >10000 206a >10000 
3 
 
205b 260 ± 36 206b >10000 
4 
 
205c >10000 206c >10000 
5 
 
205d 32 ± 1 206d 615 ± 15 
a The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Technical bulletin 
288) was employed in this study. IC50 data are the mean value of three 
experiments with statistical significance calculated. The value for 
psymberin/ircinistatin A in this assay is 0.42 nM. 
 
The biological effect attributed to the tetrahydropyran core in psymberin/ircinistatin 
A 3 was then further studied.92, 93 In a previous study, it was found that irciniastatin B 
131 (C-11 substituted with O) was about 10 times more active in inhibiting cell 
growth compared to psymberin/ircinistatin A 3 (C-11 substituted with -OH).70 
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Therefore, 11-deoxy-psymberin/11-deoxy-ircinistatin A was chosen as a model for 
modification so as to confirm the importance of the C-11 position in the 
tetrahydropyran unit. 
 
Four diastereomers of 11-deoxy-psymberin/11-deoxy-ircinistatin A were synthesised, 
including 207, 208, 209 and 210 (Figure 30), and the biological activities were tested 
in numerous human cancer cell lines. 
 
 
Figure 30 Stracture of 11-deoxy-psymberin/11-deoxy-ircinistatin A 207 and its 
diastereomers 208, 209 and 210.92, 93 
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Table 14 Antitumour activity of psymberin/ircinistatin A 3, 11-deoxy-psymberin/ 
11-deoxy-ircinistatin A 207 and its diastereomers 208, 209 and 210.92, 93 
(IC50 nM) 
Psymberin/Ircinistatin 
A 3 
207 208 209 210 
Cell 
line 
0.76 0.265 ± 0.008 n.d. n.d. 8.7 ± 0.18 
kidney 
(ACHN) 
0.30 
0.149 ± 
0.005 
n.d. n.d. 5.9 ± 0.18 
prostate 
(DU145) 
0.18 
0.034 ± 
0.004 
n.d. n.d. 1.6 ± 0.27 
lung 
(H226) 
0.42 
0.055 ± 
0.002 
177 ± 
6 
46 ± 7 3.0 ± 0.12 
lung 
(HOP62) 
0.27 
0.142 ± 
0.007 
n.d. n.d. 5.3 ± 0.15 
breast 
(MB231) 
0.28 
0.076 ± 
0.004 
n.d. n.d. 3.9 ± 0.48 
gastric 
(MKN45) 
0.19 
0.073 ± 
0.006 
n.d. n.d. 2.9 ± 0.21 
prostate 
(PC3) 
0.82 
0.160 ± 
0.015 
n.d. n.d. 6.1 ± 0.22 
colon 
(SW620) 
0.84 
0.066 ± 
0.004 
n.d. n.d. 3.8 ± 0.10 
normal 
(NHDF) 
IC50 data are the mean value of three experiments with statistical significance 
calculated. n.d., not detected. 
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The data indicated that 11-deoxy-psymberin/11-deoxy-ircinistatin A 207 had a higher 
cytotoxic activity compared to psymberin/ircinistatin A 3. However, the activities of 
the corresponding diastereomers 208, 209 and 210 are weaker or not present at all. 
Therefore, the hydroxyl group at the C-11 position was not important for 
cytotoxicity. 
 
In 2010, enantiomer of psymberin/ircinistatin A 211 and (+)-alkymberin 212 (Figure 
31) were synthesised by the Iwabuchi group.80 The cytotoxicity test of the 
enantiomer of psymberin towards HeLa cells indicated a GI50 value >1000 nM, which 
was not as efficient when compared to psymberin/ircinistatin A 3 (GI50 value of 1.2 
nM). However, by modifying the terminal double bond to an alkyne group the cell 
growth inhibition value was similar to that of psymberin/ircinistatin A 3. This was 
consistent with the results reported by the Huang group,92 who showed that the 
terminal double bond was tolerated replacing it by various substituents which have 
π-character. 
 
 
Figure 31 Structure of ent-psymberin/ent-ircinistatin A 211 and (+)-alkymberin 212.80 
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In 2011, Floreancig and co-workers synthesised various analogues 213, 214, and 215 
of pederin 130 and psymberin/ircinistatin A 3.75 The HCT-116 cell line was chosen to 
test the cytotoxicity.  
 
 
Figure 32 Structure of pedastatin 213.75 
 
Pedestatin 213 is a hybrid molecule of pederin 130 and psymberin/ircinistatin A 3 
(Figure 32). Based on the findings of the De Brabander group,71 the 
dihydroisocoumarin fragment in psymberin/ircinistatin A 3 was an important 
functional group for its cytotoxicity, for its cytotoxic activity, as was the cyclic 
pederate fragment in pederin 130. Thus, pedestatin 213 was synthesised by 
combining these two subunits with the original tetrahydropyran core.  
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Table 15 GI50 values of the natural products and analogs against HCT-116 cells.
75 
Entry Compound GI50 (nM) 
1 pederin 130 0.6 ± 0.1 
2 psymberin/ircinistatin A 3 0.052 ± 0.02 
3 pedestatin 213 0.004 ± 0.003a 
4 
8-desmethoxy-psymberin/ 
8-desmethoxy-ircinistatin A 214 
0.83 ± 0.1 
5 10-desmethoxy-pedestatin 215 0.068 ± 0.02 
a Average of two independent experiments. 
 
As shown in Table 15, the GI50 values of pedestatin 213 (0.004 ± 0.003 nM) indicated 
that it more efficient in inhibiting cell growth compared to both pederin 130 and 
psymberin/ircinistatin A 3. These findings are consistent with the results reported by 
the De Brabander group (Table 15, Entries 1-3).71 
 
  
Figure 33 Structure of 8-desmethoxy psymberin/8-desmethoxy ircinistatin A 214 and 
10-desmethoxy pedestatin 215.75 
 
 
134 
 
The importance of the alkoxy group in the N-acyl aminal linkage was also studied. In 
comparison with the 8-desmethoxy-psymberin/8-desmethoxy-ircinistatin A 214 and 
10-desmethoxy-pedestatin 215 (Figure 33) showed a weaker cytotoxicity compared 
to psymberin/ircinistatin A 3 and pedestatin 213. However, compounds 214 and 215 
retained excellent GI50 values (Table 15, Entries 2-5). Again, by comparing 
8-desmethoxy-psymberin/8-desmethoxy-ircinistatin A 214 and 
10-desmethoxy-pedestatin 215, the pedestatin compound 215 proved to be more 
potent compared to the psymberin/ircinistatin A analogue 214 and showed a greater 
ability in inhibiting cell growth (Table 15, Entries 4-5). In summary, 
dihydroisocoumarin and cyclic pederate fragments play an important role in the 
activity of pedestatin. The alkoxy group in the N-acyl aminal linkage is not required 
for biological activity.  
 
From previous reports, the hydroxyl group at C-11 position92 as well as the C-8 
position of methoxy group75 in psymberin/ircinistatin A 3 has been shown to be 
inessential for retaining cytotoxicity. Therefore, (+)-8-desmethoxy-11-deoxy- 
12-didesmethyl-psymberin/(+)-8-desmethoxy-11-deoxy-12-didesmethyl-ircinistatin 
A 216 (Figure 34), which was synthesised by the Smith group in 2016,96 was chosen 
as a psymberin/ircinistatin A 3 analogue. The gem-dimethyl group was assumed to 
be an important substituent for protein target binding.75 However, by removal of the 
gem-dimethyl group, C-8 and C-11 substituents showed that 216 still possessed a 
good level of cytotoxicity to against HCT-116 cell line even though the biological 
activity was reduced 800-fold compared to psymberin/ircinistatin A 3 (Table 16). 
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Figure 34 Stracture of 216 
(+)-8-desmethoxy-11-deoxy-12-didesmethyl-psymberin/ 
(+)-8-desmethoxy-11-deoxy-12-didesmethyl-ircinistatin A.96 
 
 Table 16 IC50 values of the psymberin/ircinistatin A 3 and 216 to against 
HCT-116 cell line.96 
Entry Compound 
IC50 
(HCT-116) 
(nM) 
1 
psymberin/ircinistatin A  
3 
0.2 
2 
(+)-8-desmethoxy-11-deoxy-12-didesmethyl-psymberin/ 
(+)-8-desmethoxy-11-deoxy-12-didesmethyl-ircinistatin A 
216 
160 
 
The (+)-8-desmethoxy-11-deoxy-12-didesmethyl-psymberin/(+)-8-desmethoxy-11- 
deoxy-12-didesmethyl-ircinistatin A 216 was a good tumour cell growth inhibitor, 
however the presence of gem-dimethyl group was not essential for cytotoxic 
activity. 
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The tolerance of substituent at C-11 position was also investigated, and three 
analogues were synthesised (Figure 35). As shown in Table 17, 11-epi-psymberin/ 
11-epi-ircinistatin A 217 proved to be very potent against cancer cell lines with a 
similar value compared to psymberin/ircinistatin A 3 (Table 17, Entries 1 and 2). The 
C-11 position was also modified to an acetyl functional group 218, which gave similar 
cytotoxicity results when compared to psymberin/ircinistatin A 3 (Table 17, Entries 1 
and 3). Previous studies reported that the benzoyl group in the C-11 position 219 
possessed lower potency than psymberin/ircinistatin A 3, 217 and 218. However, 
compound 219 still maintained a good level of cytotoxicity (Table 17, Entries 1, 2, 3 
and 4). Therefore, variations of C-11 did not significantly reduce the cytotoxic 
activity.  
 
 
Figure 35 Structure of C-11-psymberin/C-11-ircinistatin A analogues 217, 218, and 
219.96 
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Table 17 Proliferative cell growth inhibition assay and IMR-90 cytotoxicity assay IC50 
values (nM) for psymberin/ircinistatin A 3 and C-11-psymberin/C-11-ircinistatin A 
analogues.96 
  IC50 (cell line) (nM) (IC50 (IMR-90):IC50 (cell line)) 
Entry Compound A2058 H522-T1 HCT-116 IMR-90 
1 psymberin/ircinistatin A 3 0.4 (68) 1 (27) 4 (7) 27 
2 
11-epi-psymberin/ 
11-epi-irciniastatin A 217 
0.4 (85) 0.9 (38) 3 (11) 34 
3 
(+)-11-OAc-psymberin/ 
(+)-11-OAc irciniastatin A 
218 
0.4 (68) 0.7 (39) 2 (14) 27 
4 
(−)-11-OBz-psymberin/ 
(−)-11-OBz-irciniastatin A 
219 
2.7 (30) 5.4 (15) NA 81 
 
In summary, several important observations were obtained from the SAR studies 
carried out by different research groups (Figure 36). These include the following: 
1. A terminal olefin in psymberate side chains may be changed to another group 
with π-character as long as the C-4 methoxyl group and C-5 hydroxy are present. 
2. The dihydroisocoumarin unit and tetrahydropyran core are essential for the 
biological activity of psymberin/ircinistatin A 3. 
3. The C-8 methoxyl group, C-11 hydroxyl group and C-12 gem-dimethyl group are 
not essential for cytotoxic activity. 
4. It is important to maintain the stereochemistry at the C-4, C-8 and C-9 positions.  
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Figure 36 Structure–activity relationship studies of psymberin/ ircinistatin A 3. 
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2.2. Results and discussion 
2.2.1. Retrosynthetic approaches 
 
 
Scheme 72 Retrosynthetic analysis of psymberin/ircinistatin A 3. 
 
The retrosynthetic analysis of psymberin/ircinistatin A 3 is depicted in Scheme 72. 
From a synthetic perspective, we envisioned that psymberin/ircinistatin A 3 would 
be disconnected to three fragments, including the amide side chain 3a, the 
tetrahydropyran core 3c and the dihydroisocoumarin unit 3d. The disconnection of 
the amide bond between N-7 and C-8, resulted in the amide side chain 3a and 
aldehyde 3b. Further disconnection at C-16 and C-17 of fragment 3b, revealed the 
aromatic side chain 3d, and the 2,6-trans tetrahydropyran core 3c was obtained. 
Fragment 3b could be prepared by coupling of 3c and 3d via an aldol reaction. 
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There are several known methods to construct the amide side chain 3a72, 97-99 and 
aromatic side chain 3d.83, 100 Therefore, we focused on the synthetic approach to 
synthesise the tetrahydropyran core 3c via a stereodivergent oxy-Michael reaction.41 
According to the SAR studies reported by the Huang group, because of its potent 
cytotoxic activity, the tetrahydropyran core is an important feature in 
psymberin/ircinistatin A 3.91 Although many groups have proposed several synthetic 
approaches to construct psymberin/ircinistatin A 3, the highly substituted of 
2,6-trans tetrahydropyran unit, which contains the gem-dimethyl group, has been a 
challenge to synthesise.  
 
 
Scheme 73 Retrosynthetic analysis of the tetrahydropyran core of 
psymberin/ircinistatin A 225. 
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Our retrosynthetic approach included, disconnection at the O-1 and C-6 bond of 225, 
leading to the α,β-unsaturated thioester 224. We envisioned that the 
tetrahydropyran core would be synthesised from the cyclisation precursor 224 by 
useing buffered TBAF oxy-Michael reaction conditions. These conditions had been 
successfully applied for the synthesis of diospongins 1 and 2 by the Clarke group.41 
 
Cyclisation precursor 224 could be prepared through the cross metathesis of 
thioester 66 and diol 223. Diol 223 could be prepared from diastereoselective 
reduction of the Mukaiyama aldol product 222. The aldol product 222 would be 
generated from the Mukaiyama aldol reaction of 3,3-dimethyl-2-[(trimethylsilyl)oxy]- 
1,4-pentadiene 221 and benzyloxyacetoaldehyde 220 (Scheme 73).  
 
2.2.2. Attempted synthesis of the tetrahydropyran core of psymberin/ircinistatin 
A via stereodivergent oxy-Michael cyclisation 
The synthesis of 3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 221 is presented 
in Scheme 74. 
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Scheme 74 Synthesis of 3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 221. 
 
The synthesis began with Grignard formation and trapping with 
chlorotrimethylsilane. 1-Chloro-3-methyl-2-butene 226 and magnesium turnings 
were stirred at 0 °C in THF to form the Grignard reagent, then freshly distilled 
chlorotrimethylsilane 227 was added at room temperature. The mixture was stirred 
for 17 hours to give prenyltrimethylsilane 228 in a yield of 77%.101 This reaction was 
carried out on a multi-gram scale (10 g) level, and further purification was not 
required. 
 
It was envisioned that prenyltrimethylsilane 228 would be an important starting 
material for the synthesis of 3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 221. 
Allylic trimethylsilanes have been shown to be an useful intermediates in organic 
synthesis as they can react with electrophiles to give substitution reaction with allylic 
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rearrangement.102-104 The general mechanism of electrophilic substitution of allyl 
silanes is shown in (Scheme 75).  
 
 
Scheme 75 General mechanism of electrophilic substitution of unsaturated silanes. 
 
As shown in Scheme 75, prenyltrimethylsilane 228 would be transformed into 
3,3-dimethyl-pent-4-en-2-one 231 by treatment with acetyl chloride 229 and 
aluminium chloride 230 to give product 231 in 93% yield.103  
 
3,3-Dimethyl-pent-4-en-2-one 231 was reacted with trimethylchlorosilane in the 
presence of triethylamine and sodium iodide in acetonitrile to give 3,3-dimethyl-2- 
[(trimethylsilyl)oxy]-1,4-pentadiene 221 in 95% yield after distillation under reduced 
pressure.  
 
Benzyloxyacetaldehyde 220 was synthesised in two steps according to the procedure 
reported by Oda.105 For the initial reaction, commercially available 
cis-2-butene-1,4-diol 232 was used in the presence of sodium hydride in DMF to 
protect the hydroxyal groups as O-benzyl groups use of benzyl bromide, to give 
1,4-bis(benzyloxy)but-2-ene 233 in 92% yield. The product was used directly without 
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any further purification. The subsequent oxidative cleavage of 
1,4-bis(benzyloxy)but-2-ene 233 was achieved by ozonolysis, to form 
benzyloxyacetoaldehyde 220 in a yield of 93% (Scheme 76). 
 
 
Scheme 76 Synthesis of benzyloxyacetoaldehyde 220. 
 
Following successful synthesis of 3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 
221 and benzyloxyacetoaldehyde 220, attempts were made to investigate the 
conditions for the Mukaiyama aldol reaction in order to form the desired product 
222. 
 
Initially, the aldol reaction was run at −78 °C in dichloromethane by treating 1.0 
benzyloxyacetoaldehyde 220 with 1.0 equivalent of silyl enol ether 221 in the 
presence of 1.1 equivalents of titanium tetrachloride. After stirring for 7 hours at −78 
°C, the reaction was not completed. Based on the 1H NMR spectrum, the reaction 
had only given 7% conversion to the desired product (Table 18, Entry 1). As the 
reaction had not gone to completion, it was suggested that increasing the amount of 
silyl enol ether 221 would be required. The silyl enol ether 221 was increased to 1.1 
equivalents (Table 18, Entry 2) and 2.0 equivalents (Table 18, Entry 3), respectively. 
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Analysis of the 1H NMR spectra of the crude reaction showed that the conversion 
had increased, however, the reaction was still incomplete. Next, the temperature was 
changed to −40 °C, which again did not show any improvement. (Table 18, Entry 4) In 
order to optimise the conditions, changing the reaction time was evaluated next. 
Extending the reaction time to 17 hours resulted in completion of the reaction, 
resulting in 51% yield of the aldol product (Table 18, Entry 5). Due to the difficulty in 
maintaining the temperature under −78 °C for 17 hours, we next started the reaction 
at −78 °C, and gradually warmed up the temperature to room temperature. 
Interestingly, the aldol product 222 was obtained under these conditions.  
 
Table 18 Investigating the reaction conditions in the Mukaiyama aldol reaction. 
 
Entry 220/eq. 221/eq. Temperatur/°C Time/h Yield/% 
1 1.0 1.0 −78 7 7 1 
2 1.0  1.1 −78 7 23 1 
3 1.0 2.0 −78 7 54 1 
4 1.0  2.0 −40 7 26 1 
5 1.0 2.0 −78 to rt. 17 51  
1. 1The conversion to form 222 was calculated by the 1H NMR spectrum of the crude 
reaction mixture. 
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The silyl enol ether 221 was difficult to purify. During the purification step, the use of 
Kugelrohr distillation resulted in decomposition, which meant the amount of the silyl 
enol ether 221 that could be utilised in the aldol reaction was small. Therefore, to 
scale up the aldol product in this step, alternative reaction conditions were 
investigated. 
 
By avoiding the preparation step of silyl enol ether, the approach included direct 
deprotonation of 3,3-dimethyl-pent-4-en-2-one 231 using LDA at −78 °C, then 
benzyloxyacetoaldehyde 220 was added to generate the aldol product 222. However, 
the yield of aldol product 222 under these reaction conditions was lower (30.4%) 
compared to the yield when using the Mukaiyama aldol reaction. The reasons of the 
lower yield may possibly be due to the retro-aldol reaction. Therefore, for further 
studies, the aldol product 222 was generated by using the Mukaiyama aldol reaction. 
 
According to the literature, the relative stereochemical assignment of the 
C-2 and C-4 tetrahydropyran core is 2S* and 4R*.67, 70, 73 Therefore, to generate the 
syn-1,3 diol 223, a diastereoselective reduction of aldol product 222 was needed, as  
shown in Scheme 77. 
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Scheme 77 Synthesis of syn-diol 223 under Narasaka–Prasad reduction. 
 
In theory, syn-1,3 diol was expected to be a major product of Narasaka–Prasad 
reduction,57, 58 while, Evans–Saksena reduction54, 55 favours the formation of anti-1,3 
diol over syn-1,3 diol (discussed in chapter 1.2.3). 
 
The Narasaka–Prasad reduction was successfully applied to the synthesis of syn-1,3 
diol unit 79 in diospongin A 1 and diospongin B 2, therefore, it was expected to 
reduce the aldol product 222 under the same reaction conditions to give syn-1,3 diol 
223. Synthesis of syn-1,3 diol 223 was achieved by using sodium borohydride and 
triethylborane as a chelating agent which led to the reduction of acylic 
β-hydroxyketone 222 in 96% crude yield. The product was analysed by the crude 1H 
NMR spectrum. Interestingly, it was suggested that the product was a mixture of syn 
and anti diastereomers. However, it was difficult to determine the diastereomeric 
ratios by analysis of the crude 1H NMR spectrum. Fortunately, these two 
diastereoisomers could be separated by using column chromatography, which gave a 
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major product in 70% yield and a minor product in 26%. Unfortunately, we were 
unable to determine the identity of the major diastereomer. 
 
Meanwhile, the Evans–Saksena reduction was also carried out by reducing the acylic 
β-hydroxyketone 222 with sodium triacetoxyborohydride. As shown in Scheme 78, 
only one diastereomer 234 was generated for this reaction, however the yield was 
poor (32%). The 1H NMR spectrum, matched the spectroscopic data of the minor 
product obtained from the Narasaka–Prasad reduction, therefore, the major product 
of the Narasaka–Prasad reduction was assumed to be the syn-1,3 diol. 
 
 
Scheme 78 Synthesis of anti-diol 234 under Evans–Saksena reduction. 
 
Structural assignment of the syn-1,3 diol 223 and anti-1,3 diol 234 were further 
established by 13C NMR studies of their 1,3-diol acetonides 235 and 236, respectively. 
According to the literature, the stereochemistry of syn-1,3 diol and anti-1,3 diol were 
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able to be determined by converting them into acetonides.106-108 The difference in 
structural configuration between syn-1,3 diol acetonides (chair configuration) 237 
and anti-1,3 diol acetonides (twist-boat) 238, resulted in different chemical shifts of 
the acetal methyl groups and acetal carbon in the 13C NMR spectrum as shown in 
Table 19.  
 
Table 19 13C NMR chemical shifts the gem-dimethyl groups in the syn- and anti- 
acetonides. 
 
 
 syn-1,3-diol acetonide 237 anti-1,3-diol acetonide 238 
acetal methyl 19 and 30 ppm 25 ppm 
acetal carbon 98.6 ppm 100.5 ppm 
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In general, the 13C NMRchemical shifts of the acetal methyl group in the syn-1,3 diol 
acetonide 237 were shown at 19 ppm for the axial carbon and 30 ppm for the 
equatorial carbon, and its acetal carbon was displayed at 98.6 ppm. In contrast, the 
acetal methyl group in the anti-acetonide 238 were shifted around 25 ppm and the 
acetal carbon was shifted at 100.5 ppm.  
 
The synthesis of 1,3-diol acetonides 235 and 236 were accomplished by following the 
procedure reported by the Sabitha group (Scheme 79).109 
 
 
Scheme 79 Synthesis of 1,3-diol acetonides 235 and 236. 
 
Transformation of diols 223 and 234 to acetonides 235 and 236 were carried out by 
using 2,2-dimethoxypropane in the presence of a catalytic amount of 
4-methylbenzenesulfonic acid. The reaction did not go to completion and resulted in 
a poor yield. However, enough product was formed to analyse the 13C NMR spectrum 
after purification, and the results are presented in Figure 37 and Table 20.  
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Figure 37 13C NMR and HMQC spectra of acetonide 235. 
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Table 20 13C NMR data of compound 235 and 236. 
  
(400 MHz, CDCl3) (400 MHz, CDCl3) 
145.2 (C-5) 144.8 (C-5) 
138.4 (C-17) 138.5 (C-17) 
128.5, 128.0, 127.8 (C-Ar) 128.5, 127.9, 127.7 (C-Ar) 
112.1 (C-12) 112.3 (C-12) 
98.7 (C-9) 100.6 (C-9) 
75.3 (C-2) 73.4 (C-16) 
74.0 (C-6) 73.0 (C-2) 
73.6 (C-16) 72.9 (C-6) 
68.9 (C-3) 66.8 (C-3) 
40.1 (C-4) 40.0 (C-4) 
30.2 (C-10) 30.4 (C-1) 
28.6 (C-1) 24.9 (C-10) 
23.1 (C-13) 24.3 (C-11) 
22.7 (C-14) 23.1 (C-13) 
19.8 (C-11) 22.8 (C-14) 
 
The chemical shift in the 13C NMR spectrum of the resulting acetonide 235 is shown 
in Table 20. Its acetal methyl group (C-10 and C-11) and acetal carbon (C-9) were 
shown at 19.8, 30.2 and 98.7 ppm, respectively. All the spectroscopic data matched 
to those reported in the literature.106-108 Therefore, the stereochemistry of 223 was 
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determined to be a syn-1,3 diol.  
 
Figure 38 13C NMR and HMQC spectra of acetonide 236. 
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The stereochemistry of anti-1,3 diol 234 was also established by the same method 
(Table 20 and Figure 38). For acetonide 236, which was obtained from 234, the 
chemical shifts of the acetal methyl groups (C-10 and C-11) were 24.9 and 24.3 ppm 
and acetal carbon (C-9) shifted at 100.6 ppm. To our delight, all chemical shifts were 
identical to the results reported by Rychnovsky, suggesting that the stereochemistry 
of 1,3-diol 234 is anti.106-108 
 
A related syn-1,3-diol acetonide 239 was synthesised by the Pietruszka group, which 
had a similar structure to our syn-1,3-diol acetonide 235. By comparing the NMR 
spectroscopic data of our 1,3-diol acetonide product 235 with the reported NMR 
data of 239 by Pietruszka and co-workers (Table 21), it could be confirmed that 
1,3-diol 223 had the syn stereochemistry.84 
 
As shown in Table 21, in the Pietruszka group, the acetal methyl groups were 
assigned at 29.9 ppm and 19.6 ppm. The chemical shift of the acetal carbon (C-9) 
shifted at 98.7 ppm, which was in agreement with our findings. By comparing the 13C 
NMR data of 235 and 239, the stereochemistry of syn-1,3-diol 223 could also be 
confirmed. 
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Table 21 13C NMR data of compounds 235 and 239.  
Our results
 
Pietruszka’s results84
 
- 167.0 (C-23) 
145.2 (C-5) 155.0 (C-5) 
138.4 (C-17) 138.2 (C-17) 
128.5, 128.0, 127.8 (C-Ar) 127.6, 127.8, 128.4 (C-Ar) 
112.1 (C-12) 119.3 (C-12) 
98.7 (C-9) 98.7 (C-9) 
75.3 (C-2) 74.8 (C-2) 
74.0 (C-6) 73.7 (C-6) 
73.6 (C-16) 73.5 (C-16) 
68.9 (C-3) 68.6 (C-3) 
- 60.7 (C-25) 
40.1 (C-4) 40.3 (C-4) 
30.2 (C-10) 29.9 (C-10) 
28.6 (C-1) 28.7 (C-1) 
23.1 (C-13) 22.6 (C-13) 
22.7 (C-14) 22.6 (C-14) 
19.8 (C-11) 19.6 (C-11) 
- 14.3 (C-26) 
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To continue our synthesis of the tetrahydropyran core of 225 the next reaction to be 
performed was the cross-metathesis (Table 22). 
 
Initially, it was envisaged that diol 223 and thioester 66 could be coupled using the 
metathesis procedure reported by Lipshutz.59 Therefore, the synthesis of cyclisation 
precursor 224 was carried out using the 1.0 equivalent of diol 223 and 3.0 
equivalents of thioester 66. After treatment with 10 mol% of 2nd generation of 
Hoveyda-Grubbs catalyst and 10 mol% of copper(I) iodide in refluxing diethyl ether 
(Table 22, Entry 1), no reaction was observed. Next, the reaction was trialled using 
the optimised conditions reported previously to the synthesise the C-20–C-32 core of 
phorboxazole.9 The amount of copper(I) iodide was increased to 15 mol%, however, 
the reaction failed to generate any product (Table 22, Entry 2). We next attempted to 
increase the amount of copper(I) iodide and catalyst loading to 50 mol% (Table 22, 
Entry 3), however again no product was formed. Next, we investigated changing the 
solvent from diethyl ether to dichloromethane and increasing the temperature to 40 
°C (Table 22, Entry 4). Although many new spots were displayed on the TLC, 1H NMR 
spectroscopic analysis of the crude reaction mixture showed no corresponding 
double bond signals of the desired product. Given that these reactions were 
unsuccessful, an alternative catalyst was tried. Disappointingly, the 2nd generation of 
Grubbs catalyst also failed to form the α,β-unsaturated thioester 224 (Table 22, Entry 
5), even though the catalyst loading was increased to 50 mol% (Table 22, Entry 6). In 
addition, an excess in diol 223 was used (Table 22, Entry 7). It was assumed that 
stoichiometric excesses of olefin 223 may lead to some initiation. However, this too 
was unsuccessful.  
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Table 22 The reaction conditions attempted for the synthesis of compound 224. 
 
Entry 
Diol 
223/eq. 
Thioester 
66/eq. 
Catalyst CuI/mol% Solvent Temperature 
1 1.0 3.0 
Hoveyda-Grubbs 
2nd 10 mol% 
10 Et2O reflux 
2 1.0 3.0 
Hoveyda-Grubbs 
2nd 10 mol% 
15 Et2O reflux 
3 1.0 3.0 
Hoveyda-Grubbs 
2nd 50 mol% 
50 Et2O reflux 
4 1.0 3.0 
Hoveyda-Grubbs 
2nd 10 mol% 
10 CH2Cl2 reflux 
5 1.0 3.0 
Grubbs 2nd 10 
mol% 
- CH2Cl2 reflux 
6 1.0 3.0 
Grubbs 2nd 50 
mol% 
- CH2Cl2 reflux 
7 3.0 1.0 
Grubbs 2nd 10 
mol% 
15  CH2Cl2 reflux 
 
158 
 
It was envisaged that modifying acrolyl olefins 66 to crotyl olefin 240 may slow its 
homodimerization so cross metathesis can compete (Scheme 80). Unfortunately, 
under these reaction conditions, 224 was not observed by analysing the crude 1H 
NMR spectrum, only recovered starting material. 
 
 
Scheme 80 Attempted synthesis of compound 224 by using cross-metathesis. 
 
The sterically hindered substrate 223 could be classified as a type III olefins. 
Electron-deactivated olefins 66 was classified into types II olefin according to the 
classification method reported by Grubbs and co-workers.110 To drive the cross 
metathesis between type III and type II olefins, the low reactivity of type III olefin 
required to use stoichiometric excesses and was carried out in neat reaction 
conditions. With the limited amount of type III olefin 223, this synthentic route was 
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considered as an unsuitable one. An alternative route for synthesising 
α,β-unsaturated thioester 224 was sought. It was suggested that the α,β-unsaturated 
thioester 224 would be prepared in 3 different ways (Scheme 81).  
 
1. Through a Reformatsky reaction of aldehyde 243 and thioester 244 (Scheme 81, 
a). It was assumed that the Reformastsky reaction may offer an attractive 
approach for the synthesis of α,β-unsaturated thioester 242 in the proposed 
system.111 The resulting compound 241 obtained from Reformastsky reaction, 
would be eliminated in a subsequent step to afford the desired product 242. 
2. The α,β-unsaturated thioester 242 may be obtained from the aldol reaction 
between ketone 245 and aldehyde 243, which was similar to the Reformastsky 
reaction (Scheme 81, b). Furthermore, the aldol product 241 would be 
eliminated to give α,β-unsaturated thioester 242. 
3. The α,β-unsaturated thioester 224 may be synthesised through a Wittig reaction 
between 246 and (2-oxo-2-(p-tolylthio)ethyl)triphenylphosphonium bromide 247 
in the presence of base (potassium tert-butoxide) (Scheme 81, c). 
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Scheme 81 Synthetic routes to prepare compounds 224 and 242. 
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Initially, both the Reformastsky111 and Aldol reactions were investigated (Scheme 81, 
a and b). The starting material 243 for both reactions was prepared in a 2-step 
sequence (Scheme 82).  
 
 
Scheme 82 Synthesis of TBS-protected aldehyde 243. 
 
Diol 223 was protected with TBSOTf to provide the TBS-ether 249 in a good yield 
(78%). The resulting TBS-ether 249 was converted to TBS-protected aldehyde 243 via 
ozonalysis of 249. However, attempts to purify it by chromatography were 
challenging. Therefore, it was decided that another oxidative cleavage reaction 
should be introduced. The dihydroxylation of olefin 249 with catalytic amounts of 
osmium tetroxide and the co-oxidant NMO provided the diol compound, which was 
then treated with sodium (meta)periodate to give 243 in 67% yield. The 243 was 
pure enough to be utilised in the subsequent reaction. 
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Synthesis of S-p-tolyl 2-bromoethanethioate 244 was performed, following the 
procedure reported by Himber.112 The reaction began with the use of commercially 
available bromoacetyl bromide 250 and 4-methylbenzenethiol 90 in the presence of 
pyridine to generate S-p-tolyl 2-bromoethanethioate 244 in 81% yield after 
purification (Scheme 83).  
 
 
Scheme 83 Synthesis of S-p-tolyl 2-bromoethanethioate 244. 
 
The synthesis of S-(4-methylphenyl)ethanethioate 245 also began with commercially 
available acetyl chloride 229 and 4-methylbenzenethiol 90 in the presence of 
pyridine. After purification, S-(4-methylphenyl)ethanethioate 245 was obtained in 
64% yield (Scheme 84). 
 
 
Scheme 84 Synthesis of S-(4-methylphenyl)ethanethioate 245. 
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After completing the synthesis of all starting materials, attempted to synthesise 241 
via Reformastsky111 and aldol reactions (Scheme 81, a and b) were undertaken. 
Treating TBS-protected aldehyde 243 with 244 in refluxing THF and in the presence of 
Zn, the β-hydroxy thioesters 241 was obtained via a Reformastsky reaction 
(Scheme 85). 
 
 
Scheme 85 Synthesis of 241 via a Reformastsky reaction. 
  
Under aldol reaction conditions, deprotonation of 245 with LDA at −78 °C, followed 
by adding the aldehyde 243, resulted in generation of the aldol product 241 (Scheme 
86).  
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Scheme 86 Synthesis of 241 via the aldol reaction. 
 
Interestingly, both reactions gave a spot with the same Rf value on the TLC, which 
was assumed to be the desired product 241. The crude reaction mixture was purified 
by column chromatography, and many products were isolated. However, even after 
being purified multiple times with column chromatography, impurities were still 
present in the 1H NMR spectrum of the most promising product. Because only a 
small amount of crude product was obtained, additional purification methods, such 
as recrystallization and distillation could not be performed. Therefore, this 
compound was used in the next step without any further purification. 
 
In subsequent steps, the elimination reaction was investigated by following the 
reported mesylation procedure (Scheme 87).113 
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Scheme 87 Synthesis of compound 242 via the elimination reaction of 241. 
 
It was assumed that by treating 241 with methanesulfonyl chloride in the presence 
of triethylamine, followed by addition of DBU would result in formation of 242. 
However, the reaction failed to generate any identifiable products. 
 
Given that the elimination was unsuccessful, it was thought that by using alternative 
reaction conditions (with TFA in DCE and water) may result in the desired product 
242 (Scheme 88).  
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Scheme 88 Attempted synthesis of 242 under TFA acid condition. 
 
According to the previous results regarding the synthesis of diospongin A 1 and B 2 in 
chapter 1.2.3,41 TFA could catalyse the oxy-Michael cyclisation to form the 
cis-tetrahydropyran ring. Therefore, it was envisaged that application of the TFA 
conditions in our elimination reaction, may result in both elimination of product 242 
and undesired cis-tetrahydropyran 251 cyclised product. 
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Figure 39 1H NMR spectrum of the elimination reaction crude product mixture from 
the 241. 
 
Whilst the results were not unexpected, treatment of 241 with TFA appeared to 
show the presence of the elimination product 242 and cyclised product 251, as seen 
in the 1H NMR spectrum of the unpurified reaction mixture (Figure 39). The 
characteristic (double bond) peaks a and b of elimination product 242 were observed 
at 6.64-6.61 ppm 242a and 5.89-5.86 242b ppm, respectively. Additionally, as shown 
by our previous results, two protons next to the carbonyl group c of the 
cis-tetrahydropyran showed at 2.53-2.99 ppm (Figure 40). Therefore, the 
double-doublet peaks at 2.84 and 2.58 ppm with in the 1H NMR spectrum were 
suggested to represent the two protons next to the carbonyl group of cyclised 
product 251c. 
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Figure 40 Chemical shifts of the cyclisation precursors 78 and 122 and the 
cis-tetrahydropyrans 76 and 125 at a, b and c positions. 
 
The reaction mixture was purified by column chromatography on silica gel, 
unfortunately, due to time constraints, purification of the elimination product 242 
and the cyclised product 251 could not be fully and conclusively characterised.  
 
At the same time, the Wittig reaction was under investigated using 224 (Scheme 81, 
c). 
 
Synthesis of the starting material 246 was achieved via oxidative cleavage of the 
double bond of diol 223 using ozone as an oxidant, followed by the addition of an 
excess amount of dimethyl sulfide to form aldehyde 246 in 92% yield (Scheme 89). 
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Scheme 89 Synthesis of compound 246 via ozonalysis. 
 
Formation of the phosphonium salts 247 by treatment of S-p-tolyl 
2-bromoethanethioate 244 with triphenylphosphine in benzene, proceeded 
smoothly and provided (2-oxo-2-(p-tolylthio)ethyl)triphenylphosphonium bromide 
247 in 93% yield (Scheme 90).114  
 
 
Scheme 90 Synthesis of phosphonium salt 247. 
 
Upon completion of the synthesis of both starting materials, 246 and 247, we turned 
our attention to the Wittig reaction to construct the α,β-unsaturated thioester 224 
(Scheme 81, c).  
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Scheme 91 Attempted synthesis of thioester 224. 
 
However, upon trying the Wittig reaction by treating 246 with 247 in the presence of 
potassium tert-butoxide in THF a complex crude reaction mixture was formed, which 
was apparent in many species on TLC and no obvious double bond peaks were 
present in the crude 1H NMR spectrum. This may be due to the cyclisation that 
spontaneously occurred under these reaction conditions. Notably, 247 did not fully 
dissolve in THF, although a colour change was observed when it was deprotonated by 
potassium tert-butoxide. Without further separation and characterisation, the 
activity of the resulting ylide was unknown. 
 
In order to examine the activity of ylide 248, it was pre-made separately by the 
following procedure and characterised by 1H NMR spectroscopy.112 Ylide 248 was 
obtained by using triethylamine as a base to deprotonate 247 in a moderate yield 
(51%) (Scheme 92). 
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Scheme 92 Synthesis of ylide 248. 
 
Ylide 248 was then submitted to a model Wittig reaction with 220. Given the 
successful transformation of aldehyde 220 to 252 by treating 
2-benzyloxyacetoaldehyde 220 with ylide 248 in refluxing benzene, it was suggested 
that ylide 248 was successfully prepared and a promising compound for use in the 
real system. The isolated yield for this reaction, however, was low (20%) (Scheme 
93). 
 
 
Scheme 93 Model study of the Wittig reaction. 
 
Given the difficulties that were encountered during the purification of the reaction 
mixture by chromatography, and in order to prevent any cyclisastion in the Wittg 
reaction, TBS-protected aldehyde 243 was used. 
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Treatment of aldehyde 243 with ylide 248 in refluxing benzene for 17 hours, 
indicated that the reaction went to completion. Moreover, analysis of the crude 
reaction mixture by 1H NMR spectroscopy, indicated that the desired product was 
present. Unfortunately, due to time constraints, did not lead to the isolation and 
assignment of the desired product 242 (Scheme 94). 
 
 
Scheme 94 Attempted synthesis of compound 242 via the Wittig reaction. 
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2.3. Conclusions and Future work 
In this study, approaches toward the tetrahydropyran core of psymberin/ircinistatin 
A 225 were described. The synthetic plan to 225 focused on the ring closure step, 
which could be achieved via the stereodivergent oxy-Michael cyclisation.  
 
To construct 225, the aldol reaction between 3,3-dimethyl-2-[(trimethylsilyl)oxy]- 
1,4-pentadiene 221 and benzyloxyacetoaldehyde 220 was applied in 51% yield. The 
C-2 and C-4 stereocentres of 225 were installed followed by a reduction of 222 under 
Narasaka–Prasad conditions to afford 1,3-syn diol 223 in 70% yield. Next, the 
synthesis of cyclisation precursor 224 was attempted via cross metathesis of 
thioester 66 and diol 223. However, the synthesis of cyclisation precursor 224 failed 
even after many attempts. The other reactions were revised to form the cyclisation 
precursor 224. To achieve this, the Aldol reaction and the Reformatsky reaction 
followed by elimination were tried. To our delight, the cyclisation precursor 242 and 
spontaneous cyclised product 251 were formed in the elimination step. 
 
Further studies were aimed to optimise the cyclisation precursor forming step and to 
characterise both the cyclisation precursor 242 and the spontaneously cyclised 
product 251 formed in the elimination step. Also, synthesis of the tetrahydropyran 
core of psymberin/ircinistatin A 225. 
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3. Studies Towards the (L)-Proline Benzyl Ester-catalysed Asymmetric Aldol 
Reaction in Aqeous Conditions 
3.1. Introduction  
3.1.1. Asymmetric aldol reactions 
The aldol reaction has been recognised as one of the most commonly used 
carbon–carbon bond-forming reactions in organic synthesis.115  
 
 
Scheme 95 General reaction scheme of the aldol reaction. 
 
In general, the aldol reaction joins with two carbonyl group-containing molecules 
under either acid or base catalysis to form a β-hydroxyketone (Scheme 95), and has 
the potential to install one or two stereogenic centres. Several methods have been 
developed to control both the relative and absolute stereochemistry of these 
centres.  
 
Recently, List, Barbas, Lerner and their co-workers have presented a new strategy 
that (L)-proline can act as an efficient and remarkably selective organocatalyst, 
which was enabled for use in the intermolecular direct aldol reaction.116, 117 
Therefore, proline and its derivatives have received increased attention and have 
been applied as an enamine catalyst in many research areas. 
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3.1.2. Proline as an organocatalyst 
In the early 1970s, proline was first applied to Robinson annulation reactions by two 
research groups independently Hajos and Parrish,118 and Eder, Sauer and 
Wiechert.119 
 
Hajos and Parrish showed that proline catalysed the formation of 255 from triketone 
253 by using 3 mole percent of (L)-proline 254 in DMF in a high yield (100%) and 
enantioselectivities (93% ee) (Scheme 96).118 
 
 
Scheme 96 (L)-Proline-catalysed asymmetric Robinson annulations.118 
 
However, over 30 years later, proline was not fully and widely studied until it was 
reinvestigated by List and co-workers in 2000.116 List, Lerner and Barbas have 
demonstrated the use of proline as a catalyst for the direct asymmetric aldol 
reaction between acetone 256 and a variety of aldehydes to form aldol products 
261-266 in moderate to good yields and enantioselectivities (Scheme 97). 
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Scheme 97 (L)-Proline-catalysed direct aldol reactions between acetone and 
aldehydes.116 
 
The work by List on the intermolecular application of the proline-catalysed direct 
asymmetric aldol reaction opened a new field of enamine-catalysed aldol reactions. 
The concept of the application of small organic molecules (organocatalysts) as 
catalysts has received significant attention from the organic chemistry community. 
Since then, many researchers have carried out the mechanistic studies and 
investigated the new types of chiral amines as catalysts. 
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3.1.3. Mechanism of the proline-catalysed aldol reaction 
To date, several mechanisms have been proposed to account for proline-catalysed 
asymmetric aldol reaction.118, 120-125 However, the generally accepted mechanism 
was most recently proposed by List and co-workers (Figure 41).116, 126  
 
 
Figure 41 Proposed mechanistic cycle for proline-catalysed intermolecular aldol 
reaction.116, 126 
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The mechanism involved the formation of aminal 268 and 274, iminium ions 269 and 
273 and proceeded via an enamine intermediate 270. The carbonyl compound 267 
first reacted with the amino group to form the aminal intermediate 268, and then 
generated an iminium intermediate 269. Next, tautomerisation resulted in the 
formation of key enamine intermediate 270. The carbon-carbon bond forming step 
was proceeded through a Zimmerman-Traxler-type transition state 272, then both 
hydrolysis of the iminium 273 and aminal 274 intermediate to afforded the aldol 
product 275 and recovered the catalyst 254. This mechanism was analogous to the 
accepted aldolase type I reaction mechanism in nature (Figure 42).  
 
 
Figure 42 Mechanism of type I aldolases.127 
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Type I aldolases was accessed via an enamine mechanism. The enzyme first reacts 
with the compound 276 to generate a nucleophilic enamine 278. Then this 
intermediate undergoes addition to 279 leading to the formation of iminium adduct 
281. Finally give the aldol adduct 282 is obtained from the hydrolysis of the substrate 
from the enzyme (Figure 42). 
 
The proline catalyst can hence be regarded as a mimic of the type I aldolase 
metal-free enzyme. From this mechanism, it is assumed that the proline can be 
regarded as a bifunctional catalyst since amine can be treated as an enamine catalyst, 
and carboxylic acid is acting as Brønsted acid co-catalyst. The carboxylic acid was 
proposed to protonate of the carbonyl group acceptor in C-C bond formation step. 
Later the Houk group128 conducted computational studies, which were able to 
support the mechanism proposed by List in which the hydrogen bonding of the 
carboxylic acid to carbonyl group, provided an intramolecular acid catalysis.  
 
There were several reasons why proline has become an important molecule in 
asymmetric catalysis. Proline is an amino acid, which is an abundant chiral molecule 
readily available in both enantiomeric forms, less toxic and inexpensive than metal 
catalysts and gives high stereoselectivity. Additionally, proline contained two 
functional groups, a carboxylic acid and an amine group, which may act as both acid 
and base. The carboxylic group was significantly important to activate the carbonyl 
acceptor via hydrogen-bonding. For these reasons, proline was an effective catalyst 
in the aldol reaction.  
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3.1.4. Highly diastereo- and enantioselective direct aldol reactions in water 
From the green chemistry perspective, water is the solvent of interest. In 1980, 
Breslow and co-workers presented an example by using water as a reaction medium 
that lead to increased reactivity of Diels–Alder reactions.129, 130 Since then, reactions 
carried out in water have received much attention by organic chemists. 
 
Organocatalysts are less sensitive to the presence of water compared to metal 
catalysts. The study of aldol reaction in the use of organocatalysts in aqueous 
solutions has recently gained considerable attention. In 2001, a study conducted by 
Barbas group, demonstrated that the aldol reaction was tolerant of the addition of 
small amounts of water (up to 4 vol% corresponding to ca. 20 eq. in a 0.1 M reaction), 
without affecting the enantiomeric excess of the aldol product.117 
 
Later studies on the effect of water as an additive in proline catalysed aldol reactions 
were conducted by Pihko131, 132 and co-workers in 2004 (Scheme 98). 
 
 
Scheme 98 Aldol reaction between acetone and iso-butyraldehyde and 
benzaldehyde in DMF with water as additive as reported by the Pihko group.131 
 
 
181 
 
Their results showed an increase in stereoselectivity and yield compared to the 
findings presented by Barbas.117 The aldol reactions between acetone 256 with 
iso-butyraldehyde 61 and benzaldehyde 23 showed significantly higher yields. In 
addition, better stereoselectivity was achieved after the addition of water (50-500 
mol%). Pihko had stated that there were two main reasons why water additives may 
accelerate the reaction and increase the stereoselectivity: (a) because water 
increased the solubility of the reaction mixture and (b) to hydrolyse the 
oxazolidinone intermediate. In 2007, the formation of the oxazolidinone in proline 
catalysed aldol reaction in water was further proven by Blackmond and co-workers 
(Figure 43).133 
 
 
Figure 43 Equilibrium of iminium ion and oxazolidinone.133 
 
In 2002, the Janda group reported the first organocatalytic aqueous aldol reaction 
between acetone 256 and 4-chlorobenzaldehyde 285 in water by using nornicotine 
286 as catalyst (Scheme 99).134 
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Scheme 99 Organocatalytic aqueous aldol reaction as reported by the Janda 
group.134 
 
Although the enantioselectivity was low, it provided promising results that 
organocatalytic aldol reactions could be carried out in an aqueous environment. 
Further studies, have been undertaken to develop catalysts that would allow for the 
aldol reactions to be conducted in water as a sole solvent. Inspired by natural 
aldolase antibodies that the hydrophobic active site in their structure allowed the 
reaction occurring in water.135 Therefore, modifying the proline catalyst with the 
hydrophobic groups was sought. 
 
In 2006, the Barbas group136 developed a diamine-based catalyst 289 (with a 
hydrophobic long chains) with TFA additive (0.05 mol),137, 138 which catalysed the 
direct asymmetric aldol reaction of cyclohexanone 288 with 4-nitrobenzaldehyde  
257 in water to provide 290 in a high yield (99%) and excellent enantioselectivity (up 
to 94% ee) (Scheme 100). 
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Scheme 100 Diamine 289/TFA-catalysed aldol reactions in water.136 
 
In the same year, the Hayashi group reported the use of a silyloxyproline 291 as a 
catalyst for the direct aldol reactions in the presence of water (Scheme 101).139 
 
 
Scheme 101 Silyloxyproline-catalysed direct aldol reactions in water.139 
 
By using 10 mol% of the catalyst 291, excellent enantioselectivities of anti-aldol 
products were obtained. However, both reactions conducted by Barbas and Hayashi 
group have the same problem, the volume of ketone present in the reaction is 
greater than that of water. Therefore, these reactions cannot be classified as truly 
run “in water”, it can simply be defined as run ‘‘in the presence of water’’. The 
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reaction proceeded in a biphasic system with water being present as a second 
phase.140 
 
Previous studies by our group, successfully demonstrated the aldol dimerisation of 
TIPS-protected glycolaldehyde 293 in water. The use of (L)-proline benzyl ester 294 as 
a catalyst for a reaction time of 5 hours resulted in 295 in 80% yield and 15% ee. 
(Scheme 102).141, 142 
 
 
Scheme 102 Aldol dimerisation of protected glycolaldehyde in water.141, 142 
 
The enantioselectivity of this reaction is lower than those of the organocatalysed 
aldol reactions run in organic solvents reported by List,116 MacMillan and 
Córdova.143-145 However, the enantioselectivity higher than the previous reactions 
that were run in purely aqueous solution.146-148  
 
Janda stated that competing mechanisms between enamine catalyst and general 
base catalysis will be present in water. In order to confirm this hypothesis, further 
reactions were conducted at pH 7 (buffered) and pH 6 (buffered) and compared to 
those run in water.149 The results are presented in Table 23. 
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Table 23 The dimerisation of TIPS-protected glycolaldehyde run at different pH 
levels.141, 142 
 
 
 
Entry Medium Yield/% ee/% 
1 water 80 15 
2 pH 7 phosphate buffer 70 47 
3 pH 6 citric acid phosphate buffer 33 22 
 
The reaction run in pH 7 phosphate buffer solution provided the highest ee (47% ee), 
however, in pH 6 buffer solution and water media, lower enantioselectivities were 
obtained. These results confirmed that general base and acid catalyst competed with 
the enamine catalyst resulting in the formation of a non-enantioselective product, 
which resulted in a reduction of the enantioselectivities.  
 
The reaction run in water and pH 7 phosphate buffer solution gave a similar yield. 
This may explain that the enamine-catalysed reaction was as active as the 
base-catalysed reaction. However, the yield dropped to 33% under pH 6 phosphate 
buffer. It was suggested presumably that the (L)-proline benzyl ester was hydrolysed 
to the corresponding acid and alcohol in acid media, thus the concentration of the 
catalyst was decreased, leading to a lower yield.150 
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Given the successful results of aldol dimerisation in water by using the (L)-proline 
benzyl ester as a catalyst. In order to assess the ability of (L)-proline benzyl ester to 
catalyse aqueous aldol reactions. The reaction of cyclohexanone with a variety of 
aldehyde acceptors was chosen at pH 6 and pH 7 phosphate buffer and water, over 
periods of 5 hours and 24 hours. 
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3.2. Results and discussion 
3.2.1. Background and previous results 
In previous studies, (L)-proline benzyl ester 294 was used as an organocatalyst in the 
aqueous aldol dimerisation of 293 to give 295 in 70% yield and 47% ee (Scheme 
103).141, 142, 150 
 
 
Scheme 103 The aldol dimerisation of protected glycolaldehyde in water.141, 142, 150 
 
Further studies to determine whether catalyst 294 was able to promote other 
aqueous aldol reactions were undertaken.150 The reaction between cyclohexanone 
288 and 4-nitrobenzaldehyde 257 in aqueous solution was chosen, as this reaction 
had been widely studied before.117, 139 Moreover, the conditions for the analysis of 
both the % d.r. and ee are well documented (Scheme 104).151 
 
 
Scheme 104 (L)-proline-catalysed aldol reaction between cyclohexanone 288 and 
4-nitrobenzaldehyde 257.150 
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The pH value in water was found to be around pH 8-9. To determine the effect of pH 
on enantioselectivities and yield the studies were run in both water and pH 7 buffer 
solution for comparison. It was assumed that the enantioselectivities would be 
higher in pH 7 buffer solution compared to the reactions run in water. As the slightly 
basic condition in water will make general base catalysed reaction compete with the 
enamine formation mechanism, which can lead to a decrease in enantioselectivities.  
 
Table 24 The aldol reaction of cyclohexanone 288 and 4-nitrobenzaldehyde 257 in 
water and pH 7 media catalysed by (L)-proline benzyl ester.141, 142, 150 
 
 
Entry Media Time/h 
Conversion 
/% 
d.r. 
(anti:syn) 
Major 
Product 
% ee 
(anti) 
% ee 
(syn) 
1 water 5 74 3:1 290 31 13 
2 water 48 77 8:1 290 21 6 
3 pH 7 5 74 4:1 290 43 19 
4 pH7 48 57 5:1 290 46 11 
 
As shown in Table 24, in general, the anti-aldol adduct 290 was the major product 
and the ee for the anti product 290, which were much higher than the ee of the syn 
product 297. To our delight, compared to the reaction run in water, the higher 
enantioselectivity was obtained in pH 7 buffer solution over the entire reaction 
189 
 
period, which confirmed the hypothesis that the reaction run in neutral condition 
had the highest enantioselectivity. These results were explained by maximising the 
enamine-mediated reaction pathway and minimizing the racemic general 
base-catalysed pathway in pH 7 media. The lower enantioselectivity in water clearly 
explained that the general base catalyst existed in the reaction.  
 
In previous studies, Burroughs demonstrated that the catalyst would be degraded 
from the ester substituent to the corresponding acid and alcohol with a longer 
reaction period.150 Therefore, 5 hours was chosen as the optimal reaction time. 
When increasing the reaction period, the enantiomeric excess decreased from 31% 
ee to 21% ee (Table 24, Entries 1 and 2). In contrast, in pH 7 buffer solution, 
enantioselectivities were of a similar value. 
 
To evaluate if the retro-Aldol reactions occurred with longer reaction times in water, 
the syn enantiomer 297 was treated with 10 mol% of (L)-proline benzyl ester 294 in 
water for 48 hours.150 It was found that the enantioselectivities decreased from 19% 
to 8%, which can be explained by the presence of the retro-aldol reaction (Scheme 
105). 
 
 
Scheme 105 Retro-aldol investigation conducted by Burroughs.150 
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Further investigation into the reactions run in pH 6 buffer solution were carried out 
by a fellow member of the Clarke’s group, Sharp.152 The results are presented in 
Table 25. 
 
Table 25 The aldol reaction of cyclohexanone 288 and 4-nitrobenzaldehyde 257 in pH 
6 media catalysed by (L)-proline benzyl ester.152 
 
 
Entry Time/h Conversion/% 
d.r. 
(anti:syn) 
Major 
Product 
% ee 
(anti) 
% ee 
(syn) 
1 5 27 3:1 290 30 21 
2 24 21 2:1 290 76 18 
 
 
When comparing the enantioselectivities between pH 7 (Table 24, Entries 3 and 4), 
water (Table 24, Entries 1 and 2) and pH 6 buffer solution (Table 25, Entries 1 and 2), 
the reaction run in pH 6 buffer solution presented the lowest enantiomeric excess 
during a 5-hour reaction time. Most surprisingly was the anti- product increase in 
enantioselectivity from 30% to 76% ee over 24 hours (Table 25, Entries 1 and 2), 
which was not consistent with the expected trend. It was envisioned that the 
acid-mediated mechanism will competed with the enamine formation, thereby 
leading to a decrease in the resulting enantioselectivity. The reason behind this may 
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be that the optimal conditions for enamine formation are under acid conditions. 
Previous studies by Singh and co-workers in 2009 indicated that the highest 
enantiomeric excess was obtained for the aldol reaction of cyclohexanone 288 and 
4-nitrobenzaldehyde 257 at pH 4-5 for 24-hour reaction times (Scheme 106).153 The 
pH 6 buffer solution was closer to the optimal pH for enamine formation. 
 
 
Scheme 106 The aldol reaction of cyclohexanone 288 and 4-nitrobenzaldehyde 257 
in pH 4-5 media as reported by Singh and co-workers.153 
 
Hayashi and co-workers investigated the same reaction in the presence of water 
using catalyst 291 and obtained aldol product 290 in 86% yield, with an 
enantioselectivity over 99% ee, and diastereoselectivity of 20:1 anti:syn (Scheme 
107).139 
 
 
Scheme 107 Silyloxyproline-catalysed direct aldol reactions in water.139 
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In another study by Barbas and co-workers,136 TFA was used as a co-catalyst to 
generate an ee of 94%, with a yield of 99% and diastereoselectivity of 89:11 anti:syn 
(Scheme 100). Unfortunately, the enantioselectivities decreased to 1% ee when no 
acid co-catalyst was being used. The reason for this was that TFA may act as a buffer 
to maximum the enamine catalysis in the reaction. The general base catalysis caused 
by the addition of the diamine to water may be reduced. 
 
However, studies by both the Hayashi group and Barbas group have the same 
problem; an excess of cyclohexanone 288 being present in the reaction, means that 
cyclohexanone 288 can be regarded as an organic solvent and that water can only act 
as a co-solvent. 
 
Clarke’s group built on earlier work of Janda,154 showing that the pyrrolidine catalyst 
required electron-withdrawing substituents on the arylpyrrolidines substrate for it to 
become an effective catalyst. In comparison to the catalyst conducted by Janda, the 
(L)-proline benzyl ester 294 was chosen by Burroughs (Clarke group), as this proline 
derivative also possessed an electron withdrawing group, which could be a potent 
catalyst in the aldol reaction between cyclohexanone 287 and 4-nitrobenzaldehyde 
257.150 In addition, (L)-proline benzyl ester did not have a carboxylic acid group that 
provides essential hydrogen-bonding interactions in organic solvents. Therefore, 
unlike proline, the lack of hydrogen bonding interaction in water (L)-proline benzyl 
ester can still serve as an efficient catalyst. 
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3.2.2. Cross-Aldol reaction between cyclohexanone and different aryl aldehydes 
Further studies focused on the scope of the aqueous aldol reaction and examined 
the crossed-aldol reaction between cyclohexanone and different substituted of 
benzaldehydes by using (L)-proline benzyl ester as a catalyst under pH 7 buffer 
solution for 5 hours and 24 hours, respectively the results can be found in Table 26. 
 
In general, it was observed that anti-aldol adduct was the major product for all 
reactions. The value of conversion was calculated by crude NMR as the reaction did 
not go to completion in 24 hours. The conversion increased with longer reaction 
times (Table 26, Entries 1-16) which were contrary to previously published results. In 
previous studies, the yield of the aldol reaction between cyclohexanone 288 and 
4-nitrobenzaldehyde 257 decreased in the longer reaction period (Table 24, Table 
25). However, the lower yield may be due to the reactivity of these aldehyde 
substrates, which was less than 4-nitrobenzaldehyde 257. All aldehydes matched up 
this trend, except for anisaldehyde 299 (Table 26, Entries 7 and 8), which failed to 
form the product, and only starting material was recovered. The heteroaromatic 
aldehyde, 4-pyridinecarboxaldehyde 302 was seemed to be more reactive than other 
aldehydes that reacted with cyclohexanone. The reaction was nearly complete in 5 
hours with good ee (60%). Treating 4-pyridinecarboxaldehyde 302 at a longer 
reaction times also resulted in a similar ee (Table 26, Entries 15 and 16). 
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Table 26 The aldol reaction between cyclohexanone and different aldehydes. 
 
Entry R T/h 
Conversion 
/% 
% ee 
(anti) 
d.r. 
(anti:syn) 
Major 
Product 
1 4-Br 258 5 72  38 3:1 anti-303 
2 4-Br 258 24 84  28 4:1 anti-303 
3 4-Cl 285 5 44  27 6:1 anti-304 
4 4-Cl 285 24 66  13 5:1 anti-304 
5 H 23 5 13  89 4:1 anti-305 
6 H 23 24 70  74 6:1 anti-305 
7 OMe 299 5 0 - - anti-306 
8 OMe 299 24 0 - - anti-306 
9 2-Cl 259 5 41  23 2:1 anti-307 
10 2-Cl 259 24 76  7 2:1 anti-307 
11 2-NO2 300 5 38  35 1:1 anti-308 
12 2-NO2 300 24 88  26 1:1 anti-308 
13 2-furaldehyde 301 5 19  41 2:1 anti-309 
14 2-furaldehyde 301 24 45  32 1:1 anti-309 
15 
4-pyridinecarboxaldehyde 
302  
5 99  60 3:1 
anti-310 
16 
4-pyridinecarboxaldehyde 
302 
24 100  64 2:1 
anti-310 
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In contrast to the conversion, the ee value of the reaction decreased with increasing 
reaction time. This implies retro-aldol domination over a longer reaction times. 
(Table 26, Entries 1-14). 
 
The aldehyde acceptor with the electron-withdrawing group at para-position may 
accelerate rates. However, it was disappointing that the ee of these aldehyde 
acceptors like 4-bromobenzaldehyde 258 and 4-chlorobenzaldehyde 285 (Table 26, 
Entries 1-4) were substantially lower compared to previous findings in 
4-nitrobenzaldehyde 257. The highest ee obtained was 89% ee for benzaldehyde 23 
(Table 26, Entry 5). The ee for 2-Cl 259 and 2-NO2 benzaldehyde 300 (Table 26, 
Entries 5-6 and 9-12) was also lower than the 4-nitrobenzaldehyde 257. Interestingly, 
the aldehyde with an electron donating group at para-position 299 (Table 26, Entries 
7 and 8) did not form any aldol products. This may be due to the reduced 
electrophilicity of the aldehyde acceptor. 
 
3.2.3. Cross-Aldol reaction between various ketone donors and 
4-nitrobenzaldehyde 
The cross-aldol reaction was further carried out between different ketone donors 
and 4-nitrobenzaldehyde 257. Actone 256 (Table 27, Entries 1 and 2) and 
3-pentanone 311 (Table 27, Entries 3 and 4) were chosen for further studies. 
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Table 27 The aldol reaction between various ketones with 4-nitrobenzaldehyde by 
using (L)-proline benzyl ester as a catalyst. 
 
 
Entry Ketone Time/h Conversion/% 
% ee 
(anti) 
dr 
(anti:syn) 
Major 
product 
1 Acetone 256 5 62 13 2:1 anti-261 
2 Acetone 256 24 98 61 10:1 anti-261 
3 
3-Pentanone 
311 
5 0 - - - 
4 
3-Pentanone 
311 
24 0 - - - 
 
Results can be found in Table 27. The reactions were not completed during a 5 or 24 
hours reaction time. As shown in the crude 1H NMR spectra, the aldehyde peak was 
presented and the reaction with only 62% of conversion in 5 hours. The conversion 
increased with longer reaction times, however, after 24 hours, starting material could 
still be observed in the crude 1H NMR spectrum. The use of acetone 256 (Table 27, 
Entries 1 and 2) as a ketone donor gave products with a low ee compared to 
cyclohexanone 288. Unfortunately, the reaction with 3-pentanone 311 (Table 27, 
Entries 3 and 4) failed to give any product. The ee increased from 13% to 61% over 
24 hours. It seems that these two ketone donors were less active to react with 
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4-nitrobenzaldehyde 257 under buffered conditions for 24 hours compared to the 
use of cyclohexanone 288 as a ketone source.  
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3.3. Conclusions and Future work 
In summary, the wide scope of aqueous aldol reactions between cyclohexanone and 
different substituted of benzaldehydes has been demonstrated.The (L)-proline 
benzyl ester was used as a catalyst, which was successfully proven to be an 
accessible organocatalyst to promote the asymmetric aldol reaction with diverse 
aldehyde acceptors in water. This organocatalyst system provided a moderate yield 
and ee, and no excess ketone or acid additive was required. 
 
In general, investigating of the aldol reactions between cyclohexanone and a variety 
of benzaldehydes presented some trends. The major diastereomer was the anti 
product and all the reactions had not gone to completion within 24 hours, except for 
the 4-pyridinecarboxaldehyde. It was found that the conversion increased with 
longer reaction times. In contrast, the ee dropped with longer reaction times. This 
trend was consisted with previous results reported by Burroughs who found the ee 
decreased because of degradation of the catalyst at longer periods.150 The highest ee 
was observed when using benzaldehyde as an acceptor with a 5-hour reaction time 
under pH 7 buffer media to give 89% ee. Aldehydes with an electron donating group 
at the para- position did not provide any aldol products. This may be due to the 
reduced electrophilicity of the aldehyde acceptor.  
 
Moreover, the (L)-proline benzyl ester was capable to catalyse the acetone and cyclic 
ketone donor with 4-nitrobenzaldehyde to form an aldol product in a moderate yield 
and ee. However, 3-pentanone failed to give any aldol products.  
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Further studies may be focoused on the mechanistic studies, which may help to 
account for the diastereoselectivity. Investigating the reaction under pH 6 (buffered 
solution) is worthwhile, as the pH 6 media was proposed to be closer to the optimal 
pH for the formation of enamine.153 
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4. Experimental  
4.1. General experimental 
All reagents were commercially available and used as received except for the TMSCl. 
The TMSCl was distilled over calcium hydride before use. All the reactions were 
carried out under an inert atmosphere conditions in a closed system. 1H NMR 
spectra were recorded on a Jeol ECX-400 (400 MHz), Jeol ECS-400 (400 MHz) or a 
Bruker DRX 500 (500 MHz) spectrometer at ambient temperature. 13C NMR spectra 
were recorded on a Jeol ECX-400 (101 MHz) or Jeol ECS-400 (101 MHz) spectrometer. 
Spectra were processed using MestreNova. Data are reported as follows: chemical 
shift are reported in parts per million (ppm) and δ 7.26 ppm was referenced to CDCl3; 
coupling constants (J) are quoted in Hertz; multiplicity (s = singlet, d = doublet, t = 
triplets, br = broad, m = multiplet). Enantiomer ratios were determined by HPLC on 
an Agilent 1100 Series system with the use of Chiralpak OD, OJ-H, AS-H column or 
Chiralcel AD-H column in comparison with literature. TLC was utilised the 
glass-backed plates coated with Merck Silica gel 60 F254, and the compounds were 
visualised by irradiation with UV light or by treatment with a anisaldehyde stain or a 
cerium ammonium molybdate stain. Purification of the product was carried out by 
flash column chromatography using high-purity grade silica gel, pore size 60 Å, 
200-425 mesh particle size supplied by Sigma-Aldrich. 
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4.2. Experimental Procedures for Chapter one 
 
Octa-1,7-diene-4,5-diol 84 
Lab book: YT-4-58, NMR: a2326yth (YT-2-63-5-2) 
 
 
Allyl bromide (14.29 mL, 20.00 g, 165.32 mmol, 2.40 eq.) and 40% aqueous glyoxal 
(7.91 mL, 10.05 g, 68.88 mmol, 1.00 eq.) were dissolved in a THF/water (1:1 v/v, 140 
mL, 0.50 M) solvent mixture. Tin powder (19.63 g, 165.32 mmol, 2.40 eq.) was added. 
After sonicating for 6 hours, the reaction mixture was quenched with 25% potassium 
hydroxide solution (56 mL, w/w in water) and diluted with diethyl ether (60 mL). 
Solid sodium chloride was added until the aqueous phase was saturated and the 
solution was filtered through celite. The aqueous phase was extracted with diethyl 
ether (3 x 20 mL). The combined organic extracts were dried (magnesium sulfate), 
filtered and concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (1:1, ethyl acetate-hexane) to give 
octa-1,7-diene-4,5-diol 84 as a yellow oil (7.12 g, 72%). 1H NMR (400 MHz, CDCl3): δ 
5.87-5.76 (2H, m, H-2, H-7), 5.14-5.06 (4H, m, H-1, H-8), 3.66-3.46 (2H, m, H-4, H-5), 
2.92 (1H, br, OH), 2.33-2.18 (4H, m, H-3, H-6); 13C NMR (101 MHz, CDCl3): δ 134.9 
(C-2), 134.6 (C-7), 118.0 (C-1), 117.9 (C-8), 73.1 (C-4), 72.9 (C-5), 38.2 (C-3), 36.3 (C-6); 
IR (film): νmax 3368.7, 3077.0, 2983.9, 2909.3, 1640.9, 1432.4, 1418.0, 1046.3, 991.1, 
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912.1, 868.0 cm-1; ESI-MS: m/z calcd for C8H14NaO2 [M+Na
+] 165.0886, found 
165.0888 (−1.2 ppm error). The 1H NMR data was in agreement with the 
literature.155 
 
But-3-enal 70 
Lab book: YT-2-92, NMR: c8727yth (YT-2-72) 
 
 
 
Octa-1,7-diene-4,5-diol 84 (1.69 g, 12.00 mmol, 1.00 eq.) was dissolved in a 
dichloromethane/water (1:1 v/v, 20 mL, 0.60 M) solvent mixture. Sodium 
(meta)periodate (3.05 g, 14.26 mmol, 1.20 eq.) was added at 0 °C. After stirring for 
30 minutes, the reaction was allowed to warm to room temperature and stirred for 
another 7 hours. The organic phase was separated and washed with water (2 x 20 
mL), brine (2 x 20 mL), dried (magnesium sulfate) and filtered to give but-3-enal 70 as 
a colourless solution in dichloromethane. The crude product was used directly 
without further purification. 1H NMR (400 MHz, CDCl3): δ 9.69 (1H, t, J = 1.9 Hz, H-6), 
5.91 (1H, ddt, J = 17.2, 10.3, 6.9 Hz, H-2), 5.36-5.26 (2H, m, H-1), 3.19 (2H, ddd, J = 
6.9, 3.1, 1.9 Hz, H-3). The 1H NMR data was in agreement with the literature.156 
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Trimethyl((1-phenylvinyl)oxy)silane 81 
Lab book: YT-3-40, NMR: d2663yth (YT-3-30) 
 
 
 
Acetophenone (4.00 g, 3.89 mL, 33.29 mmol, 1.00 eq.) was dissolved in dry 
acetonitrile (200 mL, 0.16 M) under N2 at room temperature. Triethylamine (26.83 g, 
36.96 mL, 166.45 mmol, 5.00 eq.) was added dropwise over 30 minutes to the 
solution which was then heated to 30-35 °C. After stirring for 30 minutes, 
chlorotrimethylsilane (14.47 g, 17.02 mL, 133.16 mmol, 4.00 eq.) and sodium iodide 
(9.98 g, 66.58 mmol, 2.00 eq.) were added. The reaction temperature was then 
raised to 40-45 °C and stirred for 17 hours. After cooling the reaction mixture to 
room temperature, the solution was filtered through celite and washed with hexane 
(100 mL). The filtrate was then extracted with hexane and concentrated in vacuo to 
give trimethyl((1-phenylvinyl)oxy)silane 81 as a colourless oil (6.20 g, 97%). 1H NMR 
(400 MHz, CDCl3): δ 7.60-7.57 (2H, m, H-Ar), 7.35-7.28 (3H, m, H-Ar), 4.92 (1H, d, J = 
1.7 Hz, H-1a), 4.43 (1H, d, J = 1.7 Hz, H-1b), 0.27 (9H, s, H-12, H-13, H-14). The 1H 
NMR data was in agreement with the literature.50, 157 
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3-Hydroxy-1-phenylhex-5-en-1-one 80 
Lab book: YT-6-8, NMR: a2298yth (YT-4-16-2) 
 
 
 
Trimethyl((1-phenylvinyl)oxy)silane 81 (3.18 g, 16.55 mmol, 1.00 eq.) was dissolved in 
dry dichloromethane (40 mL, 0.40 M). But-3-enal 70 (1.16 g, 16.55 mmol, 1.00 eq.) 
was added dropwise at −78 °C under N2. After stirring for 15 minutes, titanium 
tetrachloride (1.99 mL, 18.21 mmol, 1.10 eq.) was added and stirred for 4 hours. The 
reaction mixture was quenched with cold water (20 mL) and saturated sodium 
bicarbonate solution (20 mL). The organic phase was separated and the aqueous 
phase was extracted with dichloromethane (3 x 20 mL). The combined organic 
extracts were dried (magnesium sulfate), filtered and concentrated in vacuo to give a 
crude product, which was then purified by flash column chromatography on silica 
(1:3, ethyl acetate-hexane) to give 3-hydroxy-1-phenylhex-5-en-1-one 80 as a yellow 
oil (1.60 g, 51%). 1H NMR (400 MHz, CDCl3): δ 7.95-7.92 (2H, m, Ar-H), 7.59-7.54 (1H, 
m, Ar-H), 7.47-7.43 (2H, m, Ar-H), 5.87 (1H, ddt, J = 17.2, 10.2, 7.1 Hz, H-6), 5.18-5.11 
(2H, m, H-7), 4.30 (1H, ddt, J = 8.7, 6.2, 3.1 Hz, H-4), 3.33 (1H, br, OH), 3.17 (1H, dd, J 
= 17.6, 3.1 Hz, H-3a), 3.06 (1H, dd, J = 17.6, 8.7 Hz, H-3b), 2.42-2.29 (2H, m, H-5); 13C 
NMR (101 MHz, CDCl3): δ 200.7 (C-2), 136.8 (C-Ar), 133.6 (C-Ar), 128.2 (C-Ar), 118.0 
(C-7), 67.2 (C-4), 44.3 (C-3), 41.02 (C-5); IR (film): νmax 3438.1, 3076.4, 2980.2, 2904.2, 
1675.8, 1597.0, 1580.1, 1448.5, 1209.5, 1044.9, 1000.7, 916.3, 753.0, 688.7, 584.2 
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cm-1; ESI-MS: m/z C12H14NaO2 [M+Na
+] 213.0886, found 213.0883 (1.3 ppm error). 
 
(1S*,3S*)-1-phenylhex-5-ene-1,3-diol 79 
Lab book: YT-5-24, NMR: p3591yth (YT-4-63) 
 
 
 
A 1.00 M solution of triethyl borane in hexanes (5.79 mL, 5.79 mmol, 1.10 eq.) was 
dissolved in a THF/methanol (5:1, v/v, 12 mL) solvent mixture under N2 at room 
temperature. After stirring the reaction mixture for 2 hours, the solution was cooled 
down to −78 °C and 3-hydroxy-1-phenylhex-5-en-1-one 80 (1.00 g, 5.25 mmol, 1.00 
eq.) was added slowly. After stirring for 30 minutes sodium borohydride (219.04 mg, 
5.79 mmol, 1.10 eq.) was added in one portion and stirred for another 4 hours. The 
reaction mixture was quenched with saturated ammonium chloride solution (10 mL) 
and then diluted with ethyl acetate (10 mL). The organic phase was separated and 
the aqueous phase was extracted with ethyl acetate (3 x 10 mL) and the combined 
organics extracts were dried (magnesium sulfate), filtered and concentrated in vacuo 
to give a crude product, which was then purified by flash column chromatography on 
silica (1:3, ethyl acetate-hexane) to yield (1S*,3S*)-1-phenylhex-5-ene-1,3-diol 79 as 
a yellow oil (954.70 mg, 94%). 1H NMR (400 MHz, CDCl3): δ 7.29-7.18 (5H, m, Ar-H), 
5.76-5.5.65 (1H, m, H-11), 5.04-4.99 (2H, m, H-12), 4.77 (1H, dd, J = 8.4, 4.7 Hz, H-7), 
4.35 (1H, br, OH), 3.90 (1H, br, OH), 3.86-3.80 (1H, m, H-9), 2.15-2.12 (2H, m, H-10), 
1.76-1.65 (2H, m, H-8); 13C NMR (101 MHz, CDCl3): δ 144.4 (C-Ar), 134.2 (C-11), 128.4 
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(C-Ar), 127.5 (C-Ar), 125.7 (C-Ar), 118.0 (C-12), 74.8 (C-7), 71.5 (C-9), 44.5 (C-8), 42.3 
(C-10); IR (film): νmax 3364.1, 2910.5, 1398.6, 1323.6, 1063.5, 914.8, 756.9, 699.5, 
662.0, 556.8 cm-1; ESI-MS: m/z C12H16NaO2 [M+Na
+] 215.1043, found 215.1040 (1.0 
ppm error). 
 
S-p-tolyl prop-2-enethioate 66 
Lab book: YT-2-82-1, NMR: d0260yth (YT-2-82-1) 
 
 
 
Sodium borohydride (62.50 mg, 1.65 mmol, 0.03 eq.) and 4-methylbenzenethiol 
(6.85 g, 55.15 mmol, 1.00 eq.) were stirred in 15% sodium hydroxide aqueous 
solution (25 mL) at room temperature under N2 for 1 hour to give a solution of 
p-CH3C6H4S
-Na+. This solution was cooled to 0 °C before use. 
 
In a separate flask, BHT (170.00 mg, 0.77 mmol, 1.40 mol%) and acryloyl chloride 
(6.72 mL, 7.49 g, 82.73 mmol, 1.50 eq.) were dissolved in cyclohexane (35 mL) and 
cooled to 0 °C. The cold solution of p-CH3C6H4S
-Na+ was then added to this solution 
at 0 °C. After addition was completed, the resultant biphasic mixture was stirred at 
55 °C for 35 minutes. The reaction was extracted with diethyl ether and washed with 
saturated sodium bicarbonate solution and brine, the combined organic extracts 
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were dried (magnesium sulfate), filtered and concentrated in vacuo. BHT (91.00 mg) 
was added to the solution before concentrated in vacuo to prevent polymerization. 
The crude product was then purified by flash column chromatography on silica (1:30, 
ethyl acetate-hexane) to yield S-(4-methylphenyl) 2-propenthioate 66 as a colourless 
oil (5.04 g, 51%). 1H NMR (400 MHz, CDCl3): δ 7.35-7.22 (4H, m, H-Ar), 6.46 (1H, dd, J 
= 17.2, 9.6 Hz, H-10), 6.38 (1H, dd, J = 17.2, 1.6 Hz, H-11a), 5.76 (1H, dd, J = 9.6, 1.6 
Hz, H-11b), 2.39 (3H, s, H-7); 13C NMR (101 MHz, CDCl3): δ 189.1 (C-9), 140.0 (C-Ar), 
134.7 (C-Ar), 134.5 (C-11), 130.2 (C-Ar), 127.4 (C-10), 123.7 (C-Ar), 21.5 (C-7); IR 
(film): νmax 3022.7, 2920.8, 2862.3, 1902.7, 1681.3, 1611,4, 1597.6, 1493.4, 1447.8, 
1393.4, 1303.9, 1276.1, 1201.0, 1181.4, 1159.9, 1116.4, 1095.1, 1041.0, 1018.6, 
986.2, 940.0, 834.7, 806.2, 721.8, 627.6, 592.5, 528.1, 407.7 cm-1; ESI-MS: m/z 
C10H11OS [M+H
+] 179.0525, found 179.0524 (0 ppm error).  
 
(5S*,7S*,E)-S-p-tolyl 5,7-dihydroxy-7-phenylhept-2-enethioate 78 
Lab book: YT-3-67, NMR: p2148yth (YT-3-79-4) 
 
 
(1S*,3S*)-1-Phenylhex-5-ene-1,3-diol 79 (463.77 mg, 2.40 mmol, 1.00 eq.) and 
S-(4-methylphenyl) 2-propenthioate 66 (1.28 g, 7.23 mmol, 3.00 eq.) were dissolved 
in dry diethyl ether (24 mL, 0.10 M) under N2 at room temperature. Copper (I) iodide 
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(45.71 mg, 0.24 mmol, 10.00 mol%) and Hoveyda-Grubbs 2nd generation catalyst 
(150.39 mg, 0.24 mmol, 10.00 mol%) were added and the reaction mixture was 
heated to reflux. After stirring for 3 hours the reaction mixture was concentrated in 
vacuo to give a crude product, which was then purified by flash column 
chromatography on silica (1:1, ethyl acetate-hexane) to yield (5S*,7S*,E)-S-p-tolyl 
5,7-dihydroxy-7-phenylhept-2-enethioate 78 as a colourless oil (766.20 mg, 93%). 1H 
NMR (400 MHz, CDCl3): δ 7.42-7.22 (9H, m, Ar-H), 6.94 (1H, dt, J = 15.0, 7.3 Hz, H-11), 
6.21 (1H, d, J = 15.0 Hz, H-9), 4.86 (1H, dd, J = 9.9, 3.0 Hz, H-15), 4.11 (1H, br, OH), 
4.05-4.00 (1H, m, H-13), 2.39 (3H, s, H-24), 2.37-2.31 (2H, m, H-12a, H-14a), 
1.88-1.70 (2H, m, H-12b, H-14b); 13C NMR (101 MHz, CDCl3): δ 188.7 (C-8), 144.1 
(C-Ar), 142.1 (C-11), 139.7 (C-Ar), 134.6 (C-Ar), 130.1 (C-9), 128.6 (C-Ar), 128.5 (C-Ar), 
127.7 (C-Ar), 125.7 (C-Ar), 123.8 (C-Ar), 74.9 (C-15), 70.9 (C-13), 44.7 (C-12), 40.6 
(C-14), 21.4 (C-24); IR (film): νmax 3356.4, 3032.0, 2917.2, 2251.0, 1672.9, 1631.4, 
1493.4, 1463.0, 1303.8, 1016.7, 907.7, 807.6, 758.3, 728.7, 706.2, 547.1, 475.6 cm-1; 
ESI-MS: m/z C20H22NaO3S [M+Na
+] 365.1182, found 365.1184 (−0.7 ppm error).  
 
S-p-tolyl 2-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 76 
Lab book: YT-3-29, NMR: a2299yth (YT-3-29-2) 
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(5S*,7S*,E)-S-p-Tolyl 5,7-dihydroxy-7-phenylhept-2-enethioate 78 (171.20 mg, 0.50 
mmol, 1.00 eq.) and CSA (58.08 mg, 0.25 mmol, 0.50 eq.) were dissolved in DCE (5 
mL, 0.10 M) under N2 and heated to 80 °C. After stirring at this temperature for 20 
hours, the reaction was quenched with triethylamine (0.2 mL) and washed with 
saturated sodium bicarbonate solution (3 x 5 mL) and brine (3 x 5 mL). The combined 
organic extracts were dried (magnesium sulfate), filtered and concentrated in vacuo 
to give a crude product which was then purified by flash column chromatography on 
silica (1:3, ethyl acetate-hexane) to give S-p-tolyl 2-((2R*,4S*,6S*)-4-hydroxy-6- 
phenyltetrahydro-2H-pyran-2-yl) ethanethioate 76 as a colourless oil (154.60 g, 90%). 
1H NMR (400 MHz, CDCl3): δ 7.37-7.17 (9H, m, Ar-H), 4.89 (1H, dd, J = 11.8, 2.2 Hz, 
H-9), 4.49 (1H, dddd, J = 11.7, 6.9, 6.0, 2.1 Hz, H-13), 4.31 (1H, p, J = 2.8 Hz, H-11), 
2.98 (1H, dd, J = 14.8, 6.9 Hz, H-14a), 2.77 (1H, dd, J = 14.8, 6.0 Hz, H-14b), 2.34 (3H, 
s, H-18), 1.95-1.90 (1H, m, H-10a), 1.87 (1H, br, OH), 1.83-1.79 (1H, m, H-12a), 1.72 
(1H, ddd, J = 14.5, 11.8, 2.8 Hz, H-10b), 1.65 (1H, ddd, J = 14.3, 11.7, 2.8 Hz, H-12b); 
13C NMR (101 MHz, CDCl3): δ 196.0 (C-16), 142.7 (C-Ar), 139.8 (C-Ar), 134.5 (C-Ar), 
130.1 (C-Ar), 128.4 (C-Ar), 127.4 (C-Ar), 125.9 (C-Ar), 124.3 (C-Ar), 73.6 (C-9), 69.2 
(C-13), 64.6 (C-11), 49.8 (C-14), 40.0 (C-10), 38.0 (C-12), 21.4 (C-18); IR (film): νmax 
3417.0, 3057.9, 3032.0, 2914.5, 2254.6, 1698.3, 1599.4, 1494.0, 1451.0, 1377.1, 
1306.5, 1211.8, 1058.6, 972.8, 909.2, 807.1, 730.6, 697.7 cm-1; ESI-MS: m/z 
C20H22NaO3S [M+Na
+] 365.1182, found 365.1177 (1.2 ppm error). 
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S-p-tolyl 2-((2S*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 77 
Lab book: YT-4-70, NMR: p2148yth (YT-4-37-3) 
 
 
 
(5S*,7S*,E)-S-p-Tolyl 5,7-dihydroxy-7-phenylhept-2-enethioate 78 (366.00 mg, 1.07 
mmol, 1.00 eq.) was dissolved in dry THF (2 mL, 0.54 M) under N2 at room 
temperature. Then 1.00 M TBAF in THF (0.32 mL, 0.32 mol, 0.30 eq.) and acetic acid 
(2.56 μL, 3.60 mg, 0.06 mmol, 0.06 eq.) were added to the reaction mixture at −10 °C. 
After stirring for 2.5 hours, the reaction was quenched saturated sodium bicarbonate 
solution (2 mL). The aqueous phase was extracted with diethyl ether (3 x 2 mL) and 
the combined organic extracts were dried (magnesium sulfate), filtered and 
concentrated in vacuo to give a crude product, which was then purified by flash 
column chromatography on silica (1:1, ethyl acetate-hexane) to give S-p-tolyl 
2-((2S*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) ethanethioate 77 as a 
colourless oil (306.30 mg, 84%). 1H NMR (400 MHz, CDCl3): δ 7.33-7.11 (7H, m, Ar-H), 
4.89 (1H, dd, J = 7.0 Hz, H-9), 4.15-4.08 (1H, m, H-11), 3.26-3.19 (1H, m, H-13), 2.80 
(1H, dd, J = 17.8, 5.8 Hz, H-14a), 2.36 (1H, dd, J = 17.8, 10.9 Hz, H-14b), 2.33 (3H, s, 
H-18), 2.23-2.21 (2H, m, H-10a, H-12a), 1.84 (1H, ddd, J = 14.1, 7.0, 4.5 Hz, H-10b), 
1.56 (1H, dt, J = 13.7, 11.7 Hz, H-12b); 13C NMR (101 MHz, CDCl3): δ 169.5 (C-16), 
143.5 (C-Ar), 138.9 (C-Ar), 134.4 (C-Ar), 130.1 (C-Ar), 128.7 (C-Ar), 127.9 (C-Ar), 127.7 
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(C-Ar), 126.1 (C-Ar), 77.7 (C-11), 70.9 (C-9), 44.6 (C-10), 39.2 (C-13), 36.6 (C-14), 35.4 
(C-12), 21.2 (C-18); IR (film): νmax 3419.7, 3029.0, 2921.3, 2248.1, 1721.6, 1492.3, 
1240.3, 1056.7, 909.0, 810.5, 729.2, 700.9 cm-1; ESI-MS: m/z C20H22NaO3S [M+Na
+] 
365.1182, found 365.1171 (2.4 ppm error).  
 
Diospongin A 1 
Lab book: YT-3-33, NMR: d3154yth, b9994yth (YT-3-33) 
 
 
S-p-Tolyl 2-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 76 (54.00 mg, 0.16 mmol, 1.00 eq.), tris(dibenzylideneacetone) 
dipalladium(0) (14.65 mg, 16.00 μmol, 10.00 mol%), phenylboronic acid (58.53 mg, 
0.48 mmol, 3.00 eq.), and copper(I)-thiophene-2-carboxylate (91.53 mg, 0.48 mmol, 
3.00 eq.) were dissolved in dry THF (1.6 mL, 0.10 M) under N2 at room temperature. 
Then triethylphosphite (2.19 μL, 12.8 μmol, 8.00 mol%) was added at the same 
temperature. After stirring for 2.5 hours, the reaction mixture was diluted with 
diethyl ether, washed with saturated sodium bicarbonate solution (3 x 5 mL) and 
brine (3 x 5 mL). The combined organic extracts were dried (magnesium sulfate), 
filtered and concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (1:1, ethyl acetate-hexane) to give 
diospongin A 1 as a colourless oil (46.00 mg, 97%). 1H NMR (500 MHz, CDCl3): δ 7.98 
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(2H, dd, J = 5.2, 3.3 Hz, H-Ar), 7.56 (1H, t, J = 7.4 Hz, H-Ar) 7.46 (2H, t, J = 7.6 Hz, H-Ar), 
7.31-7.21 (5H, m, H-Ar), 4.93 (1H, dd, J = 11.8, 2.0 Hz, H-6), 4.68-4.62 (1H, m, H-2), 
4.38 (1H, p, J = 2.8 Hz, H-4), 3.42 (1H, dd, J = 16.0, 5.8 Hz, H-1a), 3.07 (1H, dd, J = 16.0, 
6.8 Hz, H-1b), 1.99-1.93 (2H, m, H-3a, H-5a), 1.76 (1H, ddd, J = 14.4, 11.8, 2.8 Hz, 
H-5b), 1.69 (1H, ddd, J = 14.2, 11.4, 2.8 Hz, H-3b); 13C NMR (101 MHz, CDCl3): δ 198.4 
(C-15), 142.8 (C-Ar), 137.4 (C-Ar), 133.3 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 
127.4 (C-Ar), 126.0 (C-Ar), 73.9 (C-6), 69.2 (C-2), 64.8 (C-4), 45.3 (C-1), 40.2 (C-5), 
38.6 (C-3); IR (film): νmax 3439.2, 3065.3, 3028.3, 2917.5, 2850.6, 1736.4, 1681.7, 
1599.4, 1449.1, 1288.5, 1210.7, 1058.1, 981.2, 751.6, 697.9 cm-1; ESI-MS: m/z 
C19H20NaO3 [M+Na
+] 319.1305, found 319.1289 (4.3 ppm error). The 1H NMR data 
was in agreement with the literature.22 
 
Diospongin B 2 
Lab book: YT-5-32, NMR: p6233yth (YT-5-32-7) 
 
 
S-p-Tolyl 2-((2S*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl)  
ethanethioate 77 (25.00 mg, 73.00 μmol, 1.00 eq.) was dissolved in dry THF (0.2 mL). 
Phenyllithium (0.25 mL, 160.60 μmol, 2.20 eq., 1.54 M) was added under N2 at −78 
°C then was allowed to warm to room temperature. After stirring for 24 hours, the 
reaction mixture was quenched with chlorotrimethylsilane (92.65 μL, 0.73 mmol, 
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10.00 eq.), diluted with diethyl ether and saturated sodium bicarbonate solution was 
added. The aqueous phase was extracted with diethyl ether (3 x 2 mL) and the 
combined organic extracts were dried (magnesium sulfate), filtered and concentrated 
in vacuo to give a crude product, which was then purified by flash column 
chromatography on silica (1:1, ethyl acetate-hexane) to give diospongin B 2 as a 
yellow oil (12.00 mg, 55%). 1H NMR (500 MHz, CDCl3): δ 8.00-7.98 (2H, m, H-Ar), 
7.60-7.53 (1H, m, H-Ar), 7.49-7.46 (2H, m, H-Ar), 7.37-7.22 (4H, m, H-Ar), 7.24-7.22 
(1H, m, H-Ar), 5.20 (1H, t, J = 4.3 Hz, H-6), 4.24 (1H, dddd, J = 9.5, 6.6, 7.0, 3.0 Hz, 
H-2), 4.06-4.00 (1H, m, H-4), 3.46 (1H, dd, J = 15.8, 7.0 Hz, H-1a), 3.18 (1H, dd, J = 
15.8, 6.6 Hz, H-1b), 2.53 (1H, ddt, J = 13.8, 4.3, 1.7 Hz, H-5a), 2.09-2.04 (1H, m, H-3a), 
1.92 (1H, ddd, J = 13.8, 9.9, 4.3 Hz, H-5b), 1.51 (1H, dt, J = 12.5, 9.5 Hz, H-3b); 13C 
NMR (101 MHz, CDCl3): δ 198.5 (C-15), 140.4 (C-Ar), 137.4 (C-Ar), 133.3 (C-Ar), 128.8 
(C-Ar), 128.7 (C-Ar), 128.4 (C-Ar), 127.3 (C-Ar), 126.5 (C-Ar), 72.5 (C-6), 67.1 (C-2), 
64.4 (C-4), 44.8 (C-1), 40.3 (C-3) and 36.9 (C-5); IR (film): νmax 3411.0, 2924.3, 2855.2, 
1943.2, 1939.3, 1664.1, 1448.4, 1053.7, 692.5 cm-1; ESI-MS: m/z C20H22NaO3S 
[M+Na+] 319.1305, found 319.1317 (−4.2 ppm error). The 1H NMR data was in 
agreement with the literature.33  
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S-p-tolyl 2-((2S*,4S*,6S*)-6-phenyl-4-((triisopropylsilyl)oxy) 
tetrahydro-2H-pyran-2-yl)ethanethioate 113 
Lab book: YT-3-89, NMR: p2461yth (YT-3-89-3) 
 
 
S-p-Tolyl 2-((2S*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 77 (227.40 mg, 0.66 mmol, 1.00 eq.) was dissolved in pyridine (522.06 
mg, 0.53 mL, 6.60 mmol, 10.00 eq.). TIPSOTf (0.71 mL, 808.95 mg, 2.64 mmol, 4.00 
eq.) was added to the reaction mixture under N2 at 0 °C. After 30 minutes the 
reaction was allowed to warm to room temperature and stirred for 24 hours. The 
reaction mixture was then diluted with diethyl ether and washed with saturated 
copper(II) sulfate solution (5 mL). The aqueous phase was extracted with diethyl 
ether (3 x 5 mL) and the combined organic extracts were dried (magnesium sulfate), 
filtered and concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (1:8, ethyl acetate-hexane) to give S-p-tolyl 
2-((2S*,4S*,6S*)-6-phenyl-4-((triisopropylsilyl)oxy)tetrahydro-2H-pyran-2-yl) 
ethanethioate 113 as a yellow solid (225.80 mg, 69%). 1H NMR (400 MHz, CDCl3): δ 
7.34-7.22 (7H, m, Ar-H), 7.12 (2H, d, J = 7.9 Hz, Ar-H), 5.02 (1H, dd, J = 9.1, 4.7 Hz, 
H-9), 3.78 (1H, ddt, J = 11.5, 9.5, 3.3 Hz, H-11), 3.23-3.15 (1H, m, H-13), 2.85 (1H, ddd, 
J = 17.9, 6.0, 2.1 Hz, H-14a), 2.38 (1H, dd, J = 17.9, 10.9 Hz, H-14b), 2.34 (3H, s, H-18), 
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2.26 (1H, ddd, J = 14.0, 9.5, 4.7 Hz, H-10a), 2.10-2.05 (1H, m, H-12a), 1.86 (1H, ddd, J 
= 14.0, 9.1, 3.3 Hz, H-10b), 1.54 (1H, dt, J = 13.9, 11.5 Hz, H-12b), 1.04-0.91 (21H, m, 
H-1); 13C NMR (101 MHz, CDCl3): δ 169.5 (C-16), 143.9 (C-Ar), 139.0 (C-Ar), 134.6 
(C-Ar), 130.1 (C-Ar), 128.4 (C-Ar), 127.8 (C-Ar), 127.6 (C-Ar), 126.5 (C-Ar), 76.88 (C-11), 
71.4 (C-9), 46.9 (C-10), 39.5 (C-13), 36.8 (C-14), 36.2 (C-12), 21.3 (C-18), 18.11, 18.01, 
12.26; IR (film): νmax 2943.0, 2865.4, 1738.6, 1492.5, 1462.8, 1388.4, 1369.9, 1228.5, 
1090.3, 882.6, 811.3, 701.7, 681.9 cm-1; ESI-MS: m/z C29H42NaO3SSi [M+Na
+] 
521.2516, found 521.2491 (4.8 ppm error). 
 
S-p-tolyl 
2-((2S*,4S*,6S*)-4-((tert-butyldimethylsilyl)oxy)-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 114 
Lab book: YT-3-74, NMR: k0602yth (YT-3-74-2-2) 
 
 
 
S-p-Tolyl 2-((2S*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) 
ethanethioate 77 (98.40 mg, 0.29 mmol, 1.00 eq.) and imidazole (59.23 mg, 0.87 
mmol, 3.00 eq.) were dissolved in dry DMF (2 mL, 0.15 M). TBSCl (66.32 mg, 0.44 
mmol, 1.50 eq.) was added to the reaction mixture under N2 at 0 °C. After 30 
minutes the reaction was allowed to warm to room temperature and stirred for 96 
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hours. The reaction was then quenched with 2 M hydrochloric acid (2 mL). The 
organic phase was separated and the aqueous phase was extracted with 
dichloromethane (3 x 2 mL). The combined organic extracts were dried (magnesium 
sulfate), filtered and concentrated in vacuo to give a crude product, which was then 
purified by flash column chromatography on silica (1:1, ethyl acetate-hexane) to give 
S-p-tolyl 2-((2S*,4S*,6S*)-4-((tert-butyldimethylsilyl)oxy)-6-phenyltetrahydro-2H- 
pyran-2-yl) ethanethioate 114 as a yellow oil (19.80 mg, 15%). 1H NMR (400 MHz, 
CDCl3): δ 7.30-7.09 (9H, m, H-Ar), 4.84 (1H, dd, J = 7.3, 6.3 Hz, H-9), 3.96-3.88 (1H, m, 
H-11), 3.25-3.14 (1H, m, H-13), 2.81 (1H, dd, J = 17.7, 5.9 Hz, H-14a), 2.38 (1H, dt, J = 
17.7, 11.0 Hz, H-14b), 2.31 (3H, s, H-18), 2.20 (1H, ddd, J = 14.0, 7.9, 6.2 Hz, H-10a), 
2.15-2.10 (1H, m, H-12a), 1.79 (1H, ddd, J = 14.0, 7.3, 5.3 Hz, H-10b), 1.60-1.48 (1H, 
m, H-12b), 0.82-0.78 (9H, s, H-30, H-31, H-32), −0.06 (3H, s, H-28), −0.25 (3H, s, H-29); 
13C NMR (101 MHz, CDCl3): δ 169.6 (C-16), 143.7 (C-Ar), 139.0 (C-Ar), 134.6 (C-Ar), 
130.1 (C-Ar), 128.5 (C-Ar), 127.9 (C-Ar), 127.7 (C-Ar), 126.3 (C-Ar), 77.1 (C-11), 71.4 
(C-9), 46.3 (C-10), 39.7 (C-13), 36.7 (C-14), 35.8 (C-12), 25.9 (C-30, C-31, C-32), 21.3 
(C-18), 18.2 (C-27), −4.6 (C-28), −5.0 (C-29); IR (film): νmax 3337.5, 2970.0, 2932.2, 
2883.5, 2658.3, 1407.5, 1466.5, 1378.7, 1340.6, 1306.5, 1160.1, 1128.1, 1107.5, 
816.6, 789.7, 751.5 cm-1; ESI-MS: m/z C26H36NaO3SSi [M+Na
+] 479.2047, found 
479.2025 (4.0 ppm error). 
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(6S*,8S*,E)-6,8-dihydroxy-8-phenyloct-3-en-2-one 122 
Lab book: YT-6-13, NMR: r3291yth (YT-6-13-6) 
 
 
(1S*,3S*)-1-Phenylhex-5-ene-1,3-diol 79 (200.00 mg, 1.04 mmol, 1.00 eq.) and 
3-buten-2-one (145.79 mg, 0.17 mL, 2.08 mmol, 2.00 eq.) were dissolved in dry 
diethyl ether (10 mL, 0.10 M) under N2 at room temperature. Grubbs 2
nd generation 
catalyst (88.29 mg, 104.00 μmol, 10.00 mol%) was added and the reaction was 
heated to reflux. After stirring for 2.5 hours the reaction mixture was concentrated in 
vacuo to give a crude product, which was then purified by flash column 
chromatography on silica (2:1, ethyl acetate-hexane) to yield (6S*,8S*,E)-6,8- 
dihydroxy-8-phenyloct-3-en-2-one 122 as a yellow oil (171.80 mg, 71%) and 
1-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl)propan- 
2-one 125 as a colourless oil (9.50 mg, 4%). The data for compound 122: 1H NMR 
(400 MHz, CDCl3): δ 7.39-7.27 (5H, m, H-Ar), 6.83 (1H, dt, J = 16.0, 7.2 Hz, H-4), 6.10 
(1H, d, J = 16.0 Hz, H-2), 4.93 (1H, dd, J = 10.1, 2.7 Hz, H-8), 4.13-4.08 (1H, m, 1H, 
H-6), 3.81 (1H, br, OH), 3.24 (1H, br, OH), 2.42-2.39 (2H, m, H-5), 2.24 (3H, s, H-17), 
1.88 (1H, dt, J = 14.6, 10.1 Hz, H-7a), 1.76 (1H, dt, J = 14.6, 2.7 Hz, H-7b); 13C NMR 
(101 MHz, CDCl3): δ 198.9 (C-1), 144.2 (C-4), 144.1 (C-2), 133.6 (C-Ar), 128.8 (C-Ar), 
128.0 (C-Ar), 125.7 (C-Ar), 75.4 (C-8), 71.2 (C-6), 45.0 (C-7), 40.9 (C-5), 27.1 (C-17); IR 
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(film): νmax 3386.1, 2914.8, 1667.8, 1424.6, 1362.6, 1259.8, 1064.1, 980.0, 758.6, 
701.6, 545.2 cm-1; ESI-MS: m/z C14H18NaO3 [M+Na
+] 257.1148, found 257.1148 (−0.7 
ppm error).  
 
1-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) propan-2-one 125 
Lab book: YT-6-16 and 6-17, NMR: r3506yth (YT-6-16-3) 
 
 
 
(6S*,8S*,E)-6,8-dihydroxy-8-phenyloct-3-en-2-one 122 (36.00 mg, 0.15 mol. 1.00 eq.) 
was dissolved in dry THF (1.50 mL, 0.10 M) under N2 at room temperature. Then 1 M 
TBAF in THF (0.60 mL, 0.60 mol, 4.00 eq.) was added at −10 °C and the reaction was 
allowed to warm to room temperature. After stirring for 18 hours, the reaction was 
quenched with saturated sodium bicarbonate solution (2 mL). The aqueous phase 
was extracted with diethyl ether (3 x 2 mL) and the combined organic extracts were 
dried (magnesium sulfate), filtered and concentrated in vacuo to give a crude 
product, which was then purified by flash column chromatography on silica (3:1, 
ethyl acetate-hexane) to give 
1-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl) propan-2-one 125 as 
a yellow oil (19.90 mg, 55%). 
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(6S*,8S*,E)-6,8-dihydroxy-8-phenyloct-3-en-2-one 122 (34.50 mg, 0.15 mmol, 1.00 
eq.) was dissolved in dichloromethane (3.00 mL, 0.05 M) and water (0.30 mL, 0.50 M) 
under N2 at room temperature. Then TFA (2.50 mL, 0.06M) was added at 0 °C  
and the reaction was allowed to warm to room temperature. After stirring for 20 
hours, the reaction was quenched with saturated sodium bicarbonate solution (3 x 
10 mL). The aqueous phase was extracted with dichloromethane (3 x 10 mL) and the 
combined organic extracts were dried (magnesium sulfate), filtered and concentrated 
in vacuo to give a crude product which was then purified by flash column 
chromatography on silica (2:1, ethyl acetate-hexane) to give 
1-((2R*,4S*,6S*)-4-hydroxy-6-phenyltetrahydro-2H-pyran-2-yl)propan-2-one 125 as a 
yellow oil (6.90 mg, 20%). 1H NMR (400 MHz, CDCl3): δ 7.36-7.20 (5H, m, H-Ar), 4.90 
(1H, dd, J = 11.8, 2.3 Hz, H-8), 4.50-4.43 (1H, m, H-4), 4.36 (1H, p, J = 2.9 Hz, H-6), 
2.76 (1H, dd, J = 15.5, 7.4 Hz, H-2a), 2.53 (1H, dd, J = 15.5, 5.3 Hz, H-2b). 2.20 (3H, s, 
H-17), 1.96-1.91 (1H, m, H-7a), 1.83-1.77 (1H, m, H-5a), 1.75-1.71 (1H, m, H-7b), 
1.67-1.58 (1H, m, H-5b); 13C NMR (101 MHz, CDCl3): δ 207.6 (C-1), 142.7 (C-Ar), 128.5 
(C-Ar), 127.5 (C-Ar), 125.9 (C-Ar), 73.8 (C-8), 69.0 (C-4), 64.8 (C-6), 50.1 (C-2), 40.3 
(C-5), 38.3 (C-7), 31.2 (C-17); IR (film): νmax 3351.2, 2969.9, 1706.7, 1465.8, 1378.7, 
1305.4, 1160.6, 1128.1, 950.7, 816.2, 597.2 cm-1; ESI-MS: m/z C14H18NaO3 [M+Na
+] 
257.1148, found 257.1158 (−3.4 ppm error). 
 
220 
 
1-Phenylprop-2-en-1-one 128 
Lab book: YT-6-24, NMR: r3763yth (YT-6-19-1-r) 
 
 
 
3-Chloropropiophenone (1.50 g, 8.90 mol, 1.00 eq.) was dissolved in chloroform (20 
mL, 0.45 M) under N2 at room temperature. Triethylamine (4.74 mL, 21.36 mol, 2.40 
eq.) was added and stirred for 20 hours. The reaction was quenched with 0.1 M 
hydrochloric acid (20 mL) and washed with saturated sodium bicarbonate solution 
and brine, the combined organic extracts were dried (magnesium sulfate), filtered 
and concentrated in vacuo to give a crude product which was then purified by flash 
column chromatography on silica (1:10, ethyl acetate-hexane) to give 
1-phenylprop-2-en-1-one 128 as a colourless oil (1.16 g, 98%). 1H NMR (400 MHz, 
CDCl3): δ 7.95-7.92 (2H, m, H-Ar), 7.58-7.54 (1H, m, H-Ar) 7.48-7.44 (2H, m, H-Ar), 
7.15 (1H, dd, J = 17.0, 10.6 Hz, H-2,), 6.43 (1H, dd, J = 17.0, 1.7 Hz, H-3a), 5.91 (1H, dd, 
J = 10.6, 1.7 Hz, H-3b); 13C NMR (101 MHz, CDCl3): δ 191.1 (C-1), 137.3 (C-Ar), 133.1 
(C-Ar), 132.4 (C-2), 130.3 (C-3), 128.8 (C-Ar), 128.7 (C-Ar); IR (film): νmax 3060.9, 
1670.5, 1656.0, 1595.9, 1578.8, 1447.8, 1402.8, 1304.9, 1285.6, 1179.6, 1159.5, 
1101.1, 1077.5, 1030.1, 1002.8, 992.6, 978.9, 963.7, 815.3, 747.8, 724.7, 687.9, 
652.8, 552.6 cm-1; ESI-MS: m/z C18H17O2 [M+H
+] 265.1223, found 265.1224 (0.9 ppm 
error). The 1H NMR data was in agreement with the literature.66 
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(5S*,7S*,E)-5,7-dihydroxy-1,7-diphenylhept-2-en-1-one 123 
Lab book: YT-6-23, NMR: r4068yth (YT-6-28-3) 
 
 
(1S*,3S*)-1-Phenylhex-5-ene-1,3-diol 79 (23.27 mg, 0.12 mmol, 1.00 eq.) and 
1-phenylprop-2-en-1-one 128 (31.72 mg, 0.24 mmol, 2.00 eq.) were dissolved in dry 
dichloromethane (1 mL, 0.12 M) under N2 at room temperature. Hoveyda-Grubbs 2
nd 
generation catalyst (7.52 mg, 12.00 μmol, 10.00 mol%) was added and the reaction 
was stirred at refluxing dichloromethane. After stirring for 18 hours the reaction 
mixture was concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (1:1, ethyl acetate-hexane) to yield 
(5S*,7S*,E)-5,7-dihydroxy-1,7-diphenylhept-2-en-1-one 123 as a yellow oil (23.20 mg, 
65%) and diospongin A 1 as a colourless oil (10.50 mg, 30%). The data for compound 
123: 1H NMR (400 MHz, CDCl3): δ 7.95-7.89 (2H, m, 1H, H-Ar), 7.58-7.54 (1H, m, 1H, 
H-Ar), 7.48-7.15 (2H, m, H-Ar), 7.35 (4H, m, H-Ar), 7.32-7.27 (1H, m, H-Ar), 7.10-7.03 
(1H, m, H-4), 6.97 (1H, d, J = 15.6 Hz, H-2), 4.98 (1H, dd, J = 9.9, 2.5 Hz, H-8), 
4.21-4.16 (1H, m, H-6), 3.44 (1H, br, OH), 2.86 (1H, br, OH), 2.60-2.49 (2H, m, H-5), 
1.99-1.90 (2H, m, H-7); 13C NMR (101 MHz, CDCl3): 190.7 (C-1), 145.2 (C-2), 144.2 
(C-4), 137.8 (C-Ar), 133.0 (C-Ar), 128.0 (C-Ar), 125.8 (C-Ar), 75.4 (C-8), 71.3 (C-6), 45.1 
(C-7), 41.4 (C-5); IR (film): νmax 3333.4, 29.69.7, 2930.3, 2883.2, 2659.0, 1718.8, 
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1466.6, 1407.9, 1378.4, 1340.4, 1306.1, 1160.1, 1107.5, 1128.0, 951.0, 816.6, 724.6, 
686.3, 673.7, 647.1, 597.6, 487.0 cm-1; ESI-MS: m/z C19H20NaO3 [M+Na
+] 319.1305, 
found 319.1305 (−0.5 ppm error). 
 
Dodecanethioic acid S-p-tolyl ester 107 
Lab book: YT-5-17, NMR: p5551yth (YT-5-17-2-1) 
 
 
Dodecanoic acid (711.50 mg, 3.55 mmol, 1.00 eq.) was dissolved in refluxing thionyl 
chloride (16.14 mL, 0.22 M) at 80 °C, under N2 for 2 hours. The reaction mixture was 
concentrated in vacuo and used for the next step without any purification. The 
resulting acid chloride and 4-methylbenzenethiol (529.13 mg, 4.26 mmol, 1.20 eq.) 
were dissolved in hexane (35.5 mL, 0.10 M). Triethylamine (0.99 mL, 718.45 mg, 7.10 
mmol, 2.00 eq.) was added at 0 °C and the reaction was allowed to warm to room 
temperature. After stirring for 20 hours, the reaction was filter through celite and 
washed with 1:1 mixture of hexanes and diethyl ether and the combined organic 
filtrates were concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (50:1, dichloromethane-methanol) to give 
223 
 
dodecanethioic acid S-p-tolyl ester 107 as a colourless oil (694.00 mg, 64%). 1H NMR 
(400 MHz, CDCl3): δ 7.27 (2H, d, J = 8.1 Hz, H-Ar), 7.18 (2H, d, J = 8.1 Hz, H-Ar), 2.61 
(2H, t, J = 7.5 Hz, H-11), 2.34 (3H, s, H-21), 1.69 (2H, p, J = 7.5 Hz, H-10), 1.36-1.22 
(16H, m, H-2, H-3, H-4, H-5, H-6, H-7, H-8, H-9), 0.88 (3H, t, J = 5.4 Hz, H-1); 13C NMR 
(101 MHz, CDCl3): δ 197.7 (C-12), 139.4 (C-Ar), 134.4 (C-Ar), 129.9 (C-Ar), 124.5 (C-Ar), 
43.6 (C-11), 31.9 (C-2), 29.6 (C-3), 29.5 (C-4), 29.4 (C-5), 29.3 (C-6), 29.0 (C-7), 25.6 
(C-10), 22.7 (C-8), 21.3 (C-21), 14.1 (C-1). The 1H and 13C NMR data were in 
agreement with the literature.60 
 
1-Furan-2-yl-dodecan-1-one 110 
Lab book: YT-5-26-2, NMR: p5971yth (YT-5-26-2) 
 
 
2-(Tri-n-butylstannyl)furan (125.34 mg, 0.35 mmol, 1.10 eq.), dodecanethioic acid 
S-p-tolyl ester (98.00 mg, 0.32 mmol, 1.00 eq.), CuDPP (106.68 mg, 0.38 mmol, 1.20 
eq.), TFP (5.94 mg, 8.00 mol%, 25.60 μmol) and tris(dibenzylideneacetone) 
dipalladium(0) (2.93 mg, 1.00 mol%, 3.20 μmol) were in a Schlenk tube under N2. Dry 
THF (5.1 mL) was added and the mixture was heated to 50 °C. After stirring for 18 
hours, a hexane/dichloromethane (10:1, v/v, 10 mL) solvent mixture was added and 
then the reaction was filtered through a celite. The combined organic filtrates were 
concentrated in vacuo to give a crude product, which was then purified by flash 
column chromatography on silica (5:1, hexane-dichloromethane) to give 
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1-furan-2-yl-dodecan-1-one 110 as a colourless oil (39.90 mg, 50%). 1H NMR (400 
MHz, CDCl3): δ 7.57 (1H, d, J = 1.2 Hz, H-17), 7.17 (1H, d, J = 3.6 Hz, H-15), 6.52 (1H, 
dd, J = 3.6, 1.7 Hz, H-16), 2.80 (2H, t, J = 7.5 Hz, H-11), 1.71 (2H, p, J = 7.5 Hz, H-10), 
1.38-1.22 (16H, m, H-2, H-3, H-4, H-5, H-6, H-7, H-8, H-9), 0.87 (3H, t, J = 6.8 Hz, H-1). 
The 1H NMR data was in agreement with the literature.63 
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4.3. Experimental Procedures for Chapter two 
Prenyltrimethylsilane 228 
Lab book: YT-7-26, NMR: r8502yth (YT-6-62) 
 
   
 
Magnesium turnings (10.00 g, 411.35 mmol, 2.00 eq.) and catalytic amount of iodine 
(129.44 mg, 0.51 mmol, 0.25 mol%) were dissolved in dry THF (500 mL, 0.40 M) 
under N2 at room temperature. When the solution changed colour from dark brown 
to colourless, the solution was cooled to 0 °C and 1-chloro-3-methyl-2-butene (21.51 
g, 23.18 mL, 205.68 mol, 1.00 eq.) was added dropwise over 1 hour. After stirring for 
1 hour, the reaction mixture was allowed to warm to room temperature and freshly 
distilled chlorotrimethylsilane (22.35 g, 26.11 mL, 205.68 mmol, 1.00 eq.) was added 
slowly via syringe pump over 1 hour (the white solid magnesium chloride was 
precipitated). After stirring for 17 hours, the reaction mixture was filtered through 
celite and washed with hexane (250 mL). The pale yellow solution was collected, 
then water was added and then extracted with hexane (3 x 100 mL). The combined 
organic extracts were dried (magnesium sulfate), filtered and concentrated in vacuo 
to give prenyltrimethylsilane 228 as a colourless oil and was used without any 
further purification (22.50 g, 77%). 1H NMR (400 MHz, CDCl3): δ 5.16-5.12 (1H, t, J = 
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8.5 Hz, H-2), 1.69 (3H, s, H-4), 1.55 (3H, s, H-5), 1.37 (2H, d, J = 8.5 Hz, H-1), −0.02 (9H, 
s, H-7, H-8, H-9); 13C NMR (101 MHz, CDCl3): 128.8 (C-3), 120.1 (C-2), 25.9 (C-4), 18.7 
(C-1), 17.7 (C-5), -1.6 (C-7, C-8, C-9). The 1H and 13C NMR data were in agreement 
with the literature.158 
 
3,3-dimethyl-pent-4-en-2-one 231 
Lab book: YT-7-51, NMR: r8965yth (YT-6-75-d-2-3) 
 
 
 
Aluminum chloride (4.31 g, 32.32 mmol, 1.00 eq.) was dissolved in dry 
dichloromethane (65 mL, 0.50 M) then acetyl chloride (2.77 g, 2.66 mL, 35.55 mmol, 
1.10 eq.) was added slowly at 0 °C under N2. After stirring for 30 minutes, the 
reaction mixture was cooled to −60 °C and prenyltrimethylsilane 228 (4.60 g, 32.32 
mmol, 1.00 eq.) was added and stirred for another 10 minutes. After this, ice and 
saturated ammonium chloride solution (50 mL) was added. The aqueous phase was 
extracted with dichloromethane (50 mL x 3). The combined organic extracts were 
dried (magnesium sulfate), filtered, concentrated in vacuo and purified by Kugelrohr 
distillation (70 °C at 200 mbar) to give 3,3-dimethylpent-4-en-2-one 231 as a 
colourless oil (3.35 g, 93%). 1H NMR (400 MHz, CDCl3): δ 5.92 (1H, dd, J = 17.7, 10.5 
Hz, H-4), 5.17-5.13 (2H, m, H-5), 2.11 (3H, s, H-1), 1.23 (6H, s, H-6, H-7); 13C NMR 
(101 MHz, CDCl3): 192.3 (C-2), 142.6 (C-4), 114.4 (C-5), 51.1 (C-3), 25.6 (C-1), 23.6 
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(C-6, C-7); IR (film): νmax 3410.0, 3088.9, 2973.1, 2928.4, 2868.6, 1949.3, 1709.9, 
1634.8, 1414.4, 1353.5, 1259.9, 1123.9, 1001.8, 917.7, 804.3, 651.4, 598.0, 475.6 
cm-1; ESI-MS: m/z calcd for C7H12O1 [M+H
+] 113.1312, found 113.0961. The 1H and 
13C NMR data were in agreement with the literature.159 
 
3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 221 
Lab book: YT-7-46, NMR: b3244yth (6-78-d-3-2) 
 
 
 
3,3-Dimethyl-pent-4-en-2-one 231 (3.00 g, 26.75 mmol, 1.00 eq.) was dissolved in 
dry acetonitrile (40 mL, 0.67 M) under N2 at room temperature. Then triethylamine 
(13.53 g, 18.63 mL, 133.75 mmol, 5.00 eq.) was added dropwise over 30 minutes to 
the solution and then heated to 30-35 °C. After stirring for 30 minutes, 
chlorotrimethylsilane (5.81 g, 6.79 mL, 53.50 mmol, 2.00 eq.) and sodium iodide 
(8.02 g, 53.50 mmol, 2.00 eq.) were added. The reaction temperature was then 
raised to 40-45 °C and stirred for 17 hours. After cooling the reaction mixture to 
room temperature, the solution was filtered through celite and washed with hexane 
(100 mL). The filtrate was then extracted with hexane and concentrated in vacuo, to 
give 3,3-dimethyl-2-[(trimethylsilyl)oxy]-1,4-pentadiene 221 as a colourless oil (4.67 g, 
95%). 1H NMR (400 MHz, CDCl3): δ 5.93 (1H, dd, J = 17.5, 10.6 Hz, H-4), 5.01 (1H, dd, 
J = 10.6, 1.3 Hz, H-5a), 4.97 (1H, dd, J = 17.5, 1.3 Hz, H-5b), 4,12 (1H, d, J = 1.3 Hz, 
H-1a), 3.98 (1H, d, J = 1.3 Hz, H-1b), 1.14 (6H, s, H-6, H-7), 0.20 (9H, s, H-8, H-9, H-10); 
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13C NMR (101 MHz, CDCl3): 165.0 (C-2), 145.9 (C-4), 111.3 (C-5), 87.5 (C-1), 42.8 (C-3), 
25.4 (C-6, C-7), −1.8 (C-8, C-9, C-10); IR (film): νmax 3123.5, 3088.9, 2963.3, 1619.8, 
1468.1, 1417.8, 1373.7, 1354.8, 1252.8, 1156.1, 1015.4, 912.9, 873.9, 844.09, 597.2 
cm-1. The 1H and 13C NMR data were in agreement with the literature.160 
 
(Z)-1,4-Bis(benzyloxy)but-2-ene 233 
Lab book: YT-7-70, NMR: j3066yth (YT-7-30-13) 
 
 
 
60% Sodium hydride suspension in mineral oil (11.80 g, 295.07 mol, 2.60 eq.) was 
suspended in DMF (300 mL, 0.4 M), at 0 °C cis-2-butene-1,4-diol (10.00 g, 113.49 
mmol, 1.00 eq.) was added to the reaction mixture and was allowed to warm to 
room temperature. After stirring for 1 hour, benzyl bromide (67.94 g, 47.25 mL, 
397.22 mmol, 3.50 eq.) was added dropwise to the reaction mixture and stirred for 4 
hours at room temperature. The reaction was then quenched with saturated 
ammonium chloride solution, diluted with diethyl ether, and washed with water and 
brine. The combined organic extracts were dried (magnesium sulfate), filtered and 
concentrated in vacuo to give a crude product which was then purified by flash 
column chromatography on silica (1:8, ethyl acetate-hexane) to give 
(Z)-1,4-bis(benzyloxy)but-2-ene 233 as a colourless oil (28.02 g, 92%). 1H NMR (400 
MHz, CDCl3): δ 7.40-7.28 (10 H, m, H-Ar), 5.83-5.81 (2H, m, H-2, H-3), 4.51 (4H, s, H-5, 
H-12), 4.09 (4H, d, J = 4.9 Hz, H-1, H-4); 13C NMR (101 MHz, CDCl3): 138.2 (C-Ar), 
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129.6 (C-2, C-3), 128.5 (C-Ar), 127.9 (C-Ar), 127.8 (C-Ar), 72.4 (C-5, C-12), 65.9 (C-1, 
C-4); IR (film): νmax 3327.4, 3030.8, 2862.3, 1719.8, 1698.0, 1495.9, 1453.4, 1364.1, 
1313.4, 1270.8, 1204.5, 1071.0, 1026.5, 827.4, 737.9, 697.2, 649.6, 604.8 cm-1; 
ESI-MS: m/z C18H20NaO2 [M+Na
+] 291.1350, found 291.1356 (2.1 ppm error). The 1H 
and 13C NMR data were in agreement with the literature.105  
 
2-Benzyloxyacetoaldehyde 220 
Lab book: YT-7-43, NMR: j9360yth (YT-7-43) 
 
 
*Ozone is a toxic gas. The ozonolysis experiment must be carried out in the fume 
hood. Avoid inhalation and skin or eye contact. 
 
(Z)-1,4-bis(benzyloxy)but-2-ene 233 (31.90 g, 118.87 mmol, 1.00 eq.) was dissolved 
in dry dichloromethane (400 mL, 0.3 M) under N2 at −78 °C. Ozone was then bubbled 
through the solution until the solution changed to a blue colour. Keep the fume 
hood fully down while passing ozone through the solution. After stirring for 2.5 
hours, zinc powder (11.34 g, 178.31 mmol, 1.50 eq.) and 50% acetic acid solution 
(71.46 g, 1.19 mol, 10.00 eq.) were added and the reaction was allowed to warm to 
room temperature. After stirring for 17 hours, the reaction mixture was washed with 
water (200 mL) and extracted with dichloromethane (200 mL x 3). The combined 
organic extracts were washed with saturated sodium bicarbonate solution, dried 
230 
 
(magnesium sulfate), filtered and concentrated in vacuo to give 
2-benzyloxyacetoaldehyde 220 as a colourless oil (33.25 g, 93%). 1H NMR (400 MHz, 
CDCl3): δ 9.73 (1H, s, H-10), 7.39-7.32 (5H, m, H-Ar), 4.64 (2H, s, H-3), 4.11 (2H, s, 
H-2); 13C NMR (101 MHz, CDCl3): 200.6 (C-1), 136.9 (C-Ar), 128.8 (C-Ar), 128.4 (C-Ar), 
128.2 (C-Ar), 75.4 (C-2), 73.8 (C-3); IR (film): νmax 3449.2, 3063.9, 3031.2, 2861.8, 
2719.9, 1734.4, 1605.2, 1496.4, 1454.2, 1373.6, 1317.0, 1258.9, 1206.3, 1107.6, 
1027.9, 983.0, 911.3, 853.2, 738.0, 697.3, 597.7, 524.0, 470.0, 484.7, 464.0, 477.5 
cm-1; ESI-MS: m/z C9H10NaO2 [M+Na
+] 173.0573, found 173.0572 (−0.2 ppm error). 
The 1H and 13C NMR data were in agreement with the literature.105 
 
7-(benzyloxy)-6-hydroxy-3,3-dimethylhept-1-en-4-one 222 
Lab book: YT-7-17, NMR: j1191yth (YT-7-17-2) 
 
 
 
3,3-Dimethyl-2-[(trimethylsilyl)oxy]-I,4-pentadiene 221 (3.19 g, 17.30 mmol, 2.00 eq.) 
was dissolved in dry dichloromethane (20 mL, 0.43 M) and 
2-benzyloxyacetalaldehyde 220 (1.30 g, 8.65 mmol, 1.00 eq.) was added dropwise at 
−78 °C under N2. After stirring for 15 minutes, titanium tetrachloride (1.05 mL, 9.52 
mmol, 1.10 eq) was added and the reaction was allowed to warm to room 
temperature. After stirring for 17 hours, the reaction mixture was quenched with 
231 
 
cold water (10 mL) and saturated sodium bicarbonate solution (10 mL). The aqueous 
phase was extracted with dichloromethane (20 x 3 mL) and the combined organic 
extracts were dried (magnesium sulfate), filtered and concentrated in vacuo to give a 
crude product, which was then purified by flash column chromatography on silica 
(1:2, ethyl acetate-hexane) to give 222 as a yellow oil (1.13 g, 51%). 1H NMR (400 
MHz, CDCl3): δ 7.37-7.27 (5H, m, H-Ar), 5.89 (1H, dd, J = 10.6, 17.4 Hz, H-2), 5.18-5.14 
(2H, m, H-1), 4.55 (2H, s, H-8), 4.25-4.19 (1H, m, H-6), 3.49-3.42 (2H, m, H-7), 3.07 
(1H, br, OH), 2.71-2.68 (2H, m, H-5), 1.23 (3H, s, H-15), 1.22 (3H, s, H-16); 13C NMR 
(101 MHz, CDCl3): 213.5 (C-4), 142.1 (C-2), 138.1 (C-9), 128.7 (C-Ar), 128.6 (C-Ar), 
127.9 (C-Ar), 115.0 (C-1), 73.5 (C-8), 73.3 (C-7), 67.1 (C-6), 51.1 (C-3), 40.9 (C-5), 23.5 
(C-15), 23.4 (C-16); IR (film): νmax 3449.4, 2972.8, 2927.5, 2868.7, 1706.3, 1635.4, 
1453.7, 1363.5, 1098.6, 1027.6, 919.3, 736.5, 698.1, 597.8 cm-1; ESI-MS: m/z 
C16H22NaO3 [M+Na
+] 285.1461, found 285.1450 (3.8 ppm error).  
 
(2S*,4R*)-1-(benzyloxy)-5,5-dimethylhept-6-ene-2,4-diol 223 
Lab book: YT-8-25, NMR: b3025yth (YT-6-74-2-2) 
 
 
1.00 M Solution of triethyl borane in hexanes (1.74 mL, 1.74 mmol, 1.10 eq.) was 
added to a THF/methanol (1:5, v/v, 12 mL) solvent mixture under N2 at room 
temperature. After stirring the reaction mixture for 2 hours, the solution was cooled 
down to −78 °C and 7-(benzyloxy)-6-hydroxy-3,3-dimethylhept-1-en-4-one 222 
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(415.60 mg, 1.58 mmol, 1.00 eq.) was added slowly. After stirring for 30 minutes, 
sodium borohydride (65.82 mg, 1.74 mmol, 1.10 eq.) was added in one portion and 
then reaction was allowed to warm to room temperature. After stirring the reaction 
for 17 hours, the reaction mixture was quenched with saturated ammonium chloride 
solution (10 mL) and then diluted with ethyl acetate (10 mL). The aqueous phase was 
extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts were 
dried (magnesium sulfate), filtered and concentrated in vacuo to give a crude 
product, which was then purified by flash column chromatography on silica (1:2, 
ethyl acetate-hexane) to yield 223 as a yellow oil (292.40 mg, 70%). 1H NMR (400 
MHz, CDCl3): δ 7.38-7.28 (5H, m, H-Ar), 5.83 (1H, dd, J = 17.5, 10.8 Hz, H-6), 5.07 (1H, 
dd, J = 17.5, 1.3 Hz, H-7a), 5.04 (1H, dd, J = 10.8, 1.3 Hz, H-7b), 4.56 (2H, s, H-8), 
4.06-4.00 (1H, m, H-2), 3.56 (1H, dd, J = 10.5, 1.6 Hz, H-4), 3.45 (1H, dd, J = 9.4, 4.0 Hz, 
H-1a), 3.40 (1H, dd, J = 9.4, 7.0 Hz, H-1b), 3.27 (1H, br, OH), 3.07 (1H, br, OH), 
1.68-1.64 (1H, m, H-3a), 1.46-1.40 (1H, m, H-3b), 1.01 (6H, s, H-15, H-16); 13C NMR 
(101 MHz, CDCl3): 145.4 (C-6), 138.0 (C-9), 128.6 (C-Ar), 128.0 (C-Ar), 127.9 (C-Ar), 
113.3 (C-7), 78.8 (C-4), 74.4 (C-1), 73.5 (C-8), 71.9 (C-2), 41.6 (C-5), 33.9 (C-3), 22.6 
(C-15), 22.5 (C-16); IR (film): νmax 3391.8, 3085.7, 3063.7, 3032.2, 2959.9, 2925.2, 
2864.9, 1637.8, 1496.1, 1453.6, 1414.8, 1362.7, 1309.7, 1204.2, 1093.4, 1028.0, 
1005.4, 911.9, 846.1, 734.8, 697.5, 608.9, 586.0, 551.9, 518.0, 507.0, 495.6, 484.6, 
473.6, 462.7 cm-1; ESI-MS: m/z C16H24NaO3 [M+Na
+] 287.1618, found 287.1614 (1.2 
ppm error).  
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(2R*,4R*)-1-(benzyloxy)-5,5-dimethylhept-6-ene-2,4-diol 234 
Lab book: YT-7-19, NMR: j1534yth (YT-7-19-4) 
 
 
Sodium triacetoxyborohydride (146.40 mg, 0.56 mmol, 1.00 eq.) was dissolved in a 
acetonitrile/acetic acid (1:1.2, v/v, 11 mL) solvent mixture under N2 at room 
temperature. 7-(benzyloxy)-6-hydroxy-3,3-dimethylhept-1-en-4-one 222 (1.03 g, 3.29 
mmol, 7.00 eq.) was added to the solution at −35 °C and then reaction was allowed 
to warm to room temperature. After stirring the reaction for 17 hours, the reaction 
mixture was quenched with 10% Rochelle salt (10 mL) and extracted with ethyl 
acetate (40 mL). The combined organic extracts were dried (magnesium sulfate), 
filtered and concentrated in vacuo to give a crude product, which was then purified 
by flash column chromatography on silica (1:2, ethyl acetate-hexane) to yield 234 as 
a yellow oil (47.50 mg, 32%). 1H NMR (400 MHz, CDCl3): δ 7.38-7.28 (5H, m, H-Ar), 
5.82 (1H, dd, J = 17.4, 11.0 Hz, H-6), 5.08 (1H, dd, J = 11.0, 1.3 Hz, H-7a), 5.04 (1H, dd, 
J = 17.4, 1.3 Hz, H-7b), 4.57 (1H, s, H-8a), 4.56 (1H, s, H-8b), 4.14-4.08 (1H, m, H-2), 
3.63 (1H, dd, J = 13.2, 1.6 Hz, H-4), 3.53 (1H, dd, J = 9.4, 3.5 Hz, H-1a), 3.36 (1H, dd, J 
= 9.4, 7.8 Hz, H-1b), 2.65 (1H, br, OH), 2.10 (1H, br, OH), 1.65-1.59 (1H, m, H-3a), 
1.45-1.38 (1H, m, H-3b), 1.01 (3H, s, H-15), 1.00 (3H, s, H-16); 13C NMR (101 MHz, 
CDCl3): 145.3 (C-6), 138.0 (C-9), 128.6 (C-Ar), 127.9 (C-Ar), 127.9 (C-Ar), 113.4 (C-7), 
74.6 (C-1), 74.3 (C-4), 73.4 (C-8), 68.1 (C-2), 41.4 (C-5), 34.2 (C-3), 23.0 (C-15), 22.3 
(C-16); IR (film): νmax 2965.6, 2252.1, 1454.0, 1365.3, 1091.7, 904.3, 726.9, 649.9, 
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597.8, 476.9 cm-1; ESI-MS: m/z C16H24NaO3 [M+Na
+] 287.1618, found 287.1619 (0.0 
ppm error).  
 
(4S*,6R*)-4-((benzyloxy)methyl)-2,2-dimethyl-6-(2-methylbut-3-en-2-yl)- 
1,3-dioxane 235 
Lab book: YT-7-23-1, NMR: j2118yth (YT-7-23-1) 
 
 
 
Diol 223 (48.50 mg, 0.18 mmol, 1.00 eq.) and 4-methylbenzenesulfonic acid (3.42 mg, 
18.00 μmol, 0.10 eq.) were dissolved in dry THF (1.8 mL, 0.10 M), then 
2,2-dimethoxypropane (44.27 μL, 37.49 mg, 0.36 mmol, 2.00 eq.) was added at room 
temperature and stirred for 17 hours. The reaction was quenched with saturated 
sodium bicarbonate solution (5 mL) and extracted with dichloromethane (5 mL). The 
combined organic extracts were dried (magnesium sulfate), filtered and concentrated 
in vacuo to give a crude product, which was then purified by flash column 
chromatography on silica (1:5, ethyl acetate-hexane) to yield 235 as a yellow oil 
(11.10 mg, 20%).1H NMR (400 MHz, CDCl3): δ 7.37-7.27 (5H, m, H-Ar), 5.88 (1H, dd, J 
= 17.4, 11.1 Hz, H-5), 4.99 (1H, dd, J = 11.1, 1.5 Hz, H-12a), 4.97 (1H, dd, J = 17.4, 1.5 
Hz, H-12b), 4.60 (1H, d, J = 12.3 Hz, H-16a), 4.53 (1H, d, J = 12.3 Hz, H-16b), 4.07-4.00 
(1H, m, H-3), 3.53 (1H, dd, J = 11.8, 2.4 Hz, H-2), 3.48 (1H, dd, J = 10.0, 6.0 Hz, H-6a), 
3.35 (1H, dd, J = 10.0, 4.9 Hz, H-6b), 1.42 (3H, s, H-10), 1.39 (3H, s, H-11), 1.21-1.01 
(2H, m, H-1), 0.99 (3H, s, H-13), 0.98 (3H, s, H-14); 13C NMR (101 MHz, CDCl3): 145.2 
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(C-5), 138.4 (C-17), 128.5 (C-Ar), 128.0 (C-Ar), 127.8 (C-Ar), 112.1 (C-12), 98.7 (C-9), 
75.3 (C-2), 74.0 (C-6), 73.6 (C-16), 68.9 (C-3), 40.1 (C-4), 30.2 (C-10), 28.6 (C-1), 23.1 
(C-13), 22.7 (C-14), 19.8 (C-11); IR (film): νmax 3439.2, 2924.6, 2861.7, 1637.8, 1496.4, 
1453.7, 1415.1, 1378.9, 1261.5, 1199.8, 1169.3, 1100.5, 1028.3, 1000.2, 911.5, 866.8, 
850.3, 802.6, 735.1, 697.1, 608.2, 524.5, 475.7 cm-1; ESI-MS: m/z C19H28NaO3 [M+Na
+] 
327.1931, found 327.1927 (1.3 ppm error).  
 
(4R*,6R*)-4-((benzyloxy)methyl)-2,2-dimethyl-6-(2-methylbut-3-en-2-yl)-1,3-dioxan
e 236 
Lab book: YT-7-21-1, NMR: k0740yth (YT-7-21-1) 
 
 
Diol 234 (72.90 mg, 0.28 mmol, 1.00 eq.) and 4-methylbenzenesulfonic acid (5.33 mg, 
28.00 μmol, 0.10 eq.) were dissolved in dry dichloromethane (1.75 mL), then 
2,2-dimethoxypropane (58.32 mg, 68.85 μL, 0.56 mmol, 2.00 eq.) was added at room 
temperature and stirred for 17 hours. The reaction was quenched with saturated 
sodium bicarbonate solution and extracted with dichloromethane (5 mL). The 
combined organic extracts were dried (magnesium sulfate), filtered and concentrated 
in vacuo to give a crude product, which was then purified by flash column 
chromatography on silica (1:4, ethyl acetate-hexane) to yield 236 as a yellow oil 
(15.50 mg, 18%). 1H NMR (400 MHz, CDCl3): δ 7.36-7.26 (5H, m, H-Ar), 5.88 (1H, dd, J 
= 17.4, 11.0 Hz, H-5), 5.00 (1H, dd, J = 11.0, 1.4 Hz, H-12a), 4.58 (1H, dd, J = 17.4, 1.4 
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Hz, H-12b), 4.62 (1H, d, J = 12.3 Hz, H-16a), 4.54 (1H, d, J = 12.3 Hz, H-16b), 3.97-3.91 
(1H, m, H-3), 3.51 (1H, dd, J = 10.0, 6.3 Hz, H-2), 3.47 (1H, dd, J = 10.4, 6.5 Hz, H-6a), 
3.41(1H, dd, J = 10.4, 4.0 Hz, H-6b), 1.67-1.38 (2H, m, H-1), 1.36 (3H, s, H-10), 1.34 
(3H, s, H-11), 0.99 (3H, s, H-13), 0.96 (3H, s, H-14); 13C NMR (101 MHz, CDCl3): 144.8 
(C-5), 138.5 (C-17), 128.5 (C-Ar), 127.9 (C-Ar), 127.7 (C-Ar), 112.3 (C-12), 100.6 (C-9), 
73.4 (C-16), 73.0 (C-2), 72.9 (C-6), 66.8 (C-3), 40.0 (C-4), 30.4 (C-1), 24.9 (C-10), 24.3 
(C-11), 23.1 (C-13), 22.8 (C-14); IR (film): νmax 3332.4, 2969.7, 2931.7, 2882.5, 2658.8, 
1466.6, 1378.5, 1367.9, 1340.5, 1306.4, 1160.1, 1128.1, 1108.0, 951.0, 816.7 cm-1; 
ESI-MS: m/z C19H28NaO3 [M+Na
+] 327.1931, found 327.1918 (4.0 ppm error).  
 
(E)-2-ButenoicAcid S-(4-Methylphenyl)Ester 240 
Lab book: YT-7-37-3, NMR:j2256yth (YT-7-37-3) 
 
 
 
Sodium borohydride (12.48 mg, 0.33 mmol, 0.03 eq.) and 4-methylbenzenethiol 
(1.37 g, 11.03 mmol, 1.00 eq.) were stirred in 15% sodium hydroxide aqueous 
solution (5 mL) at room temperature under N2 for 1 hour to give a solution of 
p-CH3C6H4S
−Na+. This solution was cooled to 0 °C before use.  
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In a separate flask, BHT (33.05 mg, 0.15 mmol, 1.40 mol%) and crotonoyl chloride 
(1.73 g, 1.59 mL, 16.55 mmol, 1.50 eq.) were dissolved in cyclohexane (7 mL) and 
cooled to 0 °C. The cold solution of p-CH3C6H4S
−Na+ was then added to this solution 
at 0 °C. After addition was completed, the reaction was left to warm to 55 °C for 35 
minutes. The reaction was extracted with diethyl ether and washed with saturated 
sodium bicarbonate solution and brine, the combined organic extracts were dried 
(magnesium sulfate), filtered and concentrated in vacuo. BHT (18.20 mg) was added 
to the solution before concentrated in vacuo to prevent polymerization. The crude 
product was then purified by flash column chromatography on silica (1:30, ethyl 
acetate-hexane) to yield (E)-2-butenoicacid S-(4-Methylphenyl)ester 240 as a 
colourless oil (1.09 g, 51%). 1H NMR (400 MHz, CDCl3): δ 7.33-7.21 (4H, m, H-Ar), 
6.99 (1H, dq, J = 15.3, 1.5 Hz, H-10), 6.21 (1H, dq, J = 15.3, 6.9 Hz, H-11), 2.38 (3H, s, 
H-7), 1.92 (3H, dd, J =6.9, 1.5 Hz, H-13 ); 13C NMR (101 MHz, CDCl3): 188.6 (C-9), 
142.0 (C-10), 139.7 (C-Ar), 134.8 (C-Ar), 130.1 (C-Ar), 129.5 (C-11), 124.2 (C-Ar), 21.5 
(C-7), 18.2 (C-13); IR (film): νmax 3026.0, 2979.2, 2916.0, 2866.0, 2252.4, 1905.4, 
1678.2, 1636.0, 1597.8, 1493.2, 1440.2, 1398.8, 1375.7, 1303.3, 1210.0, 1181.7, 
1153.4, 1116.7, 1084.5, 1037.7, 1017.9, 959.2, 933.0, 907.1, 805.3, 729.9, 705.2, 
646.9, 619.7, 572.9, 534.0, 509.2, 474.5 cm-1; ESI-MS: m/z C11H12NaO2 [M+Na
+] 
215.0501, found 215.0497 (1.7 ppm error). The 1H and 13C NMR data were in 
agreement with the literature.161 
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S-p-tolyl 2-bromoethanethioate 244 
Lab book: YT-7-53-2, NMR: j4392yth (YT-7-53-2) 
 
 
 
4-Methylbenzenethiol (2.00 g, 16.10 mmol, 1.00 eq.) was dissolved in diethyl ether 
(30 mL, 0.54 M), then pyridine (1.30 mL, 1.27 g, 16.10 mmol, 1.00 eq.) was added at 
room temperature under N2. After stirring for 20 minutes, bromoacetyl bromide 
(1.40 mL, 3.25 g, 16.10 mmol, 1.00 eq.) was added to the solution at 0 °C and then 
reaction was allowed to warm to room temperature. After stirring the reaction for 
17 hours, the reaction mixture was quenched with water (15 mL) and saturated 
sodium bicarbonate solution (15 mL). The aqueous phase was extracted with diethyl 
ether (3 x 30 mL). The combined organic extracts were washed with copper(II) 
sulfate (3 x 30 mL), dried (magnesium sulfate), filtered and concentrated in vacuo to 
give a crude product which was then purified by flash column chromatography on 
silica (1:8, ethyl acetate-hexane) to give S-p-tolyl 2-bromoethanethioate 244 as a 
yellow oil (3.20 g, 81%). 1H NMR (400 MHz, CDCl3): δ 7.47-7.19 (4H, m, H-Ar), 4.10 
(2H, s, H-11), 2.34 (3H, s, H-7); 13C NMR (101 MHz, CDCl3): 191.7 (C-9), 140.5 (C-Ar), 
134.6 (C-Ar), 130.4 (C-Ar), 123.3 (C-Ar), 33.3 (C-11), 21.5 (C-7); IR (film): νmax 2923.8, 
2252.9, 1697.3, 1598.1, 1493.8, 1398.1, 1213.2, 1151.6, 1063.2, 904.6, 808.4, 726.8, 
649.5, 625.8, 597.6, 545.9, 506.8, 471.0 cm-1; ESI-MS: m/z C9H9BrNaO2 [M+Na
+] 
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266.9450, found 266.9442 (2.9 ppm error), C9H10BrO2 [M+Na
+] 244.9630, found 
266.9625 (−1.5 ppm error). The 1H and 13C NMR data were in agreement with the 
literature.112 
 
(2-oxo-2-(p-tolylthio)ethyl)triphenylphosphonium bromide 247 
Lab book: YT-7-71, NMR: j8469yth (YT-7-71-crude) 
 
 
 
S-p-tolyl 2-bromoethanethioate 244 (6.18 g, 25.21 mmol, 1.00 eq.) was dissolved in 
benzene (10 mL, 2.50 M), then triphenylphosphine (6.61 g, 25.21 mmol, 1.00 eq.) 
was added under N2 at room temperature. After stirring for 17 hours, the white solid 
was collected and washed with benzene. The solvent was removed under vacuo to 
give (2-oxo-2-(p-tolylthio)ethyl)triphenylphosphonium bromide 247 as a white solid 
(11.91 g, 93%). 1H NMR (400 MHz, CDCl3 ): δ 7.82-6.93 (19H, m, H-Ar), 5.94 (2H, d, J = 
13.32 Hz, H-11), 2.22 (3H, s, H-7); 13C NMR (101 MHz, CDCl3): 190.4 (C-9), 140.8 
(C-Ar), 135.2 (C-Ar), 135.2 (C-Ar), 134.4 (C-Ar), 134.4 (C-Ar), 134.3 (C-Ar), 134.1 (C-Ar), 
134.0 (C-Ar), 130.6 (C-Ar), 130.5 (C-Ar), 130.4 (C-Ar), 130.3 (C-Ar), 129.9 (C-Ar), 128.5 
(C-Ar), 118.6 (C-Ar), 117.7 (C-Ar), 40.7 (C-11), 21.5 (C-7); IR (film): νmax 3055.9, 3019.4, 
2825.3, 1727.3, 1586.9, 1485.2, 1438.1, 1342.1, 1110.7, 996.5, 864.4, 808.3, 749.7, 
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720.8, 688.3, 523.7 cm-1; ESI-MS: m/z C27H24OPS 427.1280, found 427.1271 (3.6 ppm 
error). The 1H and 13C NMR data were in agreement with the literature.112 
 
S-p-tolyl 2-(triphenylphosphoranylidene) ethanethioate 248 
Lab book: YT-8-16, NMR: c0071yth (YT-8-16) 
 
 
 
(2-oxo-2-(p-tolylthio)ethyl)triphenylphosphonium bromide 247 (133.80 mg, 0.26 
mmol, 1.00 eq.) was dissolved in chloroform (1.3 mL, 0.20 M) under N2 at room 
temperature, then triethylamine (0.12 mL, 87.02 mg, 0.86 mmol, 3.30 eq.) was 
added. After stirring for 4 hours, water (1.3 mL) was added and the aqueous phase 
was extracted with dichloromethane (3 x 5 mL) and the combined organic extracts 
were dried (magnesium sulfate), filtered and concentrated in vacuo to give S-p-tolyl 
2-(triphenylphosphoranylidene) ethanethioate 248 as a colourless oil (57.14 mg, 
51%). 1H NMR (400 MHz, CDCl3): δ 7.79-7.09 (19H, m, H-Ar), 3.62 (1H, d, J = 22.2 Hz, 
H-11), 2.29 (3H, s, H-7). The 1H NMR data was in agreement with the literature.112 
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(5S*,7R*)-5-((benzyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-7-(2-methylbut-3-en-
2-yl)-4,8-dioxa-3,9-disilaundecane 249 
Lab book: YT-7-75-1, NMR: j6596yth (YT-7-75-1) 
 
 
 
Diol 223 (327.90 mg, 1.24 mmol, 1.00 eq.) was dissolved in dry dichloromethane 
(12.0 mL, 0.10 M), then pyridine (0.50 mL, 490.42 mg, 6.20 mmol, 5.00 eq.) was 
added to the solution at 0 °C under N2. After stirring for 20 minutes, TBSOTf (1.14 mL, 
1.31 g, 4.96 mmol, 4.00 eq.) was added to the solution at 0 °C and then reaction was 
allowed to warm to room temperature. After stirring the reaction for 17 hours, the 
reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL) 
and extracted with dichloromethane (3 x 10 mL). The organic phase was washed with 
copper(II) sulfate (3 x 10 mL) and brine (3 x 10 mL). The combined organic extracts 
were dried (magnesium sulfate), filtered and concentrated in vacuo to give a crude 
product, which was then purified by flash column chromatography on silica (1:5, 
ethyl acetate-hexane) to yield 249 as a yellow oil (456.5 mg, 78%). 1H NMR (400 MHz, 
CDCl3): δ 7.36-7.25 (5H, m, H-Ar), 5.85 (1H, dd, J = 17.9, 10.5 Hz, H-6), 4.98 (1H, dd, J 
= 17.5, 1.5 Hz, H-9a), 4.94 (1H, dd, J = 10.5, 1.5 Hz, H-9b), 4.51 (2H, s, H-11), 
4.00-3.94 (1H, m, H-2), 3.46 (1H, dd, J = 6.7, 4.4 Hz, H-10), 3.39 (1H, dd, J = 9.8, 4.0 Hz, 
H-1a), 3.35 (1H, dd, J = 9.8, 5.6 Hz, H-1b), 1.88-1.44 (2H, m, H-3), 0.96 (6H, s, H-7, 
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H-8), 0.89 (6H, s, H-23, H-24, H-25), 0.88 (6H, s, H-31, H-32, H-33), 0.08-0.05 (12H, m, 
H-21, H-22, H-28, H-29); 13C NMR (101 MHz, CDCl3): 146.2 (C-6), 138.7 (C-12), 128.4 
(C-Ar), 127.7 (C-Ar), 127.6 (C-Ar), 111.8 (C-9), 75.7 (C-10), 75.1 (C-1), 73.4 (C-11), 70.0 
(C-2), 42.6 (C-5), 39.9 (C-3), 26.3 (C-20), 26.1 (C-30), 24.7 (C-7), 22.4 (C-8), 18.4 (C-23, 
C-24, C-25), 18.4 (C-31, C-32, C-33), −3.1 (C-21), −4.0 (C-22), −4.2 (C-28), −4.3 (C-29); 
IR (film): νmax 2954.8, 2928.6, 2885.7, 2856.0, 1637.5, 1496.4, 1471.9, 1462.7, 1414.0, 
1377.7, 1360.3, 1251.5, 1212.9, 1089.1, 1058.7, 1028.7, 1004.4, 973.2, 938.7, 911.6, 
834.2, 807.5, 773.3, 7333.2, 696.4, 666.3, 611.5, 565.4, 462.2 cm-1; ESI-MS: m/z 
C28H52NaO3Si2 [M+Na
+] 515.334719, found 515.333206 (3.3 ppm error).  
 
(3R*,5S*)-6-(benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)-2,2-dimethylhexanal 
243 
Lab book: YT-8-12, NMR: j8794yth (YT-8-12) 
 
 
(5S*,7R*)-5-((benzyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-7-(2-methylbut-3-en-2
-yl)-4,8-dioxa-3,9-disilaundecane 249 (48.00 mg, 97.38 μmol, 1.00 eq.) and NMO 
(22.82 mg, 194.76 μmol, 2.00 eq.) were dissolved in a tert-butanol/THF (1:7, v/v, 2 
mL) solvent mixture. Then osmium tetroxide (0.50 mg, 1.95 μmol, 0.02 eq.) was 
added to the reaction mixture under N2 at room temperature and stirred for 17 
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hours. The reaction was diluted with dichloromethane and washed with sodium 
thiosulfate. The aqueous phase was extracted with dichloromethane (3 x 10 mL) and 
the combined organic extracts were dried (magnesium sulfate), filtered and 
concentrated in vacuo to give a crude product, which was then dissolved in water (1 
mL) and dichloromethane (1 mL). Then sodium (meta)periodate (41.66 mg, 194.76 
μmol, 2.00 eq.) was added to the solution at 0 °C and then reaction was allowed to 
warm to room temperature. After stirring the reaction for 17 hours, the reaction 
mixture was washed with brine (3 x 5 mL) and water (3 x 5 mL). The combined 
organic extracts were dried (magnesium sulfate), filtered and concentrated in vacuo 
to give (3R*,5S*)-6-(benzyloxy)-3,5-bis((tert-butyldimethylsilyl)oxy)- 
2,2-dimethylhexanal 243 as a yellow oil (32.40 mg, 67%). 1H NMR (400 MHz, CDCl3): 
δ 9.54 (1H, s, H-1), 7.37-7.26 (5H, m, H-Ar), 4.52 (2H, s, H-7), 3.97-3.91 (2H, m, H-3, 
H-5), 3.43-3.37 (2H, m, H-6), 1.91-1.55 (2H, m, H-4), 1.05 (3H, s, H-14), 0.99 (3H, s, 
H-15), 0.89 (9H, s, H-18, H-19, H-20), 0.86 (9H, s, H-24, H-25, H-26), 0.08-0.06 (12H, 
m, H-16, H-17, H-22, H-23); 13C NMR (101 MHz, CDCl3): 206.5 (C-1), 138.4 (C-8), 
128.5 (C-Ar), 127.8 (C-Ar), 127.7 (C-Ar), 74.7 (C-6), 73.5 (C-7), 72.6 (C-3), 69.3 (C-5), 
51.7 (C-2), 39.5 (C-4), 26.1 (C-18, 19, 20, 24, 25, 26), 19.1 (C-14), 18.3 (C-21), 18.3 
(C-27), 17.5 (C-15), −3.3 (C-16), −4.2 (C-17), −4.3 (C-22), −4.4 (C-23); IR (film): νmax 
2954.1, 2928.2, 2855.8, 1727.2, 1471.6, 1361.1, 1253.1, 1092.3, 1005.0, 835.7, 808.9, 
775.1, 733.8, 697.2 cm-1; ESI-MS: m/z C27H50NaO4Si2 [M+Na
+] 517.313984, found 
517.313295 (2.1 ppm error).  
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S-(4-methylphenyl) ethanethioate 245 
Lab book: YT-8-18-2, NMR: j9533yth (YT-8-18-2) 
 
 
 
4-Methylbenzenethiol (1.30 g, 10.47 mmol, 1.00 eq.) was dissolved in dry 
dichloromethane (4 mL, 2.62 M) under N2 at room temperature, then pyridine (0.85 
mL, 818.18 mg, 10.47 mmol, 1.00 eq.) was added slowly at the same temperature 
and stirred for 30 minutes. The solution was then cooled down to 0 °C and acetyl 
chloride (0.74 mL, 817.18 mg, 10.47 mmol, 1.00 eq.) was added. After stirring for 30 
minutes, the reaction was allowed to warm to room temperature. After stirring the 
reaction for 17 hours, the reaction mixture was quenched with water (4 mL) and 
washed with saturated sodium bicarbonate solution (4 mL). The aqueous phase was 
extracted with dichloromethane (3 x 10 mL) and the combined organic extracts were 
dried (magnesium sulfate), filtered and concentrated in vacuo to give a crude 
product which was then purified by flash column chromatography on silica (1:8, ethyl 
acetate-hexane) to give S-(4-methylphenyl) ethanethioate 245 (1.11 g, 64%). 1H 
NMR (400 MHz, CDCl3): δ 7.31-7.21 (4H, m, H-Ar), 2.41 (3H, s, H-8), 2.38 (3H, s, H-9);
 
13C NMR (101 MHz, CDCl3): 194.8 (C-7), 139.9 (C-Ar), 134.6 (C-Ar), 130.2 (C-Ar), 124.5 
(C-Ar), 30.3 (C-8), 21.5 (C-9); IR (film): νmax 3396.3, 3024.8, 2968.7, 2922.3, 2870.5, 
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1902.9, 1703.5, 1597.9, 1493.7, 1399.2, 1378.0, 1352.1, 1303.9, 1209.7, 1181.7, 
1114.4, 1093.7, 1040.5, 1018.1, 949.4, 806.5, 704.3, 642.8, 609.5, 527.0, 507.2, 
469.2 cm-1; ESI-MS: m/z C27H50NaO4Si2 [M+Na
+] 517.313984, found 517.313295 (2.1 
ppm error). The 1H and 13C NMR data were in agreement with the literature.162
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4.4. Experimental Procedures for Chapter three 
4.4.1 The preparation of (L)-Proline benzyl ester 
 
(L)-Proline benzyl ester 294 
NMR: k5895yth 
 
 
 
(L)-Proline benzyl ester hydrochloride (24.20 mg, 0.10 mmol) was washed with 
saturated sodium bicarbonate solution (2 mL) then extracted with chloroform (3 × 1 
mL). The combined organic extracts were dried (magnesium sulfate), filtered and 
concentrated in vacuo to provide the free ester. (22.19 mg, 92%). 1H NMR (400 MHz, 
CDCl3): δ 7.39-7.31 (5H, m, Ar), 5.16 (2H, s, H-9), 3.87 (1H, dd, J = 8.6, 5.7 Hz, CHNH), 
3.14-2.93 (2H, m, NHCH), 2.21-2.12 (1H, m, NHCH). 
 
4.4.2 General Procedure for the Preparation of Aldol Products 
To a mixture of the pH 7 buffer solution (1 mL) and aldehyde (1.00 mmol) was added 
the corresponding ketone donor (1.00 mmol) followed by (L)-proline benzyl ester 
(0.10 mmol). After stirring for 5-24 hours, the reaction mixture was diluted with 
water (10 mL) and the aqueous phase was extracted with ethyl acetate (3 x 10 mL). 
The organic extracts were combined, dried (magnesium sulfate), filtered and 
concentrated in vacuo to give a crude product which was then purified by flash 
column chromatography to provide the aldol product. 
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2-[Hydroxy-(4-bromo-phenyl)-methyl]-cyclohexan-1-one 303 
NMR: m7069yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.49-7.45 (2H, m, H-1), 7.21-7.18 (2H, m, H-2), 4.75 (1H, 
dd, J = 8.7, 2.7 Hz, H-3), 3.98 (1H, d, J = 2.8 Hz, OH), 2.59-2.45 (1H, m, H-5), 2.39-2.31 
(1H, m, H-6), 2.13-2.04 (1H, m, H-6), 1.83-1.78 (1H, m, H-9), 1.71-1.48 (5H, m, H-7, 
H-8, H-9). The enantiomeric excess was determined by HPLC with a Chiralcel AD-H  
column, i-PrOH:Hexane = 10:90, flow rate 0.8 mL/min, tR = 18.36 min (minor), tR = 
21.91 min (major). The 1H NMR data was in agreement with the literature.163 
 
2-[Hydroxy-(4-chloro-phenyl)-methyl]-cyclohexan-1-one 304 
NMR: m6244yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.33-7.30 (2H, m, H-1), 7.27-7.24 (2H, m, H-2), 4.76 (1H, 
dd, J = 8.7, 2.5 Hz, H-3), 3.99 (1H, d, J = 2.8 Hz, OH), 2.59-2.52 (1H, m, H-5), 2.51-2.45 
(1H, m, H-6), 2.39-2.31 (1H, m, H-6), 2.13-2.06 (1H, m, H-7), 1.83-1.48 (5H, m, H-7, 
H-8, H-9). The enantiomeric excess was determined by HPLC with a Daicel Chiralpak 
AD column, i-PrOH:Hexane = 10:90, flow rate 0.5 mL/min, tR = 27.37 min (minor), tR = 
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31.94 min (major). The 1H NMR data was in agreement with the literature.164 
 
2-[Hydroxy-(2-chloro-phenyl)-methyl]-cyclohexan-1-one 307 
NMR: m7712yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.54 (1H, dd, J = 7.7, 1.7 Hz, H-Ar), 7.37-7.28 (2H, m, 
H-Ar), 7.23-7.19 (1H, m, H-Ar), 5.35 (1H, dd, J = 8.1, 3.9 Hz, H-6), 4.03 (1H, d, J = 4.0 
Hz, OH), 2.71-2.64 (1H, m, H-5), 2.49-2.44 (1H, m, H-1), 2.38-2.30 (1H, m, H-1), 
2.12-2.05 (1H, m, H-2), 1.84-1.49 (5H, m, H-2, H-3, H-4). The enantiomeric excess was 
determined by HPLC with a Daicel Chiralpak OD column, i-PrOH:Hexane = 5:95, flow 
rate 0.8 mL/min, tR = 12.08 min (major), tR = 15.04 min (minor).
 The 1H NMR data 
was in agreement with the literature.164 
 
2-[Hydroxy-(2-nitro-phenyl)-methyl]-cyclohexan-1-one 308 
NMR: m7107yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.85 (1H, dd, J = 8.2, 1.3 Hz, H-Ar), 7.77 (1H, dd, J = 7.9, 
1.2 Hz, H-Ar), 7.64 (1H, td, J = 7.8, 1.3 Hz, H-Ar), 7.45-7.41 (1H, m, H-Ar), 5.45 (1H, 
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dd, J = 6.7, 3.4 Hz, H-6), 4.18 (1H, d, J = 4.3 Hz, OH), 2.79-2.72 (1H, m, H-5), 
2.48-2.43 (1H, m, H-1), 2.38-2.29 (1H, m, H-1), 2.14-2.07 (1H, m, H-2), 1.88-1.83 (1H, 
m, H-2), 1.88-1.63 (4H, m, H-3, H-4). The enantiomeric excess was determined by 
HPLC with a Daicel Chiralpak OJ column, i-PrOH:Hexane = 5:95, flow rate 1.0 
mL/min, tR = 21.40 min (minor), tR = 23.39 min (major). The 
1H NMR data was in 
agreement with the literature.164 
 
2-[Hydroxy-phenyl-methyl]-cyclohexan-1-one 305 
NMR: m6674yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.38-7.27 (5H, m, H-Ar), 4.79 (1H, dd, J = 8.8, 2.3 Hz, 
H-6), 3.96 (1H, d, J = 2.7 Hz, OH), 2.65-2.58 (1H, m, H-5), 2.53-2.46 (2H, m, H-1), 
2.40-2.28 (3H, m, H-2, H-3), 2.12-2.01 (3H, m, H-3, H-4). The enantiomeric excess was 
determined by HPLC with a Daicel Chiralpak OJ column, i-PrOH:Hexane = 10:90, flow 
rate 1.0 mL/min, tR = 8.65 min (major), tR = 10.44 min (minor).
 The 1H NMR data was 
in agreement with the literature.164 
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2-[Hydroxy-(pyridin-4-yl)-methyl]-cyclohexan-1-one 310 
NMR: m8227yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 8.64-8.55 (2H, m, H-1), 7.25-7.23 (2H, m, H-2), 4.77 (1H, 
d, J = 8.2 Hz, H-3), 4.03 (1H, br, OH), 2.62-2.55 (1H, m, H-5), 2.51-2.45 (1H, m, H-6), 
2.42-2.31 (1H, m, H-6), 1.85-1.64 (6H, m, H-7, H-8, H-9). The enantiomeric excess was 
determined by HPLC with a Daicel Chiralpak AD column, i-PrOH:Hexane = 10:90, flow 
rate 1.0 mL/min, tR = 22.76 min (minor), tR = 24.80 min (major).
 1H NMR data was in 
agreement with the literature.164 
 
2-[Hydroxy-(furan-2-yl)-methyl]-cyclohexan-1-one 309 
NMR: m7330yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.38-7.37 (1H, m, H-9), 6.33-6.27 (2H, m, H-7, H-8), 4.82 
(1H, d, J = 8.5 Hz, H-6), 3.90 (1H, br, OH), 2.94-2.87 (1H, m, H-5), 2.49-2.31 (2H, m, 
H-1), 1.84-1.58 (6H, m, H-2, H-3, H-4). The enantiomeric excess was determined by 
HPLC with a Daicel Chiralpak AD column, i-PrOH:Hexane = 10:90, flow rate 0.5 
mL/min, tR = 28.20 min (minor), tR = 29.91min (major). The 
1H NMR data was in 
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agreement with the literature.163 
 
4-[hydroxy-4-(4-nitrophenyl)]-butan-2-one 261 
NMR: m9017yth 
 
 
 
1H NMR (400 MHz, CDCl3): δ 8.12-8.09 (2H, m, H-5, H-6), 7.48 (2H, d, J = 8.7 Hz, H-4, 
H-7), 5.21 (1H, t, J = 6.1 Hz, H-3), 3.86 (1H, br, OH), 2.82 (2H, d, J = 6.6 Hz, H-2), 2.17 
(3H, s, H-1). The enantiomeric excess was determined by HPLC with an AS-H column 
column, i-PrOH:Hexane = 30:70, flow rate 0.5 mL/min, tR = 27.96 min (major), tR = 
34.65 min (minor). The 1H NMR data was in agreement with the literature.165
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6. Abbreviations 
Ac Acetyl 
aq. Aqueous 
Ar (in NMR) Aromatic proton signal 
BHT Butylated hydroxytoluene 
Bn Benzyl 
BPTPI benzene-fused-phthaloyl-piperidinonate 
br Broad 
Bu Butyl 
cm-1 Wavenumber 
COSY Correlation spectroscopy 
CSA Camphorsulfonic acid 
CuDPP Cu(I) diphenylphosphinate 
CuTC Copper(I)-thiophene-2-carboxylate 
d Doublet 
d.r. Diastereomeric ratio 
DBU 1,8-Diazabicycloundec-7-ene 
DCE 1,1-Dichloroethene 
DCM Dichloromethane 
DEAD Diethyl diazenedicarboxylate 
DEPT Distortionless enhancement by polarisation transfer 
DFT Density functional theory 
DIBAL-H Diisobutylaluminium hydride 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
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DMP Dess-Martin periodinane 
DMSO Dimethylsulfoxide 
E+ Electrophile 
ee Enantiomeric excess 
eq. Equivalents 
ESI Electrospray ionisation 
Et Ethyl 
g Gram (s) 
GI50 50% growth inhibition 
h Hour (s) 
HDA hetero-Diels–Alder  
HFIP Hexafluoro-2-propanol 
HMBC Heteronuclear multiple bond correlation 
HMQC Heteronuclear multiple quantum correlation 
HPLC High-performance liquid chromatography 
Hz Hertz 
i-Pr Isopropyl 
IR Infrared 
J Coupling constant in Hz 
L Literature 
LC50 Lethal Concentration, 50% 
LDA Lithium diisopropylamide 
LHMDS Lithium bis(trimethylsilyl)amide 
LUMO Lowest unoccupied molecular orbital 
M Molar 
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m Multiplet 
m/z Mass to charge ratio 
M+ Molecular ion 
Me Methyl 
mg Milligram(s) 
MHz Mega Hertz 
min Minutes (s) 
mL Millilitre (s) 
mmol Millimole (s) 
mol Mole (s) 
MOM Methoxymethyl ether 
MS Mass spectrometry 
Ms Methanesulfonyl 
MS Molecular sieves (4Å) 
MW Microwave irradiation 
n Nano 
nBu Normal-butyl 
NMO 4-Methylmorpholine N-oxide 
NMR Nuclear magnetic resonance spectroscopy 
NOE Nuclear overhauser effect 
p Pentet 
ppm Parts per million 
Py Pyridine 
q Quartet 
R Undefined group 
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Rf Retention factor 
rt Room temperature 
s Singlet 
SAR Structure–activity relationship 
sat. Saturated 
t Triplet 
TBAF Tetrabutylammonium fluoride 
TBDPS Tertiary-butyl(chloro)diphenylsilane 
TBS Tertiary-butyldimethylsilyl 
tBu  Tertiary-butyl 
TEMPO 2,2,6,6-Tetramethyl-1-piperidinyloxy 
TES Triethylsilyl 
Tf Trifluoromethanesulfonyl 
TFA Trifluoroacetic acid 
TFP Tri(2-furyl)phosphine 
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 
TLC Thin layer chromatography 
TMEDA N,N, N’,N’-tetramethylethylenediamine 
Ts p-Toluenesulfonyl 
UV Ultraviolet 
δ Chemical shift 
μ Micro 
μL Micro Liters 
ν Vibration frequency (cm-1) 
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